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Abstract
Haematopoietic stem cells (HSCs) are the best-characterised adult stem cells and en-
sure life-long maintenance of the blood system. Under homeostatic conditions most
of the HSCs are found in a quiescent state, but can be activated in response to stress
(Wilson et al., 2008). Infection is a major source of natural stress to the haematopoi-
etic system, leading to exhaustion of large amounts of immune cells during the defence
against invading pathogens. Reestablishment of homeostasis following infection de-
pends on the replacement of immune cells by haematopoietic progenitors. Interest-
ingly, recent studies have indicated that HSCs themselves can be activated in response
to infection (Essers et al., 2009; Sato et al., 2009; Baldridge et al., 2010; Takizawa et al.,
2011). However, whether HSCs are able to directly sense the infectious state remains
unclear. In this work, we have investigated the in vivo short-term response of HSCs to
lipopolysaccharide (LPS), a major cell wall component of Gram-negative bacteria. Low
dose administration of LPS tomice induces a rapid TLR4dependent proliferation of even
themost dormant HSCs, without impairing their long-term repopulating potential. This
activation is accompanied by upregulation of stem cell antigen 1 (Sca-1) and dependent
on the expression of Sca-1 on HSCs. Both in vitro and in vivo data demonstrate that
activation of HSCs via LPS is not a direct effect of LPS on HSCs. Instead, LPS treatment
stimulatesmyeloid cells in the BM,most probably inammatorymonocytes, to produce
inammatory cytokines, which in turn induce the activation of HSCs. Furthermore, our
results suggest that the activation of HSCs is mediated by initial cell-cell-interaction of
thesemyeloid cells with HSCs. Using geneticmousemodels we show that the activation
of HSCs is regulated by combined IFNα, IFNγ and TNFα signalling. Moreover, TNFα alone
induces a Sca-1 dependent activation of HSCs in vivo, making these cells susceptible to
chemotherapy. In addition to IFN and TNFα signalling also IL-1β signalling is necessary to
mediate the LPS-induced activation of HSCs. Interestingly, IL-1β itself leads to increased
proliferationofHSCs,most likely throughdirect activationof IL-1 signalling in these cells.
Thus, our work provides novel cellular and genetic insights into the identity of LPS in-
duced cytokine production, leading to HSC activation. Thus, providing a way to rapidly
induce the production of mature immune cells upon infection, leading to a fast restora-
tion of homeostasis upon bacterial infections. Furthermore, our work provides new in-
sights into the role of the pro-inammatory cytokines TNFα and IL-1β in the regulation
of HSC function.
I
Zusammenfassung
Hämatopoetische Stammzellen (HSCs) gehören zu den am besten charakterisierten
adulten Stammzellen und ermöglichen die lebenslange Aufrechterhaltung des Blutsys-
tems. Unter homöostatischen Bedingungen benden sich die meisten HSCs in einem
ruhendenZustand, können jedoch als Reaktion auf Stress aktiviertwerden (Wilson et al.,
2008). Infektionen sind eine wesentliche Quelle natürlicher Stresssituationen für das
hämatopoetische System, da sie während der Abwehr gegen die eindringenden Patho-
gene zu einer Erschöpfung großer Mengen von Immunzellen führen. Die auf eine In-
fektion folgende Wiederherstellung der Homöostase hängt vom Ersatz der Immun-
zellen durch hämatopoetische Vorläuferzellen ab. Interessanterweise haben jüngste
Studien gezeigt, dass HSCs selbst als Reaktion auf Infektionen aktiviert werden kön-
nen (Essers et al., 2009; Sato et al., 2009; Baldridge et al., 2010; Takizawa et al., 2011).
Ob HSCs jedoch in der Lage sind den infektiösen Zustand direkt wahrzunehmen, bleibt
unklar. In dieser Arbeit haben wir die kurzzeitige Reaktion von HSCs auf Lipopolysac-
charid (LPS), einenHauptbestandteil der ZellwandGram(-) Bakterien, in vivo untersucht.
Die Verabreichung geringer Mengen von LPS an Mäuse führt zu einer schnellen TLR4-
abhängigenProliferation ruhender Stammzellen, ohnedabei das Langzeit-Besiedelungs-
potential dieser Zellen zu beeinträchtigen. Diese Aktivierung wird von einer Hochreg-
ulierung von stem cell antigen 1 (Sca-1) begleitet und ist gleichzeitig abhängig von der
Expression von Sca-1 auf HSCs. Sowohl in vitro als auch in vivo Ergebnisse zeigen,
dass die Aktivierung der HSCs kein direkter Effekt von LPS auf die HSCs ist. Stattdessen
führt LPS-Behandlung zu einer Stimulierungmyeloider Zellen imKnochenmark, höcht-
wahrscheinlich von inammatorischen Monozyten. Die myeloiden Zellen produzieren
dann inammatorische Zytokine, die wiederum die HSCs aktitivieren. Des Weiteren,
weisen unsere Ergebnisse darauf hin, dass die Aktivierung der HSCs durch anfängliche
Zell-Zell-Interaktion zwischen diesen myeloiden Zellen und den HSCs vermittelt wird.
Zusätzlich können wir mit genetischen Modellen aufzeigen, dass die Aktivierung der
HSCs durch eine Kombination aus IFNα-, IFNγ- und TNFα-Signalgebung reguliert wird.
Außerdem zeigen wir, dass in vivo TNFα alleine eine Sca-1-abhängige Aktivierung von
HSCs auslösen kann, wodurch diese anfällig für Chemotherapie werden. Zusätzlich zu
IFN und TNFα-Signalgebung konnten wir zeigen, dass IL-1β-Signalgebung für die LPS-
induzierte Aktivierung von HSCs notwendig ist und dass IL-1β selbst zu einer erhöhten
Proliferation von HSCs führt, die sehr wahrscheinlich durch eine direkte Aktivierung
von IL-1β-Signalgebung in HSCs ausgelöst wird.
Unsere Arbeit liefert folglich neue zelluläre und genetische Einsicht in die Identität der
LPS-induzierten Zytokin-Produtkion, die eine Aktivierung von HSCs auslöst. Dadurch
kommt es tu einer zur raschen Produktion differenzierter Immunzellen, die zu einer
schnellen Wiederherstellung der Homöostase nach einer bakteriellen Infektion führt.
Des Weiteren, bietet unsere Arbeit neue Erkenntnisse über die Rolle der pro-inam-
matorischen Zytokine TNFα und IL-1β bei der Regulierung der Funktion von HSCs.
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1. Introduction
1.1. Haematopoietic stem cells and the haematopoietic system
1.1.1. An early history of HSC research
The rst evidence of HSCs arose shortly after the bombings of Hiroshima and Na-
gasaki, when physicians observed that those people who died over a prolonged period
from lowerdoses of irradiation suffered fromhaematopoietic failure. Their haematopoi-
etic system was unable to regenerate sufcient white blood cells to cope with infec-
tions, as well as enough platelets to clod their blood (reviewed in Domen et al., 2006).
A few years later, scientists were able to show that mice exposed to a lethal dose of
irradiation died from similar symptoms, but could be rescued by bone marrow trans-
fer fromnon-irradiated animals. As this rescue did not only occurwhen irradiatedmice
were transplantedwithmousebonemarrow, but alsowhen theywere transplantedwith
bone marrow from rats or guinea pigs, ’humoral’ or chemical factors rather than cells
where suggested to be the source of the recovery (Lorenz et al., 1951). In 1956, however,
two groups were able to show that the recovery after bonemarrow transplantation into
lethally irradiated animalswas due to a repopulation of the recipient by the transplanted
cells. By using cells with chromosomal translocations or rat cells transplanted intomice,
it was proven that the donor cells survived and repopulated the recipient (Ford et al.,
1956; Nowell et al., 1956). With this observation the search for the haematopoietic stem
cell began.
The rst experiments proving that specic cells of the bonemarrow are able to differ-
entiate into various cell types where completed in the 1960s. It was shown that colonies
formed on the spleen after transplantation of bone marrow cells were of clonal nature,
with all cells in one colony emerging from one single transplanted cell (Becker et al.,
1963). Subsequently, it was demonstrated that single colony-forming cells were able to
differentiate along more than one pathway, because the colonies consisted of different
cell types, such as granulocytes and erythrocytes (Wu et al., 1967). Nevertheless, these
spleen colonies consist of cells of myeloid origin only. Thus, these experiments could
indeed show the existence of single cells able to differentiate into various cell types of
1
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the myeloid lineage, however if these cells were simultaneously able to reconstitute the
lymphoid lineage was not clear. The proof for the existence of single haematopoietic
cells with the potential to differentiate into all cell types of the myeloid as well as the
lymphoid lineage was demonstrated in 1977. Chromosomal aberrations were used to
identify single cell clones and prove that some of the transplanted cells were able to re-
constitute the myeloid as well as the lymphoid lineage. Furthermore, the existence of
cells able to form cells of either the myeloid or the lymphoid lineage, but not both, was
shown (Abramson et al., 1977). These results were the rst evidence for the existence
of a HSC, with the ability to differentiate into all cell types of the blood system, as well
as the existence of restricted progenitors, which were only capable of differentiation
into cells from the myeloid or the lymphoid lineage, today known as common myeloid
progenitors (CMPs) or common lymphoid progenitors (CLPs).
1.1.2. Functional HSC assays
Functional HSC assays are necessary to analyse the stem cell potential of different
cell populations, such as differentiation and self-renewal. These functional assays can
be subdivided into in vitro assays or in vivo short-term and long-term repopulation
assays. The in vitro and short-term assays asses the potential of progenitors, while
long-term repopulation assays can be used to asses the self-renewal potential, quan-
tity and quality of HSCs. An important in vitro assay is the the colony-forming unit
(CFU) or colony-forming cell (CFC) assay, amethod based on the ability of HSPCs to form
colonies in semi-solid methylcellulose medium in the presence of cytokines (Cashman
et al., 1983). These colonies can be counted and characterised, according to their lineage
restriction as erythrocyte (CFU-E or erythroid-restricted burst-forming units, BFU-E),
megakaryocyte (CFU-Mk), granulocyte/monocyte (CFU-GM) or mixed colonies (CFU-
GEMM) (Cashman et al., 1983; Coulombel et al., 1983; Purton and Scadden, 2007). The
measurement of B and T lymphocyte potential with this assay is more difcult and re-
quires specialised culture conditions (reviewed in Purton and Scadden, 2007). Among
the long-term in vitro assays are the long-term culture-initialising cell (LTC-IC) assay
(Dexter et al., 1977; Whitlock and Witte, 1982; Sutherland et al., 1989) and the Cobble-
Stone Area Forming Cell (CAFC) assay (Ploemacher et al., 1989). Both of these assays are
based on the assumption that only HSCs can retain their clonogenic potential in cul-
ture over a long period. In both assays the bone marrow cells are cultured for several
weeks with a stromal feeder layer. In the LTC-IC assay the frequency of LT-initiating
cells is estimated through limiting dilutions (Sutherland et al., 1989). The CAFC assay is
based on the observation, that HSPCs creep into the stromal layer and settle there as
2
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clusters of tightly packed cells, the cobblestone areas. The CAFCs represent primitive
haematopoietic cells and their frequency in different subsets within the haematopoi-
etic hierarchy can be quantied by the frequency of CAFCs over time (Ploemacher et al.,
1989). In both assays the clonogenic potential of long-term cultured cells is assessed by
a CFU assay. However, all of thesemethodmeasure the in vitro colony forming potential
of progenitors, rather than HSCs (reviewed in Purton and Scadden, 2007). The colony
forming potential of transplanted bone marrow cells can be analysed by the Colony-
Forming Unit-Spleen (CFU-S) assay. For this assay, bone marrow cells are transplanted
into lethally irradiatedmice and the formation of colonies on the spleen is analysed be-
tween 10 and 14 days after transplantation (Till and McCulloch, 1961).
Nevertheless, these methods cannot be used to evaluate the actual stem cell potential
within a fraction of bone marrow cells. For this purpose long-term repopulation assays
are used. For all of these assays, bone marrow cells are transplanted into lethally irradi-
ated mice and the repopulation of the recipient with the donor cells is assessed after 4
monthor later. All of these assays are basedon the original bonemarrow transplantation
experiments (Lorenz et al., 1951; Ford et al., 1956; Nowell et al., 1956), but enable a more
rened readout. In competitive repopulation assays, a dened number of bonemarrow
cells from the source to be studied are transplanted together with a dened number of
HSCs from a source of known repopulation potential. The frequency of repopulating
units (RU) can then be assessed in comparison to a control transplantation (Harrison,
1980). This assay is, for example, used to asses the engraftment potential of HSCs from
transgenicmice in comparison to wildtype cells. However, this assay cannot distinguish
between differences in the quality of HSCs and differences in the number of HSCs. This
assay is also critically dependent on the number of HSCs in the analysed population. To
analyse the frequency of HSCs in a given bone marrow sample, limiting-dilution assays
are used. In these assays, cells are transplanted in a series of dilutions, together with
competing or rescue bone marrow cells. The number of cells in the sample can then
be calculated from the number of repopulated recipients (Taswell, 1981; Szilvassy et al.,
1990). This method is costly, because many mice have to be transplanted with differ-
ent dilutions of cells, and is therefore usually used after a difference in the engraftment
potential of a given sample has been detected with the competitive repopulation assay.
Furthermore, this assay may not accurately detect HSCs at a single cell level (reviewed
in Purton and Scadden, 2007) To asses the self-renewal and long-term reconstitution
potential of a fraction of bone marrow cells, serial transplantations are used. This is
the only method to assess the actual stem cell potential, as progenitors are also have
the capacity to provide multilineage reconstitution to a primary recipient, while only
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HSCs are able to multilineage reconstitute a secondary or tertiary recipient. Cells from
a primary recipient are used as donor cells for a secondary recipient and cells from the
secondary recipient may then be used as donor cells for a tertiary recipient (Lemischka
et al., 1986). However, the results of this assay may be inuenced by impaired homing
or engraftment, rather than impaired self-renewal (reviewed in Purton and Scadden,
2007). In addition to these assays, repopulating assays are performed, using single cells
to analyse the repopulation capacity of single cells rather than a population of cells (Os-
awa et al., 1996;Wagers et al., 2002; Camargo et al., 2006; Dykstra et al., 2007; Yamamoto
et al., 2013).
Transplanted HSCs reach the bone marrow and nd their niche by a process termed
"homing". The traditional way of transplanting bone marrow cells is through tail-vein
or retro-orbital (intravenous) injection into the blood. However, many HSCs become
trapped in organs such as lung and liver, and the recovery of cells in the bone marrow
and spleenmay therefore be rather low (Szilvassy et al., 1999). Using thismethod to study
the engraftment potential of HSCs is therefore not sufcient to differentiate between
defects in engraftment or homing. To circumvent the necessity of HSCs to home to the
bonemarrow, cells can be directly injected intra-femorally into the bone cavity (Kushida
et al., 2001).
1.1.3. HSC markers and the haematopoietic hierarchy
HSCs can be identified through their cell surface phenotype
After itwas clear thatHSCs exist, themain goalwas to isolate these cells to gain a better
understanding of their properties and behaviour. Themain problems for the isolation of
HSCs were the rarity of the stem cells in the bonemarrow and their similar morphology
with other white blood cells. Thereforemany tried to identify surfacemarkers to enable
isolation of HSCs by uorescence activated cell sorting (FACS). This method, in com-
bination with the functional assays mentioned above, facilitates the identication and
isolation of single cells marked with uorescent antibodies. The rst steps in the iden-
tication of markers suitable to isolate HSCs were made in the 1980s. It was rst found
that HSCs reside within a population negative for the lineage markers B220, CD4/CD8,
Gr-1 and CD11b (Lin-) and positive for Thy1 (Müller-Sieburg et al., 1986). After show-
ing that mice transplanted with Thy1+Lin- cells survived lethal irradiation, while mice
transplanted with Thy1- cells died, it was subsequently revealed that the actual stem cell
properties reside within the Thy1 low population (Thy1lo) of Lin- cells (Müller-Sieburg
et al., 1988). As this population of Thy1loLin- cells was still heterogeneous, themarker set
to isolate HSCswas further rened. In 1988, stem cell antigen 1 (Sca-1) was established as
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one of themarkers further rening the denition of HSCs. Only 30 Thy1loLin-Sca-1+ cells
were sufcient to rescue a lethally irradiated mouse and provide long-term reconstitu-
tion to the recipient. Although it was shown that the Sca-1+ fraction of the bonemarrow
contained long-term repopulation potential, Spangrude et al. suggested that this frac-
tion contained all stem cell activity of the bone marrow (Spangrude et al., 1988). This
hypothesis was later proven, by showing that neither Thy1-, nor Lin+ or Sca-1- cells can
repopulate a recipient mouse. However, the study showed that mice transplanted with
Thy1-, Lin+ or Sca-1- cells survived longer in comparison to mice which were not trans-
planted with any bone marrow cells, suggesting that these cells contained short-term
reconstitution potential (Uchida andWeissman, 1992). Anothermarker to rene the def-
inition of HSCswas identied by proving that only the c-Kit+ fraction of Thy1loLin-Sca-1+
cells had long-term multi-lineage reconstitution potential (Ikuta and Weissman, 1992).
In the 1990s various groups contributed to the further renement of theHSCmarker set.
In 1996, it was shown that within the pool of Lin-Sca-1+c-Kit+ (LSK) cells, only the CD34-
cellswere able to long-term repopulate a recipient, while theCD34+ cells only had short-
term repopulation potential (Osawa et al., 1996). In the meantime, other markers were
proposed, such as CD43, CD38, CD27 and CD135 (Moore et al., 1994; Randall et al., 1996;
Wiesmann et al., 2000; Adolfsson et al., 2001). Of these markers only CD135 (Flt3) is
currently used as a marker for HSCs, where multi-lineage reconstitution potential was
shown to residewithin the Flt3- population of LSK cells, while Flt3+ LSK cells only recon-
stituted the lymphoid lineage (Adolfsson et al., 2001). In 2005 another set ofmarkers, the
SLAMmarkers, was identied, that helped to enhance thedenitionofHSCsmarkedly. It
was shown that HSCs expressed high levels of CD150, but low levels of CD48 and CD244,
compared to MPPs and whole bonemarrow. Furthermore, the engraftment potential of
a single sorted cell was improved from 21% for Thy1loLin-Sca-1+c-Kit+ cells to 47% by
adding CD150+CD48- to the sorting scheme. A further enhancement of the purity of
HSCs can be reached by excluding CD41+ cells, which represent megakaryocytes and
megakaryocyte progenitors (Kiel et al., 2005). Adding CD34 to the LK CD150+CD48- gat-
ing scheme is the most robust currently in use and was therefore used for most of the
in vivo analysis performed in this thesis.
The role of Sca-1 in HSC function
Althoughmost of the HSCmarkers have been identied quite a while ago, their func-
tional role in HSCs is still under debate. Sca-1 is one of these candidates. Knockout mice
for Sca-1 (Sca-1-/-) display a relativelymild haematopoietic phenotype. Itwas shown that
the T cells in these mice develop normally, but are hyperresponsive to antigen stimu-
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lation (Stanford et al., 1997). Furthermore, these mice display a mild thrombocytopenia
as well as a decrease in megakaryocytes and their precursors. Additionally, they show
a decrease granulocyte, erythrocyte, macrophage and megakaryocyte progenitor activ-
ity. Sca-1-/- HSCs have a competitive disadvantage compared to wildtype HSCs and fail
to repopulate one third of lethally irradiated secondary recipients. This data suggests
that Sca-1 is required for the regulation of HSC self-renewal and the development of
committed progenitor cells, megakaryocytes and platelets (Ito et al., 2003).
The haematopoietic hierarchy
LT-HSC ST-HSC
T cells
B cells
monocytes
granulocytes
megakaryocytes
erythrocytes
CLP
Pro-T
Pro-B
GMP
MEP
MPP
LMPP
CMP
MkEP
OPP
MyRP
Figure 1.1.: The model of haematopoietic differentiation is changing
The classical model (solid lines) of HSC differentiation proposes the long-term HSC (LT-HSC) at the top of
the haematopoietic hierarchy, subsequently differentiating into a short-term HSC (ST-HSC) and a multi-
potent progenitor (MPP) (Morrison and Weissman, 1994; Morrison et al., 1997). The rst decision of com-
mitment between the lymphoid and the myeloid lineage is made when the MPP differentiates into either
a common lympoid progenitor (CLP) (Kondo et al., 1997) or a common myeloid progenitor (CMP) (Akashi
et al., 2000; Reya et al., 2001). The revised model (dashed lines) of the haematopoietic hierarchy proposes
the rst lineage choice betweenmyeloid-restricted and lympho-myeloid progenitors (LMPP or oligopotent
progenitors, OPP), with the LMPPs/OPPs unable to differentiate intomegakaryocytes or erythrocytes (MkE).
Another type of progenitor cells corresponds to the earlier proposed CMPs (myeloid repopulating progen-
itors, MyRPs) and is able to differentiate into all cells of the myeloid lineage, including MkE. Furthermore,
the model proposes a direct short-cut from LT-HSCs to megakaryocyte/erythrocyte progenitors (MkEPs)
(Adolfsson et al., 2005; Yamamoto et al., 2013).
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With the establishment of markers to identify multipotent haematopoietic stem and
progenitor cells, scientists started to investigate the hierarchy of the haematopoietic sys-
tem and the chronology of differentiation from the HSC tomature haematopoietic cells.
At rst, a differentiation was made between CD34- long-term repopulating HSCs (LT-
HSCs), capable of multi-lineage reconstitution over a long period, CD34+ short-term
HSCs (ST-HSCs), capable of short-term self-renewal and reconstitution of a recipient
for less than 8 weeks, and multipotent progenitors (MPPs), with the potential to form
the different haematopoietic lineages but without self-renewal capacity (Morrison and
Weissman, 1994). Thereafter, it was shown that the LT-HSCs reside at the top of the
haematopoietic hierarchy, subsequently differentiating rst into ST-HSCs and then into
MPPs (Morrison et al., 1997). Hereafter, a cell population with lineage restriction for the
lympoid lineage was identied as Lin-IL-7R+Thy1-Sca-1loc-Kitlo, termed common lym-
phoid progenitor (CLP). This population showed a restriction toward lymphoid differen-
tiation in vitro aswell as in vivo. Furthermore, a single cell was able to reconstitute B cells
as well as T cells (Kondo et al., 1997). After the identication of a CLP an equivalent cell
type able to differentiate into the myeloid lineage within the IL-7R- fraction of the bone
marrow was identied, the common myeloid progenitors (CMP). These cells are able
to differentiate into granulocyte/macrophage lineage-restricted progenitors (GMPs) or
megakaryocyte/erythrocyte lineage-restricted progenitors (MEPs) (Akashi et al., 2000).
These ndings led to the proposal of the classicalmodel of haematopoietic lineage com-
mitment, where MPPs arise from ST-HSCs and in turn differentiate into CLPs or CMPs,
as the rst line of commitment to either the lymphoid or the myeloid lineage. The
CLPs subsequently differentiate into B or T cell progenitors, while the CMPs differen-
tiate further into GMPs or MEPs (Figure 1.1, solid lines) (Akashi et al., 2000; Reya et al.,
2001). The classical model was challenged when a population of progenitor cells within
the Flt3+ fraction of LSK cells with lympho-myeloid potential, but without the ability to
formmegakaryocytes or erythrocytes, was identied (Adolfsson et al., 2005). These pro-
genitors were termed lymphoid-biased multipotent progenitors (LMPP). The discovery
of those cells challenged the prediction of the classical model - that the separation of
the lymphoid and myeloid lineage is the rst step in differentiation - as it suggests an
earlier separation of cells capable of erythro-megakaryocytic differentiation (megakary-
ocyte/erythroid progenitors, MkEPs) from the rest of the progenitors. The MkEPs reside
within the Flt3- fraction of LSK cells and it was postulated that those cells emerge in
a differentiation step from HSCs to either Flt3- MkEPs or Flt3+ LMPPs (Adolfsson et al.,
2005). This observation was strengthened by a study, showing that Flt3-PU.1lo cells are
highly enriched for committed MEPs (Nutt et al., 2005) and a publication proving an
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early separation of progenitors with a restrictedmyeloid potential and progenitors with
lympho-myeloid potential (Lai and Kondo, 2006). Contradicting to this newly proposed
model, Forsberg et al. showed that the Flt3+, as well as the Flt3- cells, retain the potential
to differentiate into megakaryocytes and erythrocytes (Forsberg et al., 2006). As none
of these studies was performed using single cell techniques to specically determine
the differentiation potential of single stem and progenitor cells, the question of which
model holds true remained a controversial subject.
In 2013 two groupswere able to provide data from large-scale single cell experiments,
leading to a revised model of haematopoietic differentiation. The Nakauchi lab subdi-
vided the CD34- LSK pool of cells into three fractions, dependent on their expression of
CD150 and CD41, and transplanted approximately 300 single cells into primary and sec-
ondary recipients. This enabled the investigation of the long-termdifferentiation poten-
tial of a single cell of each of these populations (Yamamoto et al., 2013). Progenitors with
differentiation potential equivalent to CMPs, MEPs and MkPs were identied in all of
the transplanted fractions. These progenitors were thereafter termed commonmyeloid
repopulating progenitors (CMRPs), megakaryocyte-erythroid repopulating progenitors
(MERPs) ormegakaryocyte repopulating progenitors (MkRPs) respectively. Furthermore,
it was shown that these cells have a higher repopulation capacity than CD34+ LSK cells
(Yamamoto et al., 2013). After the establishment of the existence of a MkRP popula-
tion, the question of whether these megakaryocyte-primed progenitors could directly
emerge from a HSC, arose. Therefore, single cells from all three fractions were sorted
and allowed to divide once in culture before transplanting each of the daughter cells
separately. This allowed assesment of the fate of the individual daughter cells. With this
experiment, together with the abovementioned ndings, evidence for a direct differen-
tiation from LT-HSCs to MkRPs was provieded (Yamamoto et al., 2013). These ndings,
alongwith the results fromAdolfsson et al., identifying a LMPP capable of differentiation
into the lymphoid and themyeloid lineage, but not into erythrocytes ormegakaryocytes
(Adolfsson et al., 2005), led to the proposal of a revised model of HSC differentiation. In
this model the rst lineage choice is made between myeloid-restricted and lympho-
myeloid progenitors, whereby the lympho-myeloid progenitors lose the ability to pro-
duce cells of the megakaryocyte/erythrocyte lineage. The lympho-myeloid progenitors
(LMPP or oligopotent progenitors, OPP) are able to produce cells of the lymphoid lin-
eage as well as cells of the granulocyte/macrophage lineage (Akashi et al., 2000). An-
other type of progenitor corresponds to the earlier proposed CMPs (termed MyRPs by
Yamamoto et al.) and is able to produce all cells of the myeloid lineage. Furthermore,
this model proposes a direct short-cut from LT-HSCs to MkEPs (Figure 1.1, dashed lines)
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(Adolfsson et al., 2005; Yamamoto et al., 2013). This model was further supported by
another large-scale single-cell analysis published in 2013 by the group of Stuart Orkin.
Here, single cells from different bone marrow populations were used for large-scale
expression proling by qRT-PCR. Similarities between MegE primed cells and HSCs in
respect to their gene expression proles was shown. Furthermore, the study identied
two types of CMPs; one closely linked to MegEs and one more closely related to the
lympho-myeloid lineage (Guo et al., 2013). This data provides further proof for the re-
vised model of haematopoietic differentiation, with a close relationship between HSCs
and the MkE lineage and two pathways of myeloid differentiation. Further proof of the
MkEpriming ofHSCswas givenbydata showing a hierarchical relationship between von
Willebrand factor positive (vWF+) platelet-primed HSCs at the apex of the HSC hierar-
chy with a downstream differentiation to vWF- lymphoid-biased HSCs lacking platelet-
priming (Sanjuan-Pla et al., 2013). Taken together these studies clearly demonstrate that
the markers used to identify individual populations of haematopoietic cells are still not
rened enough and that these populations are still very heterogeneous. Hence, single
cell analysis will be crucial to gain a full understanding of the haematopoietic hierarchy
and thedifferentiationpotential of individual populations. Furthermore, single cell anal-
ysis will further rene the understanding of the function of haematopoietic stem and
progenitor cells and help to nd new markers for the identication of different HSPC
populations.
1.1.4. Dormant haematopoietic stem cells
A fraction of HSCs reside in a dormant state
Most of the HSCs (70%) are found in the G0 state of the cell cycle under homeostasis at
any given time point (Wilson et al., 2008). This low cycling kinetic ensures life long pro-
duction of blood cells and reduces the risk of leukaemia, as mutations mainly occur in
fast cycling cells (Wang andDick, 2005). Furthermore, it protects theHSCs fromexhaus-
tion (Orford and Scadden, 2008). The experiments showing that most of the HSCs are
quiescent were, however, a snapshot of a given time point and the question arose how
the cycling behaviour of HSCs changes over a longer period. First experiments treating
micewith BrdU over a period of time led to the conclusion, that all HSCs are cycling reg-
ularly, as during a period of oneweekmost of the primitiveHSCs had incorporated BrdU
and therefore had undergone at least one cell cycle (Bradford et al., 1997). This result was
further supported by the nding that after 6months of continuous BrdU treatment, 99%
of all LT-HSCs had divided and incorporated BrdU (Cheshier et al., 1999). The rst re-
sults of a label-retaining assay in HSCs were published in 2007 (Kiel et al., 2007). Mice
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were treatedwith BrdU for 10 days, followed by a BrdU-free chase period of 70 days and
subsequent analysis of the presence of BrdU in HSCs bymicroscopy. From these exper-
iments it was concluded that a dormant population of HSCs does not exist, as all HSCs
were labeled within 10 days and only 6% of HSCs retained the label after the chase pe-
riod (Kiel et al., 2007). However, the existence of a fraction of dormant HSCs within the
pool of LSK CD150+CD48-CD34- cells was demonstrated by similar label-retaining ex-
periments (Wilson et al., 2008). Mice were treated with BrdU for 10-13 days followed by
a BrdU-free chase for up to 306 days. After 13 days almost all cellswithin the LSK fraction
were labelled with BrdU, as BrdU itself induced cycling of these cells. After a chase of 70
days around 30% of HSCs retained the BrdU label and after 306 days, therewere still ap-
proximately 5% BrdU+ label-retaining cells (LRCs) detectable. These results could be re-
produced in anothermousemodel, expressing a histone H2B-GFP fusion protein under
the control of a tetracycline-responsive regulatory element. Using mathematical mod-
elling two populations of HSCs were predicted: a dormant population (d-HSCs), cycling
only every 145 days and representing around 15% of all HSCs and an active population
(a-HSCs), cycling approximately every 36 days. Furthermore, it was shown that only the
dormant fraction of HSCs was able to ensure long-term multi-lineage engraftment in
transplantation experiments (Wilson et al., 2008). Amore thoroughmathematical anal-
ysis of thedata producedbyWilson et al. revealed an evenhigher proportionof dormant
HSCs, namely 30-45%, which are dividing every 149-193 days (van derWath et al., 2009).
Another study, however, suggests that dormant as well as cycling HSCs are able to long-
term reconstitute lethally irradiated recipients to the same extend (Takizawa et al., 2011).
In this study, LSK cells were isolated and labeled with CFSE, to track single cell divisions,
before transplanting them into non-irradiated recipients. Analysis of the divisional his-
tory of the transplanted cells revealed a population of cells that did not divide within 21
weeks. This population of cells that had not divided was compared to≥5x-divided cells
that had divided ve times or more within 7 or 12-14 weeks, in transplantation assays.
Surprisingly the ≥5x-divided cells were able to long-term repopulate the recipients in
serial transplantations. Furthermore, these cells were able to give rise to a population
of non-cycling HSCs after transplantation (Takizawa et al., 2011). These results suggest
that not only the dormant HSCs are able to long-term reconstitute a lethally irradiated
recipient. However, the initial isolation and labelling of the LSK cells before transplan-
tation may alter their cycling behaviour and therefore the results may not reect the
actual homeostatic conditions. A recently published study, shows that the divisional
history of HSCs is a better measure of HSC function than their cell-surface phenotype
(Qiu et al., 2014). This study suggests that HSCs loose their functional activity after a few
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cell divisions andmight not return to full dormancy after they have been activated. Fur-
thermore, a fraction of CD34+ cells, with robust self-renewal potential, was identied
within the population of dormant HSCs. Nevertheless, this fraction was outperformed
by CD34- dormant HSCs in secondary transplantations, suggesting a hierarchical struc-
ture within the population of dormant HSCs with the LSK CD150+CD48-CD135-CD34-
cells at the top of the hierarchy (Qiu et al., 2014). The balance between quiescence and
cycling is a critical factor, to ensure the maintenance of long-term HSCs able to self-
renew and replenish the system during the whole life of an animal.
Regulation of HSC cycling
The balance between the dormant and the activated state of HSCs needs to be tightly
regulated, not only to prevent HSC exhaustion, but to enable fast replenishment of the
system upon injury. Many intrinsic and extrinsic factors have been proposed to have a
role in the maintenance of HSC quiescence or in the activation of dormant HSCs into
cycle. The decision, for a cell to progress into an active cell cycle or to return to qui-
escence is made during early G1 phase and is inuenced by growth factors (reviewed
in Sherr and Roberts, 1999). These growth factors activate the expression of D cyclins,
which form a complex with the cyclin dependent kinases (CDK) 4 or 6. This complex
phosphorylates the transcriptional repressor Retinoblastoma (Rb), leading to an activa-
tion of the transcription factor E2F and the progression from early G1 to late G1 phase. A
further phosphorylation of Rb by a cyclinE-CDK2 complex leads to an additional tran-
scriptional activation of genes necessary for the progression into S phase. This process
is regulated by antagonising CDK inhibitors (CDKi) of two families: the INK4 and the
Cip/Kip family. The INK4 family consists of p15Ink4b, p16Ink4a, p18Ink4c and p19Ink4d and
targets the CDK4 and CDK6 complexes. The Cip/Kip family targets the CDK2 complex,
as well as the CDK4/6 complexes, and contains the CDKis p21, p27 and p57 (reviewed
in Sherr and Roberts, 1999). The role of these regulators in HSC quiescence has been
investigated in various knockout models. Mice decient for the three cyclinD kinases
or CDK4 and CDK6 die during embryogenesis due to haematopoietic failure and the fe-
tal liver HSCs from these mice show severe defects in self-renewal (Kozar et al., 2004;
Malumbres et al., 2004; Pietras et al., 2011). These studies indicate that the D cyclins,
as well as CDK4/6 are necessary for active cycling of HSCs during embryogenesis. The
role of these proteins in adult HSCs, however, remains to be further elucidated. Many
studies have been performed to investigate the role of the CDKis in establishing and
maintaining HSC quiescence. While p21 seems so have a role in the stress response of
HSCs, rather than during homeostasis, p57 has been strongly implicated to be a main
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player in HSC quiescence. Apart from high expression in HSCs, deletion studies have
revealed a necessity for p57 in the establishment of HSC quiescence (Matsumoto et al.,
2011; Zou et al., 2011). Conditional knockout of p57 using the MxCre model, led to a sig-
nicant reduction in HSC and progenitor numbers, increased apoptosis in these cells
as well as defects in the self-renewal capacity of HSCs (Matsumoto et al., 2011). An im-
paired repopulating activity of fetal liver HSCs from p57-decient mice has been shown
(Zou et al., 2011). Furthermore, it was shown that p57 inhibits the cyclinD/CDK4/6 com-
plex, by binding cyclin D and inhibiting its transport into the nucleus. Only following
release from p57, cyclin D can be transported into the nucleus, were it forms a complex
with CDK4/6, leading to an active cell cycle (Zou et al., 2011). In both of these studies,
p57-deciency led to a defect in HSC quiescence and self-renewal (Matsumoto et al.,
2011; Zou et al., 2011). However, the question remains whether p57 is only necessary to
establish quiescence after cycling of HSCs or whether it is also required to maintain the
quiescent state. As the results were obtained in cycling HSCs, after induction of Cre ex-
pression with pIC or in fetal liver HSCs, these studies point toward a role of p57 in the
establishment of quiescence after cycling of HSCs. If p57 also has a role in maintaining
the HSCs in their quiescent state needs to be further investigated (reviewed in Tesio and
Trumpp, 2011). In addition to the CDKis, the transcriptional repressors of the Rb family,
Rb, p107 and p130, known to play a role in the transition from early to late G1 phase have
also been implicated in the maintenance of HSC quiescence. While deciency in either
of the three family members does not lead to a severe phenotype, conditional knockout
of all three led to increased HSC proliferation, as well as self-renewal defects. This data
shows that the Rb family members collectively have a role in maintaining HSC quies-
cence (Viatour et al., 2008; Pietras et al., 2011). Apart from these intrinsic factors, many
extrinsic factors have been proposed to have a role in maintaining HSC quiescence.
1.1.5. Maintenance of HSC self-renewal and reconstitution potential
The self-renewal ability of HSCs is closely linked to their dormant state, while differ-
entiation is accompanied by increased proliferation. Many factors have been proposed
to be involved in themaintenance of HSC functions ranging from cytokines to signalling
pathways. The role of three signalling pathways has been extensively studied: the TGF-β
pathway, the Pten/Akt pathway and theWnt signalling pathway (reviewed in Rossi et al.,
2012). Deletion of different components of the TGF-β signalling pathway have varying
effects on HSCs. While knockout of the TGF-β type I receptor led to embryonal lethality
of mice, no effects on haematopoiesis were detected in fetal or in adult HSCs (Larsson
et al., 2001, 2003), suggesting that signalling through this receptor is not essential for
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haematopoiesis and HSCmaintenance. In constrast, the conditional deletion of Smad4,
a downstream signalling component of the TGF-β pathway, resulted in self-renewal de-
fects of adult HSCs (Karlsson et al., 2007). Furthermore, deletion of TGF-β2 led to a de-
crease in HSC repopulating ability of adult HSCs and a defect in fetal liver HSCs upon
serial transplantation (Langer et al., 2004). In addition, niche secreted TGF-β has recently
been shown to regulate HSC dormancy (Yamazaki et al., 2009). All of these ndings sug-
gest that TGF-β is a positive regulator of HSC function. The role of the Akt signalling
has been studied using various knockout models. Double-knockout of Akt1 and Akt2
signicantly impairs HSC function in competitive transplants and maintenance of LT-
HSCs. Furthermore, the HSCs in these mice displayed increased quiescence (Juntilla
et al., 2010). In accordance with these ndings, the deletion of a negative regulator of
Akt signalling, Pten, led to increased cycling of HSCs, loss of LT-HSCs and development
of myeloproliferative disorders, ultimately resulting in leukaemia (Yilmaz et al., 2006;
Zhang et al., 2006b; Guo et al., 2008). A recent study suggests that these effects are due
to an increased production of G-CSF by myeloid cells, leading to the mobilisation of
HSCs, splenomegaly and myeloproliferative disease and do not display a direct effect
of Pten-loss in HSCs (Tesio et al., 2013). Furthermore, mice decient for FoxO proteins,
which are negatively regulated by Akt signalling, display a phenotype very similar to
Pten-decientmice. Thesemice show decreased repopulating activity due to increased
cycling, but do not develop leukaemia (Tothova et al., 2007). Deletion of FoxO3a alone
already leads to loss of reconstitution ability, manifested in serial transplantation, sug-
gesting a regulatory role of FoxOs in HSC self-renewal (Miyamoto et al., 2007). Contro-
versial results have been obtained during the investigation of the role of Wnt signalling
in HSC maintenance. While Mx-Cre-mediated β-catenin deletion resulted in normal
HSC repopulation and self-renewal (Cobas et al., 2004), the Vav-Cre-induced deletion
of β-catenin led to decreased long-term repopulating ability (Zhao et al., 2007). As Vav-
Cre deletion takes place during fetal haematopoiesis, this result might reect a differ-
ential requirement for β-catenin in haematopoiesis during embryogenesis and in adult
mice. Interestingly, constitutive active β-catenin in adult mice led to a severe disrup-
tion of HSC function and a block in differentiation (Kirstetter et al., 2006; Scheller et al.,
2006). In accordance with these results, Wnt3a-null mice have reduced numbers of
fetal liver HSCs, with a severe impairment of reconstitution in serial transplantations
(Luis et al., 2009). Apart from the direct signalling components of the Wnt signalling
pathway, some studies analysed the role of inhibitors of Wnt signalling in HSC mainte-
nance. Loss of the transcription factor Sox17 led to a decrease in fetal liver HSCs, while
having minimal impact on adult HSCs (Kim et al., 2007). Furthermore, the conditional
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deletion of Apc, another negative regulator ofWnt signalling, led to increased cycling of
adult HSCs and progenitors, leading to bonemarrow failure, as well as exhaustion of the
pool of myeloid progenitors and LMPPs (Qian et al., 2008). Two other studies analysed
the effects of overexpression of two inhibitors ofWnt signalling in osteoblasts. Overex-
pression of Dkk1 led to increased cycling and reduced regeneration potential of HSCs
(Fleming et al., 2008). Similarly, overexpression of Wif1 led to loss of HSC quiescence
and decreased self-renewal (Schaniel et al., 2011). In summary, these studies suggest dif-
ferential roles for Wnt signalling in the fetal and the adult haematopoiesis, but clearly
show that a tight regulation ofWnt signalling is essential to preserveHSC function. Apart
from these signalling pathways, a number of cytokines have been suggested to be in-
volved in the regulation of HSC function. Stem Cell factor (SCF), Thrombopoietin (TPO),
Flt3-ligand, IL-3, IL-6, IL-11 and granulocyte colony-stimulating factor (G-CSF) have been
initially identied to promote the expansion of humanHSCs in culture (Bhatia et al., 1997;
Conneally et al., 1997; Miller and Eaves, 1997; Gammaitoni et al., 2003), a method used in
the clinics to increase the number of HSCs prior to bone marrow transplantation. SCF
and TPO have been shown to have a role in the maintenance of HSCs in vivo, where the
HSCs of Scf -decient Steel mice are unable to maintain long-term repopulating activ-
ity (McCarthy et al., 1977). Furthermore, mice lacking the receptor for SCF, c-Kit, show
reduced numbers of LT-HSCs, as well as a progressive depletion of HSCs in competitive
as well as non-competitive transplantations, due to increased cycling of HSCs (Thoren
et al., 2008). The phenotype of kit-mutant mice can be of use for transplantation assays.
A mouse line was generated, which lacks T and B cells (Rag2-/-) as well as NK cells (re-
ferred to as γc-/-) and is HSC-decient due to a kit-mutation (KitW/Wv). This mouse was
called Rag2-/-γc-/-KitW/Wv and enables the transplantation of HSCs without irradiation
(Waskow et al., 2009). As irradiation is amajor source of bonemarrow stress, thismouse
linewill help to investigate the behaviour and function of transplantedHSCs under con-
ditions that more closely resemble the homeostatic situation. Loss of the receptor for
TPO, cMPL, led to defects in reconstitution potential and self-renewal of HSCs (Kimura
et al., 1998). Reduced expansion of HSCs following transplantation and accelerated cy-
cling kinetics of HSCs was the consequence of loss of TPO itself, implicating a role for
TPO signalling in HSC expansion upon transplantation as well as the maintenance of
quiescence (Qian et al., 2007). Another cytokine suggested to have a role in the main-
tenance of HSCs is Angiopoietin-1 (Ang-1). It has been shown that signalling of Ang-1
through the receptor Tie2 is required for adult hematopoiesis, while it is dispensable
for fetal haematopoiesis (Takakura et al., 1998; Puri and Bernstein, 2003). More speci-
cally, Tie2 has been shown to mark a quiescent subset of HSCs, which can be found in
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close contact to osteoblasts in the bone marrow niche (Arai et al., 2004). Furthermore,
Ang-1 has been shown to enhance the ability of HSCs to become quiescent and adhere
to the bone, suggesting a role for Tie2/Ang-1 signalling in the maintenance of HSCs in a
quiescent state in the bone marrow niche (Arai et al., 2004). Cxcl12 has been suggested
as a master regulator of HSC migration and retention in the bone marrow and seems
to be especially important for the homing of HSCs to fetal and adult haematopoietic
sites (McGrath et al., 1999). Loss of Cxcr4, the receptor of Cxcl12, leads to hyperprolifera-
tion (Nie et al., 2008) and mobilisation (Christopher et al., 2009) of HSCs. These studies
show that the regulation of HSC self-renewal and differentiation is critically mediated
by several pathways and factors. Furthermore, this regulationmay be dependent on the
localisation of the HSCs within the bone marrow niche.
1.1.6. HSCs reside in specialised niches within the bone marrow
Figure 1.2.: HSCs may reside within two distinct niches
Two HSC niches have been proposed: the endosteal niche, most likely harbouring the quiescent (dormant)
HSCs and the perivascular niche, suggested to harbour the homeostatic HSCs. Different cell types have
been implied to make up the bone marrow niche, including osteoblasts, macrophages, CAR cells, nestin+
MSCs and endothelial cells. The cells of the bonemarrow niche interact with HSCs through soluble factors,
such as CXCL12 and TPO, as well as through cell-cell-interaction via for example Ang-1/Tie2 or SCF/c-Kit.
(modied from Ehninger and Trumpp, 2011)
The bone marrow environment, the so called BM niche, is essential for the mainte-
nanceofHSCquiescence and self-renewal. HSCs in thebonemarroware foundnear the
endosteum and/or near the sinusoidal endothelium. Therefore, two niches have been
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proposed: the endosteal niche, harbouring quiescent HSCs with high repopulation ac-
tivity (Zhang et al., 2003; Grassinger et al., 2010) and the perivascular niche, harbouring
most of the LSKCD150+ cells (Kiel et al., 2005), however this concept is still under discus-
sion. Over the years, several cell types have been proposed tomake up these niches and
thereby maintain HSCs. Osteoblastic cells were suggested to be part of the HSC niche,
as numbers of osteoblasts strongly correlate with HSC numbers in the bone marrow
(Zhang et al., 2003; Calvi et al., 2003; Visnjic et al., 2004). These cells are mainly found
in the endosteal niche and produce factors, like CXCL12 (Ponomaryov et al., 2000), that
support HSCmaintenance, as well as adhesionmolecules that may facilitate HSC-niche
interactions. These data support the hypothesis that osteoblasts are part of the niche,
how they regulate HSC maintenance is however not completely understood (reviewed
inMercier et al., 2012). Interestingly, G-CSF-inducedmobilisationofHSCs from thebone
marrow to the blood stream is accompanied by loss of osteoblasts and a decrease in fac-
tors required for HSC maintenance (Christopher et al., 2009; Winkler et al., 2010). This
effect has been furthermore shown to be due to loss of trophic endosteal macrophages
(osteomacs), as depletion ofmacrophages led to decreased osteoblast numbers andHSC
mobilisation comparable to G-CSF treatment (Winkler et al., 2010). Further evidence
for this nding was provided by specic depletion of CD169+ macrophages from the
bone marrow, which also led to mobilisation of HSCs (Chow et al., 2011). Additionally, it
was shown that G-CSF signalling inmyeloid cells alone is sufcient to induce osteoblast
suppression and HSC mobilisation (Christopher et al., 2011). All of these ndings sup-
port the hypothesis that macrophages have a role in the HSC niche. Another type of
immune cell has recently been suggested to be part of the HSC niche. Another type
of immune cell, regulatory T cells are found in co-localisation with HSCs in the bone
marrow. These cells seem to participate in the formation of a zone where HSPCs re-
side and might be protected from immune attack (Fujisaki et al., 2011). Furthermore,
CXCL12-abundant reticular (CAR) cells have been proposed to be part of the HSC niche.
These cells are found in close proximity to HSCs and are located in the perivascular as
well as in the endosteal region of the bone marrow (Sugiyama et al., 2006). Depletion
of CAR cells leads to reduced numbers of HSCs and increased HSC quiescence (Omatsu
et al., 2010). A population of cells very similar to these CAR cells, but less abundant, are
Nestin+ mesenchymal stem cells (MSCs). These cells are spatially associated with HSCs
and adrenergic nerve bres, which have been shown to play a role in the retention of
HSCs in the bone marrow (Katayama et al., 2006; Mendez-Ferrer et al., 2008). Deple-
tion of Nestin+ MSCs leads to reduced numbers of HSCs in the bone marrow as well
as reduced homing of transplanted HSCs (Mendez-Ferrer et al., 2010). Whether these
16
1. Introduction
Nestin+ MSCs represent a subpopulation of CAR cells is not clear yet. The contribu-
tion of these Nestin+ MSCs to the HSC niche has been challenged by two studies, show-
ing that deletion of Cxcl12 in these cells does not impair HSC numbers and frequency
(Ding andMorrison, 2013; Greenbaum et al., 2013). However, it has to be further investi-
gated whether this excludes a role for these cells in the BM niche (Hanoun and Frenette,
2013). The conditional deletion of Cxcl12 in several other cell types revealed a role for
CXCL12 expressed by endothelial and stromal cells in the maintenance of HSCs in the
bone marrow, suggesting that HSCs are mainly residing in the perivascular niche (Ding
andMorrison, 2013; Greenbaum et al., 2013). As these studies only assessed the number
of LSK CD150+CD48- cells, this does not exclude that quiescent HSCs are located in the
endosteal niche. Nevertheless, there are multiple lines of evidence suggesting a vascu-
lar contribution to the HSC niches. First, generation of HSCs occurs in association with
vascular areas and blood ow during embryonic development. Second, extramedullary
haematopoiesis in humans occurs in perivascular areas during haematopoietic stress.
Third, HSCs have been observed in the vicinity of sinusoids (Kiel et al., 2005) and en-
dothelial cells have been shown to express molecules that facilitate HSC homing and
mobilisation (reviewed in Mercier et al., 2012). Endothelial cells have been implicated to
support long-term HSCs through direct cellular contact as well as through the produc-
tion of factors that promote haematopoiesis and adhesion molecules that are thought
to facilitate HSC homing (Rai et al., 1997; Li et al., 2004; Sipkins et al., 2005; Butler et al.,
2010; Kobayashi et al., 2010). A recent study provided more evidence for the hypothe-
sis, that quiescent and proliferating HSCs reside in distinct niches (Kunisaki et al., 2013).
This study identied arterioles, lined by a rare subset of Nestin+ MSCs, called periarteri-
olar Nestin cells (Nesperi), to be found in close proximity to quiescent HSCs. In addition,
the study provided insight into the behaviour of HSCs upon activation, as treatment of
mice with polyinosinic-polycytidylic acid (polyI:C) or G-CSF led to a signicant reduc-
tion of the number of HSCs found in proximity to these arterioles. Furthermore, it was
shown that depletion of a subset of these Nesperi cells expressing the pericyte marker
NG2, led to a signicant increase in HSC cycling, as well as a reduction of HSC number
and frequency, observed in the bone marrow as well as the spleen, suggesting that de-
pletion of NG2+ Nesperi cells led to a loss of HSCs, rather than to their mobilisation. This
study suggests that arterioles form niches that are indispensable for themaintenance of
HSC quiescence (Kunisaki et al., 2013). Nonetheless, the existence of two distinct niches
as well as the contributing cell types to the bone marrow niche are still controversially
discussed.
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1.2. The response of HSCs to infection
During infection, mature immune cells are lost, either due to mobilisation to the in-
fected tissue or due to cell death (reviewed in King and Goodell, 2011a). To ensure fast
replenishment of the system haematopoiesis is induced by haematopoietic stem and
progenitor cells upon infection. The mechanisms how HSPCs can sense the infection
have been widely discussed. As HSPCs are usually not directly infected, a direct infec-
tion of HSCs is unlikely to be the cause of increased haematopoiesis (Johns et al., 2009;
Baldridge et al., 2010; King and Goodell, 2011a). More likely, however, is a direct sensing
of pathogens byHSPCs or an alteration of HSPC behaviour in response to cytokines pro-
duced upon infection. These two possibilities have been subject of numerous studies
and evidence has been provided for both scenarios.
1.2.1. The role of TLR signalling in innate immunity
The immune system of mammals consists of two major subsystems, the innate im-
munity, which builds the rst line of defence against invading pathogens, and the adap-
tive immunity, which is responsible for the elimination of pathogens in the late phase
of the immune response and the generation of an immunological memory (reviewed in
Mogensen, 2009). The innate immune system is based on physical and chemical barri-
ers to infection as well as cell types recognising pathogens through pattern-recognition
receptors (PRRs) (reviewed in Mogensen, 2009; Lester and Li, 2014). Toll-like receptors
(TLRs) are the best studied PRRs and are involved in the response to various pathogen-
associatedmolecular patterns (PAMPs). TLRs are type I transmembrane proteinswith an
ectodomain containing leucin-rich repeats that mediate the recognition of PAMPs and
an intracellular Toll/Interleukin 1 (IL-1) receptor (TIR) domain, which is conserved among
TLRs, aswell as in the IL-1 receptor (reviewed in Kawai andAkira, 2010; Akira and Takeda,
2004). In mice, twelve different TLRs are known, which can be categorised into extra-
cellular (TLR1, TLR2, TLR4, TLR5, TLR6 and TLR11) and intracellular (TLR3, TLR7, TLR8
and TLR9) TLRs. The extracellular TLRs mainly recognise microbial membrane com-
ponents, while the intracellular TLRs, which are localised in the endoplasmatic reticu-
lum (ER), endosomes, lysosomes or endolysosomes, recognise nucleic acids (reviewed
in Kawai and Akira, 2010). Specically, TLR2 forms complexes with either TLR1 or TLR6,
which bind to components of the microbial cell walls and membranes, like lipopro-
teins and peptidoglycans (Ozinsky et al., 2000; Takeuchi et al., 2001, 2002; Alexopoulou
et al., 2002; Travassos et al., 2004). TLR4 is the main receptor of lipopolysaccharide
(LPS) recognition (Poltorak et al., 1998; Qureshi et al., 1999; Hoshino et al., 1999), while
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TLR5 binds agellin (Hayashi et al., 2001), a component of bacterial agella. Of the in-
tracellular TLRs, TLR3 binds double-stranded RNA (dsRNA) (Alexopoulou et al., 2001),
like polyI:C, while TLR7 and TLR8 bind single-stranded RNA (ssRNA) (Heil et al., 2004;
Diebold et al., 2004). Furthermore, TLR9 binds unmethylated CpG DNA (Hemmi et al.,
2000), which is mimicked by synthetic CpG oligodeoxynucleotides (CpG ODNs). These
unmethylated CpG motifs are highly abundant in microbial genomes, but very rare in
the mammalian genome. Activation of TLRs leads to the recruitment of different adap-
tor proteins, namely myeloid differentiation primary response gene 88 (MyD88), TIR-
domain containing adapter-inducing interferon-β (TRIF), TIR-domain containing adap-
tor protein (TIRAP) or TRIF-related adaptor molecule (TRAM). These adaptors induce
two different pathways of TLR signalling: the MyD88-dependent pathway, involving
MyD88 and TIRAP, and theMyD88-independent pathway, involving TRIF and TRAM (re-
viewed in Kawai and Akira, 2010). All TLRs, except for TLR3, use the MyD88-dependent
pathway. The MyD88-independent pathway, is only used by TLR3 and TLR4. Activation
of the MyD88-dependent pathway mainly leads to the production of inammatory cy-
tokines, whereas the activation of theMyD88-independent pathway leads to production
of type I IFNs and inammatory cytokines (reviewed in Kawai and Akira, 2010). Upon
PAMP recognition MyD88 is recruited to the TIR domain of the TLR, leading to an asso-
ciationwith interleukin-1 receptor associated kinase (IRAK) 4, which in turn recruits and
phosphorylates IRAK1. The phosphorylation of IRAK1 leads to a subsequent autophos-
phorylation and the binding of TNF receptor associated factor 6 (TRAF6). Through acti-
vation of TAK1, a member of the mitogen-activated protein kinase kinase kinase (MAP-
KKK) family, TRAF6 induces the activation of IκB kinase (IKK) complex, leading to a
phosphorylation of inhibitors of κB (IκBs) and subsequent activation of nuclear factor
’kappa-light-chain-enhancer’ of activated B cells (NFκB) signalling and the production
of inammatory cytokines (reviewed in Akira and Takeda, 2004). Upon TLR3 and TLR4
signalling another pathway is activated by recruitment of TRIF to the TLR. TRIF sub-
sequently recruits TRAF6 and TAK1 for NFκB activation, as well as TBK1-IKKi through
TRAF3, which catalyses the phosphorylation of interferon regulatory factor 3 (IRF3) (re-
viewed in Kawai and Akira, 2010). IRF3 translocates to the nucleus upon phosphoryla-
tion, where it binds the co-activators p300 and CBP, leading to the activation of type I
IFN gene expression. The IFNs in turn activate IFN inducible genes like cxcl10 and irg1.
Furthermore, IRF3 activates IRF7, which amplies the activation of type I IFNs (reviewed
in Akira and Takeda, 2004). Apart from activating IRF3, TRAF3 also inhibits the MyD88-
dependent pathway (reviewed in Kawai and Akira, 2010). TLR4 is the only TLR, that uses
both the MyD88-dependent, as well as the MyD88-independent pathway. TLR4 binds
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LPS in a complex with MD2, involving the LPS-binding protein (LBP), that binds soluble
LPS, and CD14, which binds the LBP-LPS complex and delivers it to the TLR4-MD2 com-
plex. TLR4 initially recruits MyD88 and triggers activation of NFκB and MAPKs. Subse-
quently, TLR4 undergoes endocytosis, trafcking to endosomes, where it recruits TRAM
and TRIF, leading to IRF3 and late-phase NFκB activation. Interestingly, MyD88 as well
as TRIF activation is necessary for the TLR4 induced production of inammatory cy-
tokines, while the other TLRs can induce inammatory cytokines by solely using the
MyD88- or the TRIF-dependent pathway (reviewed in Kawai and Akira, 2010). In sum-
mary, TLR signalling leads to the production of inammatory cytokines and interferons,
which are important to mediate the innate immune response to an infection, as well as
the transition from the innate to the adaptive immunity.
1.2.2. The effects of TLR signalling on HSC behaviour and function
It has been shown that HSCs and haematopoietic progenitors express TLRs, like TLR2
and TLR4, and can directly respond to stimulation with TLR ligands (Nagai et al., 2006;
Megías et al., 2012; Zhao et al., 2014). Many studies have provided insights into the effects
of TLR signalling on HSPCs. Common to most of these studies is the increased cycling
of HSPCs in response to infections or direct TLR stimulation, as well as an increase in
mobilisation of HSPCs to the periphery and differentiation towards the myeloid lineage
(Zhang et al., 2008; Yanez et al., 2009, 2010; Takizawa et al., 2011; Esplin et al., 2011). A
skewing of HSPC differentiation towards the myeloid lineage, as well as the production
of cytokines in response to treatment with TLR ligands or pathogens in vitro has also
been shown for human HSPCs (Kim et al., 2004; Sioud et al., 2006; Singh et al., 2008),
suggesting that human HSPCs might react similar to infections as murine HSPCs. An-
other common alteration of HSC behaviour is a reduced repopulation capacity of HSCs
that have been exposed to chronic infection or chronic treatment with TLR ligands (Ro-
driguez et al., 2009; Chen et al., 2010; Takizawa et al., 2011; Esplin et al., 2011). More specif-
ically, it has been shown that LPS stimulation in vivo leads to an expansion of the HSC
pool, due to increased cycling (Zhang et al., 2008; Rodriguez et al., 2009; Takizawa et al.,
2011; Esplin et al., 2011), accompanied by a loss of repopulation potential upon chronic
TLR4 activation (Rodriguez et al., 2009; Takizawa et al., 2011; Esplin et al., 2011). Further-
more, several studies have suggested that LPS treatment in vitro aswell as in vivo leads to
amyeloid skewing of HSC differentiation, leading to an increased production ofmyeloid
cells (Nagai et al., 2006; Esplin et al., 2011; Megías et al., 2012). In addition, it has been pro-
posed that the increased differentiation towards macrophages upon LPS stimulation is
due to a direct activation of TLR4 signalling in the HSCs (Megías et al., 2012). Together,
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Figure 1.3.: Overview of different signalling pathways
The signalling pathways of TLRs, the IL-1RI and the TNFR1 show high similarities. TLR as well as IL-1RI use
MyD88 as an adaptormolecule leading to the recruitment of IRAKs and TRAF6 and a subsequent activation
of MAPK and NFκB signalling. TNFR1 does not utilise MyD88, but also activates MAPK and NFκB signalling
through RIP1 and TRAF2. Apart from the MyD88-dependent pathway TLR4 can signal via TRIF, leading to
the activation of IRF3 and subsequent production of interferons, which in turn lead to the induction of IFN
inducible genes, like cxcl10. All of these pathways ultimately lead to the regulation of genes involved in the
production of inammatory cytokines, cell proliferation and differentiation (reviewed in Akira and Takeda,
2004; Borden et al., 2007; Bradley, 2008; Weber et al., 2010; Kawai and Akira, 2010).
these studies suggest that LPS activates HSCs into cycle, leading to their differentiation
towards myeloid cells, likely through direct activation of TLR4 signalling in HSCs. How-
ever, most of these studies do not rule out a indirect effect of cytokines produced by
other cells due to TLR signalling as the cause of the effects on HSC behaviour. Indeed,
many studies have provided evidence for the role of inammatory cytokines in the reg-
ulation of HSC proliferation, differentiation and self-renewal.
1.2.3. The role of inflammatory cytokines in immunity and their effects on HSCs
The activation of TLR signalling, as well as other pathways activated during the in-
nate immune response, lead to the production of several cytokines, performing various
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functions during infection and inammation. The role of these cytokines in the promo-
tion of the immune response has been intensively studied. More recently, some of these
cytokines have also been implicated to have a role in the regulation of HSC function.
Interferons (IFNs)
IFNs are mainly produced by plasmacytoid dendritic cells (pDCs) (Perussia et al., 1985;
Asselin-Paturel et al., 2003) upon activation of theMyD88-independent pathway of TLR
signalling, through the activation of IRF3 (reviewed in Kawai and Akira, 2010). Although
IFNs have been initially identied, as they are produced upon viral infections, it is known
today that they also play a crucial role during bacterial infections (reviewed in Decker
et al., 2005). Two groups of IFNs can be distinguished: the type I interferons, includ-
ing IFNα and IFNβ, and type II interferons, namely IFNγ. The type I IFNs are bound by
a receptor complexed formed by heterodimerization of IFNAR1 and IFNAR2 upon lig-
and binding, while IFNγ binds to the IFNGR1 or IFNGR2, also leading to formation of a
receptor-complex by heterodimerization. Upon activation the receptors bind different
Janus kinases (JAKs), leading to their phosphorylation and subsequent activation of sig-
nal transducers and activators of transcription (STATs). Upon activation of IFNAR, STAT1
and STAT2 dimerize and are released from the receptor. Subsequently the STAT1-STAT2
complex translocates to the nucleus, where it binds IRF9, leading to the formation of the
IFN-stimulated gene factor 3 (ISGF3), which binds to IFN-stimulated response elements
in the promoter regions of IFN-stimulated genes (ISGs), leading to their transcription.
Apart from the inhibition of viral reproduction, IFNs lead to the expression ofMHC class
I and class II molecules, the production of adhesion molecules and chemokines, to in-
duce recruitment of leukocytes, and mediate the activation of cytotoxic effector func-
tions among cells of the innate and the adaptive immune system (reviewed in Borden
et al., 2007; Ivashikiv and Donlin, 2014). In more detail, various ISGs lead to the inhibi-
tion of virus replication, translation of viral genes and can ultimately induce apoptosis of
infected cells. An example of an ISG isMx1 (Horisberger et al., 1983; Staeheli et al., 1986).
Mx proteins interferewith intracellular trafcking and activity of viral polymerases, thus
inhibiting replication of many RNA viruses (reviewed in Haller et al., 2007). The IFN-
inducibleMx-promotor in combinationwith a Cre-element is furthermore, used in var-
ious mouse models, to induce conditional deletion of target genes (Kuhn et al., 1995).
Interferons have been shown to directly induce proliferation of HSCs (Essers et al.,
2009; Sato et al., 2009; Baldridge et al., 2010). Short-term treatment ofmicewith the TLR
ligand pIC, inducing the production of IFNα, or direct IFNα treatment led to an increased
proliferation of dormant HSCs dependent on Stat1 signalling (Essers et al., 2009). Apart
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from an increase in cycling of HSCs, an increased expression of Sca-1 could be detected
on the surface of HSPCs. Interestingly, the activation of HSCs with IFNα was not only
accompanied by an upregulation of Sca-1, but also dependent on the presence of Sca-1,
as has been shown using Sca-1-/- mice (Essers et al., 2009). In contrast to the increased
cycling of HSCs in response to short-term pIC treatment, long-term treatment led to re-
duced repopulation and self-renewal capacity in competitive transplants (Essers et al.,
2009; Sato et al., 2009). Similar effects have been shown for IFNγ, identied to be the
cause of HSC alterations in M. avium infections. The HSCs of M. avium infected mice
show increasedmobilisation to the periphery, as well as reduced engraftment potential,
dependent on IFNγ , but not IFNα , signalling. Furthermore, direct stimulation of mice
with IFNγ led to an increased cycling of HSCs, aswell as theirmobilisation to the periph-
ery (Baldridge et al., 2010). These ndings are further supported by two studies showing
that loss of the IFN-inducible immunity related p47 GTPase Irgm1 leads to HSC defects,
due to a dysregulation of IFN signalling (Feng et al., 2008; King et al., 2011b). HSCs of
Irgm1-/- mice show increased expression of IFN-inducible genes, leading to increased
cycling and impaired engraftment (Feng et al., 2008; King et al., 2011b). These effects can
be rescued by additional deletion of Stat1, leading to impaired IFN signalling, showing
that the HSC defects are caused by the increased IFN signalling in Irgm1-/- mice (King
et al., 2011b). A recently published study has challenged these ndings, proposing that
IFNγ has anti-proliferative effects on HSCs, however the ndings of this study are based
on reducednumbers of LSK cells after in vitro treatmentwith IFNγ and reduced engraft-
ment potential of these cells (de Bruin et al., 2013). Therefore, the ndings are actually
in agreement with the earlier studies, showing that excessive IFN signalling leads to ex-
haustion of the HSC pool. Furthermore, the nding that IFNγ treatment in vitro leads to
decreased cycling of HSCs might be due to a requirement of the niche environment to
induce activation of HSCs (King et al., 2013; Prendergast and Essers, unpublished data).
Tumour necrosis factor alpha (TNFα)
TNFα is a pro-inammatory cytokines produced upon infection, in part through TLR
signalling. TNFα can be produced by various types of cells, including endothelial cells,
broblasts and osteoclasts, but mainly monocytes and macrophages. TNFα is initially
expressed as pro-TNFα in amembrane-bound form, but can be released through cleav-
age, mediated by the TNFα converting enzyme (TACE), resulting in a soluble form of
TNFα. TACE can not only mediate the cleavage of pro-TNFα , but also the cleavage of its
receptor, leading to a neutralisation of TNFα action. TNFα can bind to two distinct recep-
tors, TNFR1 (TNFRSF1A, p55) mainly mediates the pro-inammatory and the apoptosis
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pathway, while binding to TNFR2 (TNFRSF1B, p75) promotes tissue repair and angiogen-
esis. Upon TNFα binding, TNFR1 recruits TNFR-associated death domain (DD) protein
(TRADD), which recruits receptor interacting protein-1 (RIP1) and TRAF2. The TRADD-
RIP1-TRAF2 complex is subsequently released from the receptor and leads to activation
of IκB, through recruitment of MEKK-3 and TAK1, ultimately leading to the activation
of NFκB signalling. Furthermore the TRADD-RIP1-TRAF2 complex recruits apoptosis-
signalling kinase-1 (ASK-1), which activates the MAP2Ks MEK-4 and MEK-6, leading to
the phosphorylation of JNK and p38 MAPK. Phosphorylated JNK subsequently phos-
phorylates c-Jun, a subunit of the transcription factor AP-1, necessary for the interac-
tion with CBP/p300 and gene activation. Many pro-inammatory effects of TNFα can
be explained by TNFα signalling in endothelial cells. In response to TNFα endothelial
cells express adhesion molecules, including ICAM-1, VCAM-1 and E-selectin, and re-
lease chemokines, such as IL-8, MCP-1 and IP-10, subsequently leading to the recruiting
of leukocytes to the site of infection. In addition, TNFα has been shown to be the cause
of lethal sepsis, asmice immunisedwith rabbit-anti serum to TNFαwere protected from
lethal effects of E. coli-derived LPS (reviewed in Bradley, 2008).
The effects of TNFα on the behaviour of HSCs have been controversially reported.
TNFα has been shown to have inhibitory as well as stimulatory effects on HSCs, de-
pendent on the mechanism of interaction (Jacobsen et al., 1992). Many studies report
a reduction in colony-formation as well as in reconstitution potential of HSPCs in re-
sponse to TNFα, for murine as well as for human cells (Broxmeyer et al., 1986; Selleri
et al., 1995; Dybedal et al., 2001; Bryder et al., 2001). Conversely, it has been shown that
HSCs of older p55-/- (TNFR1) mice are decreased in numbers and have a reduced self-
renewal capacity, indicating that signalling through p55 is essential for the regulation
of haematopoiesis at the stem cell level (Rebel et al., 1999). However, a recently pub-
lished study using double-knockout mice for both TNF receptors (Tnfrsf1 dKO) showed
an enhanced repopulation capacity of HSCs from these mice in competitive transplants
(Pronk et al., 2011). Furthermore, it has been shown that repeated TNFα treatment led
to a reduced bonemarrow cellularity as well as a reduced repopulation potential, com-
parable to the effects of long-term IFN treatment (Essers et al., 2009; Sato et al., 2009;
Baldridge et al., 2010). Therefore, the authors of this study proposed that TNFα has an
anti-proliferative effect on HSCs in vivo (Pronk et al., 2011). Nevertheless, many of these
studies have been performed in vitro and none provides information about the direct
effect of short-term TNFα treatment on the cycling behaviour of HSCs.
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CXCL9, CXCL10 and CXCL11
CXCL10, along with CXCL9 and CXCL11, are mainly produced in response to IFN sig-
nalling (reviewed in Borden et al., 2007; Groom and Luster, 2011). CXCL10, as well as
CXCL9 and CXCL11, binds to the CXC chemokine receptor 3 (Cxcr3). Upon activation
Cxcr3 coordinates the inammation, by regulating the generation of effector T cells and
their subsequent migration into the periphery, where the Cxcr3 ligands regulate the in-
teractions of effector T cells in the inamed tissue (reviewed in Groom and Luster, 2011).
A role for CXCL9, CXCL10 or CXCL11 in regulation of HSC function has so far not been
shown.
Interleukin-6 (IL-6)
The expression of IL-6 is triggered by TNFα, IL-1, LPS, viral infections or products re-
leased by necrotic cells, whereby TLR induced production of IL-6 is one of the earliest
events. The primary source of IL-6 aremonocytes andmacrophages, but T cells can also
produce IL-6 during chronic inammation. IL-6 has been proposed as a key signal for
the transition from innate to adaptive immunity, as it regulates various functions of B
and T cells (reviewed in Naugler and Karin, 2008), like B cell growth and antibody pro-
duction (Tanner and Tosato, 1992) and differentiation of T(H)-17 cells (Zhou et al., 2007).
IL-6 has furthermore been suggested to be involved in the regulation ofHSPCs uponTLR
stimulation as well as during autoimmune disease (Zhang et al., 2008; Chen et al., 2010).
IL-6 has been shown to be involved in the expansion of the LSK population upon E. coli
infection, due to increased Sca-1 expression (Zhang et al., 2008). Furthermore, IL-6 has
been shown to be involved in mTOR mediated HSC defects, observed in autoimmune
disease (Chen et al., 2010).
Interleukin-1 beta (IL-1β) and IL-1α
IL-1β belongs to the IL-1 family, which comprises 11 proteins, with IL-1α and IL-1β be-
ing the foundingmembers. While IL-1α is primarily membrane bound, IL-1β is secreted.
Both IL-1α and IL-1β bind to the type I IL-1 receptor (IL-1RI), which is ubiquitously ex-
pressed. The activation of IL-1 signalling is regulated by a third ligand of IL-1RI, IL-1
receptor antagonist (IL-1RA), which binds to IL-1RI with the same afnity as IL-1α and
IL-1β , but does not induce downstream signalling. Furthermore, a second receptor, the
type II IL-1 receptor (IL-1RII), binds IL-1α and IL-1β , but lacks the signalling competent
cytosolic part, thereby serving as a decoy receptor. Upon ligand binding, the IL-1RI un-
dergoes a conformational change, leading to the recruitment of IL-1 receptor accessory
protein (IL-1RAcP) and the subsequent recruitment of MyD88 and IRAK4, through the
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TIR domain of the receptor. The phosphorylation of IRAK4 induces a signalling cas-
cade, very similar to theMyD88-dependent signalling pathway of TLRs. Phosphorylated
IRAK4 activates IRAK1 and IRAK2, leading to the recruitment of TRAF6. Subsequently,
the IRAK1-IRAK2-TRAF6 complex is released from the receptor and leads to activation
of the NFκB, JNK and p38 MAPK pathways, resulting in the activation of IL-1 inducible
genes, like IL-6, MCP1, PGE2 and COX2 (reviewed in Weber et al., 2010). Results of the
IL-1β regulated gene expression are fever, lowered pain threshold and vasodilation. IL-1β
can also lead to increased expression of adhesion molecules on endothelial cells, lead-
ing to recruitment of immune effector cells to the infected tissue. Furthermore, IL-1βhas
been suggested to promote the differentiation of HSCs tomyeloid cells. In addition, IL-1
signalling has been shown to be essential for the development of T(H)-17 cell (reviewed
in Dinarello, 2009). So far, IL-1 signalling has not been shown to have an effect on HSCs.
1.2.4. Activation of NFκB signalling during the innate immune response
Most of the above described cytokine-induced pathways, as well as TLR signalling,
ultimately lead to the activation of NFκB signalling and subsequent activation of spe-
cic genes in many different cell types. NFκB signalling is very complex, leading to the
induction of hundreds of genes and can be induced by myriads of biochemical mecha-
nisms (reviewed in Baltimore, 2011). LPS, as well as TNFα and IL-1β, lead to the activa-
tion of the canonical pathway of NFκB signalling, through TRAFs and RIP1 (reviewed in
Oeckinghaus et al., 2011). Common to each pathway is the activation of the IKK kinase
complex, consisting of IKKα ,IKKβ and IKKγ (NEMO). The activated IKK complex sub-
sequently phosphorylates IκB, which is bound to NFκB and inhibits its translocation to
the nucleus. Phosphorylation of IκB leads to its ubiquitylation and subsequent protea-
somal degradation, releasing NFκB. NFκB then translocates to the nucleus, leading to
the activation of various genes. Among these NFκB inducible genes is also IκB, serv-
ing as a negative feedback loop to regulate NFκB activity. Binding of IκB to NFκB in the
nucleus, leads to its release from the DNA and its transport to the cytoplasm, where it
is inactivated. NFκB activation is crucial for the induction of the innate, as well as the
adaptive immunity, and regulates various cellular processes, like proliferation and dif-
ferentiation (reviewed in Baltimore, 2011). Upon TLR activation NFκB is involved in the
MyD88-induced production of inammatory cytokines, as well as in the TRIF-mediated
induction of interferons (reviewed in Akira and Takeda, 2004). A recent study has fur-
thermore, proposed that NFκB signalling is required for HSC maintenance (Stein and
Baldwin, 2013). In this study, a conditional deletion of p65 in the haematopoietic sys-
tem led to increased cycling of HSCs, increased numbers of progenitor cells and ex-
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tramedullary haematopoiesis. Furthermore, the HSCs of these mice showed a severe
engraftment defect in competitive transplantation (Stein and Baldwin, 2013). This study
suggests that NFκB is required for HSC maintenance during homeostasis, if NFκB is be-
yond that also required for the response of HSCs to infectious stimuli remains to be
investigated.
1.2.5. HSCs produce cytokines upon infection
Apart from sensing cytokines produced by other immune cells, HSPCs have been re-
cently proposed toproduce a considerable amount of cytokines. Various cytokineswere
produced by ST-HSCs andMPPs upon treatment with TLR ligands at the single cell level,
even trumping mature myeloid and lympoid cells in terms of speed, magnitude and
breadth (Zhao et al., 2014). As HSPCs are constantly circulating through the blood and
lymph to peripheral organs (Massberg et al., 2007), direct production of cytokines in re-
sponse to danger signals might be an elegant way to coordinate rapid haematopoiesis
at sites of infection. This production of cytokines by HSPCs might be especially impor-
tant in situations, where mature cells are lost. Furthermore, it was proposed that HSPCs
in the bone marrow can be subdivided into two groups, one able to sense pathogens
and produce cytokines and the other group able to react to these cytokines and induce
haematopoiesis. This hypothesis is supported by the nding that some LSK cells ex-
press either TLRs or cytokine receptors (Zhao et al., 2014). In summary, all of the above
mentioned studies provide evidence for the importance of HSPCs in the ght agains
infections and the rapid replenishment of the system after the infection is cleared. The
exactmechanisms how the effects of infections onHSCs aremediated, however, remain
to be investigated.
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Many studies have been performed investigating the response of HSCs to infections
mediated through TLR signalling (Kaulen et al., 1983; Nagai et al., 2006; Singh et al., 2008;
Zhang et al., 2008; Yanez et al., 2009, 2010; Takizawa et al., 2011; Esplin et al., 2011; Choi
et al., 2011; Megías et al., 2012). Many of these studies have, however, been performed in
vitro (Nagai et al., 2006; Yanez et al., 2009, 2010). Furthermore, the long-term effect of
TLR activation upon infection or through repeated treatment with TLR ligands has been
extensively analysed (Zhang et al., 2008; Singh et al., 2008; Rodriguez et al., 2009; Tak-
izawa et al., 2011; Esplin et al., 2011; Choi et al., 2011), while the short-term effects of TLR
signalling on the behaviour of HSCs in vivo remain unclear. We aimed to specically
investigate the role of short-term treatment with LPS, a ligand of TLR4, on the cycling
behaviour of HSCs, to analyse the rst response of HSCs to infections, rather than the
long-term outcome of this response. This is especially important as the short-term ef-
fects might be very different from the long-term effects and may help to better under-
stand the cause of the effects seen upon long-term treatment or chronic infections. In
addition, we wanted to analyse the effects of LPS, in comparison to already published
data on the effects of IFNs and other cytokines on HSCs. We have already shown that
HSCs are activated in response to IFNα treatment (Essers et al., 2009), a cytokine typi-
cally produced upon TLR4 signalling. We therefore asked, if this IFNα-mediated activa-
tion of HSCs might be part of a feedback loop induced upon infection. Furthermore, as
the question of whether HSCs can directly respond to infection is not fully investigated
to date, we wanted to analyse if the HSC response to LPS stimulation is directly me-
diated through TLR4 signalling within the HSCs, or indirectly mediated, through TLR4
signalling within another cell type. Thus, we aimed to investigate the response of HSCs
to LPS treatment, as well as the involvement of IFNα and other cytokines in this process,
using genetic mouse models, as well as in vitro approaches. This research gives new
insights into the effects of infections on HSC behaviour and function andmay therefore
help to improve the treatment of chronic infections.
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3.1. Stress induced IFNα production in the bone marrow
Upon bone marrow stress, it is mainly the fast cycling progenitors that are lost and
therefore have to be replenished by HSCs to ensure maintenance of the blood system.
The HSCs can be subdivided into two different populations: the homeostatic and the
dormant HSCs. Homeostatic HSCs are constantly but slowly cycling to ensure themain-
tenance of the haematopoietic system, while dormant HSCs are found in a long-term
quiescent state during homeostasis, but can be rapidly activated in response to bone
marrow injury (Wilson et al., 2008). This activation of dormant HSCs, together with the
production of progenitors by the homeostatic HSCs, ensures fast replenishment of the
system. It has been shown that various forms of bone marrow stress, like 5-FU or G-
CSF treatment lead to an activation of dormant HSCs (Wilson et al., 2008). Interestingly,
treatment with cytokines, like interferons, also leads to an effective activation of HSCs,
even though interferons have an anti-proliferative effect on mature bone marrow cells
(Essers et al., 2009; Sato et al., 2009; Baldridge et al., 2010). As most of thesemature cells
are lost during the combat against the disease, the activation of HSCs might be an ad-
ditional feature of the IFN production upon infection, to ensure fast replenishment of
the system after blood cell loss. We therefore askedwhether the production of IFNs and
the following activation of quiescent HSCs might be a general feature of bone marrow
injury and cell loss.
We rst wanted to analyse the production of IFNα upon different forms of bonemar-
row stress. We used a MxCre Rosa26eYFP ox2 mouse model to detect IFNα produc-
tion in the bone marrow (Kuhn et al., 1995; Srinivas et al., 2001). These mice have a Cre
element under the control of the IFNα inducible Mx promotor combined with a loxP-
stop-loxP cassette followedby eYFP under the control of the constitutively active Rosa26
promotor (Fig. 3.1 A). The Mx promotor is turned on by IFNα signalling, leading to the
expression of Cre. Cre will then excise the stop codon, thereby activating the expres-
sion of eYFP. This system enables the detection of previous IFNα production in the bone
marrow, through measurement of the eYFP expression within different bone marrow
cells. As a proof of principle experiment we treated MxCre Rosa26eYFP ox2 mice with
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Figure 3.1.: Stress induced IFNα production in the bone marrow
(A) MxCre Rosa26 eYFP ox2 mice express eYFP, after Cre expression was activated by IFNα (B-M) eYFP
expression in LSK cells after different treatments of MxCre Rosa26 eYFP ox2 mice. (B,C) PBS or 5 mg/kg
polyI:C. (D,E) PBS or 150 mg/kg 5-FU. (F,G) Irradiation with 200 or 400 rad. (H,I) Bleeding. (J,K) PBS or 0.75
mg/kg TNFα. (L,M) PBS or 25, 62.5, 125 or 250 µg/kg LPS; representative FACS proles (B,D,F,H,J,L) and quan-
titative and statistical analysis (C,E,G,I,M).
Data are the mean +/- SD of at least 3 mice per condition, representing similar results of 2-3 independent
experiments; *p ≤ 0.05, **p ≤ 0.01.
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5 mg/kg polyI:C, as polyI:C leads to a strong production of IFNα in the bone marrow.
We measured the expression of eYFP within bone marrow LSK cells by Flow Cytome-
try one week later, when cycling HSCs have returned to quiescence. Bone marrow of
mice treated with PBS or polyI:C was isolated and a FACS staining was performed in or-
der to identify LSK cells (Figure 5.1 A). While the control PBS treated cells only showed a
low expression of eYFP, the expression was signicantly increased upon treatment with
polyI:C (Figure 3.1 B and C). This shows, that eYFP is effectively activated in LSK cells
upon IFNα production in the bone marrow. As treatment with 5-FU has been shown
to lead to an activation of dormant HSCs (Wilson et al., 2008), we asked whether this
activation might be due to IFNα production in the bone marrow upon 5-FU treatment.
Although 5-FU treatment leads to an activation of HSCs, no increase in eYFP signal was
detected upon treatment of 5-FU in LSK cells of MxCre Rosa26eYFP ox2 mice (Figure
3.1 D and E), showing that no IFNα is produced upon 5-FU treatment in the bone mar-
row and the activation of HSCs upon 5-FU treatment must therefore be mediated by
another mechanism. Transplantation of bone marrow cells into lethally irradiated mice
is to date the experiment of choice to prove the self-renewal and repopulation capacity
of HSCs. However, irradiation is a severe form of bone marrow stress to the recipient
mice. To test if this formof stress leads to theproductionof IFNα in thebonemarrowand
might therefore inuence the cycling behaviour of the donor cells, we irradiatedMxCre
Rosa26eYFP ox2 mice with a sublethal dose of either 200 or 400 rad. The irradiation
did, however, not lead to an increase in eYFP expression in LSK cells (Figure 3.1 F and G),
demonstrating that irradiation does not lead to IFNα production in the bone marrow.
Nevertheless, irradiation inuences the bonemarrow niche environment and therefore
may alter the behaviour of transplanted HSCs in comparison to non-irradiated mice.
Another form of stress to the haematopoietic system is severe blood loss. As bleeding
indirectly leads to loss of bone marrow cells, because progenitor cells are activated to
replenish the lost blood cells, we bled MxCre Rosa26eYFP ox2 mice once, taking 5-6
drops of blood from the vena facialis. In our experiment we did not observe an increase
in eYFP signalwithin bonemarrow LSK cells after bleeding (Figure 3.1 H and I). Neverthe-
less, a single round of bleeding might not be severe enough to induce a stress response
in the bonemarrow and several rounds of bleedingmight therefore lead to the produc-
tion of IFNα. Whether bleeding also leads to an activation of dormant HSCs remains
to be investigated. Interferons are typically produced upon infections. To investigate
whether other cytokinesmay lead to an activation of HSCs by inducing IFNα production
in the bone marrow, we treated MxCre Rosa26eYFP ox2 mice with 0.75 mg/kg TNFα.
Comparable to the PBS treated mice, the TNFα treated mice did not show an increased
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eYFP expression in LSK cells (Figure 3.1 J and K), indicating that TNFα does not lead to
IFNα production in the bone marrow. It is well established that IFNα is produced upon
viral infections (reviewed in Borden et al., 2007). To test if this is true for bacterial in-
fections, MxCre Rosa26eYFP ox2 mice were treated with different concentrations of
lipopolysaccharide (LPS) and the eYFP expression in the bone marrow was analysed af-
ter one week. LPS is an endotoxin of the outer cell wall of Gram(-) bacteria, which is
recognised by TLR4 and often used to mimic bacterial infections. The eYFP expression
in LSK cells was signicantly higher after treatment with LPS compared to the control
PBS treated mice (Figure 3.1 L and M). These results show that also upon bacterial infec-
tion, mimicked by LPS treatment, IFNα is produced in the bone marrow.
In summary, although the baseline levels of eYFP expression are quite variable, these
experiments show that IFNα production is not a general feature of bone marrow stress.
However, as IFNα is produced upon LPS treatment, wewanted to investigate, if LPS leads
to an activation of HSCs comparable to direct interferon treatment.
3.2. LPS leads to increased proliferation of HSCs
3.2.1. LPS induces activation of HSCs in a TLR4 dependent manner
As we could show that LPS treatment of mice leads to IFNα production in the bone
marrow, we asked what effect LPS treatment would have on the behaviour of HSCs.
For this purpose, wildtype mice were treated with PBS or LPS for 18 hours. The cycling
behaviour of HSCs (LSK CD150+CD48-CD34-) was assessed by staining for intracellu-
lar (ic) Ki67 combined with Hoechst33342. This staining enables the differentiation be-
tween the G0 (icKi67negHoechstlow), the G1 (icKi67posHoechstlow) and the S, G2 and M
(icKi67posHoechsthigh) phases of the cell cycle, as Ki67 is only expressed during an ac-
tive cell cycle and Hoechst enables the identication of cells that have already doubled
their chromosome set. After treatment with LPS the quiescent HSCs of wildtype mice
exited the G0 phase of the cell cycle and moved into the active G1, S, G2 or M phase
(Figure 3.2 A and B). Whether this increase of HSCs in the G1, S, G2 or M phase of the
cell cycle is accompanied by an active proliferation, can be determined by BrdU incor-
poration. Therefore, mice were treated with BrdU 14 hours before analysis. The BrdU
incorporation in HSCs was then measured by Flow Cytometry. The HSCs of wildtype
mice showed a signicant increase in BrdU+ cells after treatment with LPS (Figure 3.2
C and D), indicating that LPS leads to an increased proliferation of HSCs. In contrast to
LPS treated wildtype mice, HSCs frommice lacking TLR4, one of the components of the
TLR4-MD2-CD14 receptor complex detecting LPS, did not show an increase in cell cycle
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Figure 3.2.: LPS-induced activation of HSCs is dependent on TLR4 signalling
(A,B) Cell cycle analysis (G0 cells icKi67negHoechstlow) of HSCs (LSK CD150+CD48-CD34-) from PBS or LPS
(0.25mg/kg, 18h) treatedwt orTLR4-/- mice. Representative FACSproles (A) and quantitative and statistical
analysis (B). (C,D) BrdU incorporation (14h) in HSCs from wt or TLR4-/- mice treated with PBS or LPS (0.25
mg/kg, 18h). Representative FACS proles (C) and quantitative and statistical analysis (D).
Data are the mean +/- SD of at least 3 mice per condition, representing similar results of 2-3 independent
experiments; *p ≤ 0.05, **p ≤ 0.01
activity (Figure 3.2 A and B), or an increase in BrdU incorporation (Figure 3.2 C and D)
upon LPS treatment, indicating that the LPS-induced activation of HSCs is dependent
on TLR4 signalling.
HSCs entered an active cell cycle, even with a low dose of 12.5 µg/kg LPS (Figure 3.3
A). However, as treatment with 250 µg/kg LPS always led to a signicant activation of
HSCs without impairing the health of the mice, while high doses of LPS led to severe
health issues, this concentration was used for further experiments. The activating effect
of LPS on HSCs is transient, with a peak in between 24 and 48 hours, while the cell cycle
status of HSCs was back to baseline after 72 hours. Interestingly, after 96 hours even
more HSCs could be found in the G0 phase of the cell cycle compared to the untreated
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Figure 3.3.: LPS induces transient activation of HSCs
(A) HSCs in G0 after treatment of wt mice with different concentrations of LPS for 18h. (B) HSCs in G0 after
treatment of wt mice with 0.25 mg/kg LPS at different time points. (C) Cell cycle analysis with icKi67 and
Hoechst after treatment of wt mice with 0.25 mg/kg LPS from different sources (Sigma, if not indicated
differently).
Data are the mean +/- SD of at least 3 mice per condition, representing similar results of 2-3 independent
experiments; *p ≤ 0.05, **p ≤ 0.01
mice (Figure 3.3 B), which may reect a short-lived increase after stimulation. All of
the above experiments, as well as all following experiments were performed with the
same source of LPS (E.coli 0111:B4, Sigma). Nevertheless, treatment ofwildtypemicewith
different sources of LPS led to the same increase in proliferation of HSCs (Figure 3.3 C),
conrming that the effect of LPS on the HSCs is not dependent on the source of LPS.
In summary, these data show that even low doses of LPS lead to a transient increase
in proliferation of HSCs in the bone marrow through activation of TLR4 signalling.
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Figure 3.4.: LPS-induced activation of dormant HSCs
(A) Set-up of LRC experiment: wt mice were injected i.p. with BrdU (18 mg/kg) and given BrdU-water (1 g/l)
for 10 days, leading to a labelling of all bone marrow cells with BrdU, following this the mice underwent a
70 day BrdU-free chase-period, resulting in a decreasing BrdU signal with every cell cycle, subsequently
mice were injected with PBS or LPS (0.25 mg/kg, 3 times), every third day. The bone marrow was analysed
10 days later (B) Number of BrdU+ LSK CD150+CD48-CD34- LRCs per 106 viable cells. (C) Number of LSK
CD150+CD48-CD34- HSCs per 106 viable cells.
Data are the mean +/- SD of at least 3 mice per condition, representing similar results of 2-3 independent
experiments; *p ≤ 0.05, **p ≤ 0.01
3.2.2. LPS leads to the activation of dormant HSCs
To investigate whether the LPS-induced activation of HSCs shown above leads to an
activation of dormant HSCs, we used a label-retaining assay with BrdU. Using BrdU to
label all bonemarrow cells for 10 days, followed by a BrdU-free chase period of 70 days,
dormant label-retaining cells (BrdU+, LRCs) can be detected. This method in combina-
tion with a FACS staining for LSK CD150+CD48-CD34- cells, enables the identication
of dormant HSCs as BrdU+ LRCs within the LSK CD150+CD48-CD34- population. Wild-
type mice were treated as described above. At the end of the BrdU-free chase period,
the mice were treated with PBS or LPS (0.25 mg/kg), three times over 7 days. The num-
ber of LRCs in these mice was analysed by Flow Cytometry 2 weeks later (Figure 3.4 A),
when the HSCs have returned to quiescence. The number of LRCs is signicantly de-
creased after LPS treatment (Figure 3.4 B), while the number of LSK CD150+CD48-CD34-
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cells is not changed (Figure 3.4 C), showing that LPS does not only lead to an activation
of homeostatic HSCs, but also activates dormant HSCs to proliferate.
3.2.3. LPS treatment does not impair the long-term reconstitution potential of
HSCs
Treating mice with LPS leads to an activation of dormant HSCs, which have been
shown to exhibit the highest repopulation activity (Wilson et al., 2008; Qiu et al., 2014),
into an active cell cycle. This raises the question, whether the self-renewal of those
cycling cells is affected. To determine the long-term reconstitution potential of LPS-
induced HSCs, CD45.2+ mice were treated with PBS or LPS (0.25 mg/kg) for 24h. The
bone marrow of these mice was isolated and transplanted i.f. into lethally irradiated
CD45.1+ mice, to exclude any effects due to impaired homing of cycling HSCs (Figure 3.5
A). We monitored the engraftment over time, by bleeding the mice every 4 weeks and
determining the percentage of CD45.2+ granulocytes in the blood. Granulocytes were
measured, because these cells are a good indicator of active haematopoiesis, as they are
short-lived (Uchida andWeissman, 1992). As shown in Figure 3.5 B, no difference in the
engraftment of LPS treated cells can be observed in the primary transplant compared
to the PBS treated cells. After 16 weeks the mice were killed and the engraftment was
analysed in blood and bonemarrow. Again no difference could be observed in the over-
all engraftment of differentiated cells between LPS treated and PBS treated cells in the
primary transplant (Figure 3.5 D). Furthermore, we analysed the percentage of engrafted
HSCs aswell as the relative number of HSCs per 106 viable bonemarrow cells. Also here,
no difference in engraftment can be detected in the primary transplant (Figure 3.5 F and
G).
In addition to this analysis, 3x106 cells from four mice were transplanted i.f. into
3 lethally irradiated CD45.1+ mice each to make secondary transplants and analyse the
long-term engraftment of the LPS treated cells (Figure 3.5 A). The engraftment of the
transplanted cells was investigated as described above. In the secondary transplant a
minor trend of lower engraftment of LPS treated cells compared to PBS treated cells can
already be observed after 4 weeks (Figure 3.5 C). The trend, of lower engraftment of LPS
treated cells, already observed in the peripheral blood, could again be detected for all
different cell populations, as well as for the overall engraftment, in the bone marrow
16 weeks after transplantation. (Figure 3.5 E). It is clear form analysis of the individual
mice that two mice, which received LPS treated cells do not show any engraftment of
CD45.2+ cells, indicating a failed injection rather then an actual engraftment defect. In
the other fourmice, in which the transplanted LPS treated cells engrafted, no difference
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Figure 3.5.: LPS treatment does not impair the long-term reconstitution potential of HSCs
(A) Set-up of transplantation experiment: CD45.2+ mice were treated with PBS or LPS (0.25 mg/kg, 24h),
3x106 Thy.1 depleted bone marrow cells of these mice were transplanted i.f. into lethally irradiated CD45.1+
mice, the engraftment of the CD45.2+ wasmonitored by bleeding themice every 4weeks, after 16weeks the
bone marrow as well as the blood was analysed for engraftment of different cell populations, furthermore
3x106 Thy.1 depleted bone marrow cells were transplanted i.f. into lethally irradiated secondary recipients,
the engraftment in these mice was analysed as described above. (B,C) Percentage of CD45.2+ granulocytes
in the PBL of primary (B) and secondary (C) recipients over time. (D,E) Percentage of CD45.2+ cells from
different populations in the bone marrow of primary (D) and secondary (E) recipient. (F and G) Percentage
(F) or relative number (G) of CD45.2+ HSCs in the bone marrow of primary recipients. (H and I) Percentage
(H) or relative number (I) of CD45.2+ HSCs in the bone marrow of secondary recipients. Symbols indicate
individual mice.
Data are the mean +/- SD of at least 3 mice per condition, representing similar results of 2-3 independent
experiments; *p ≤ 0.05, **p ≤ 0.01
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in the engraftment potential can be detected compared to the mice transplanted with
PBS treated cells (Figure 3.5 E). Of most interest are the HSCs. Again, in the secondary
transplant two mice did not show any engraftment of HSCs, matching the mice which
likewise did not show an engraftment of the other populations (Figure 3.5 H). This nd-
ing supports the hypothesis that those twomice do not show any engraftment, because
of a failed injection into the femur, as the remaining four mice show an engraftment of
CD45.2+ HSCs comparable to the mice transplanted with PBS treated cells (Figure 3.5 H
and I).
In summary, the engraftment of LPS treatedHSCs in primary recipients does not differ
from the engraftment potential of PBS treated HSCs. Although, in the secondary recipi-
ents there is a trend towards a lower engraftment of the LPS treated HSCs compared to
the PBS treated cells, this difference is not statistically signicant. To determinewhether
this difference in engraftment of individual mice is due to a failed injection or reects
actual engraftment defects, further experiments have to be performed.
3.2.4. The LPS-induced activation of HSCs is dependent on Sca-1
Sca-1 has long been recognized as amarker for HSCs (Spangrude et al., 1988), however,
besides an increase in T lymphocyte activation upon antigen recognition (Stanford et al.,
1997) and a disadvantage in competitive transplantation (Ito et al., 2003) of Sca-1-/- mice,
its function is still widely unknown. Hence, it is interesting that we can detect a Sca-1
phenotype in ourmodel of HSC activationwith LPS. Alongwith the increase inHSC pro-
liferation, there is a LPS-induced shift in Sca-1 expression on HSCs and progenitor cells
(Figure 3.6 A). This shift was due to both increased expression of Sca-1 on Sca-1+ cells as
well as an induction of Sca-1 expression on Sca-1- cells. There was a signicant increase
in Sca-1 expression on LK CD150+ cells of LPS treated wildtype mice, while no signi-
cant increase in Sca-1 expression could be detected on cells of TLR4-/- mice (Figure 3.6
B and C). These results show that the upregulation of Sca-1 after LPS is dependent on
TLR4 signalling.
Interestingly, the activation of HSCs is not only accompanied by an upregulation of
Sca-1, but is also dependent on the presence of Sca-1, since HSCs from mice lacking
Sca-1 can no longer be activated in response to LPS. While the incorporation of BrdU
was signicantly increased in LK CD150+CD48- cells of wildtype mice, no increase in
proliferation could be detected in Sca-1-/- mice (Figure 3.6 D). Taken together, these ex-
periments show that treatment with LPS leads to an increase in Sca-1 expression on the
surface of HSPCs and that the increased proliferation of HSCs after treatmentwith LPS is
dependent on Sca-1, indicating a role for Sca-1 in the stress induced activation of HSCs.
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Figure 3.6.: The LPS-induced activation of HSCs is dependent on Sca-1
(A) Representative FACSplots of lineage negative cells fromPBSor LPS (0.25mg/kg, 18h) treatedmice, show-
ing a shift of LSK cells. (B,C) Sca-1 expression on the surface of LK CD150+ cells after treatment of wt or
TLR4-/- mice with PBS or LPS (0.25 mg/kg, 18h). Representative FACS proles (B) and quantitative and sta-
tistical analysis (C). (D) BrdU incorporation (14h) in LK CD150+CD48- cells after treatment of wt or Sca-1-/-
mice with PBS or LPS (0.25 mg/kg, 18h).
Data are the mean +/- SD of at least 3 mice per condition, representing similar results of 2-3 independent
experiments; *p ≤ 0.05, **p ≤ 0.01
3.2.5. Is HSC activation a general feature of TLR signalling?
Toll-like receptors (TLRs) belong to the rst line of defence against invading pathogens
and therefore have an important role in the sensing of pathogens and the initiation of
the immune defence (reviewed in Kawai and Akira, 2010). Hence, the activation of HSC
proliferation might be a general feature of TLR signalling, ensuring a fast production of
necessary immune cells for the defence, as well as a fast replenishment of the system
after the infection is cleared. In addition to LPS, polyI:C, a TLR3 ligand has also been
shown to activate HSCs (Essers et al., 2009; Sato et al., 2009).
To investigate if apart from LPS and polyI:C, other TLR ligands might also induce acti-
vation of HSCs, wildtype mice were treated with ligands for different TLRs and the cell
cycle activity, as well as the expression of Sca-1, was analysed by Flow Cytometry. Inter-
estingly, not all of the tested TLR ligands led to an activation of HSCs (Figure 3.7 A and
39
3. Results
A B
C D
E
Figure 3.7.: Is HSC activation a general feature of TLR signalling?
(A) Cell cycle analysis (icKi67 andHoechst) ofHSCs fromwtmice treatedwith Pam3CSK4 (1.5mg/kg), Lipote-
ichoic acid (LTA, 2.5 mg/kg), Peptidoglycan (PGN, 2.5 mg/kg), Flagellin (1.0 mg/kg) or ssPolyU (1.0 mg/kg) for
18h. (B) Sca-1 expression of LK CD150+ cells from wt mice treated with Pam3CSK4 (1.5 mg/kg), Lipoteichoic
acid (LTA, 2.5mg/kg), Peptidoglycan (PGN, 2.5mg/kg), Flagellin (1.0mg/kg) or ssPolyU (1.0mg/kg) for 18h. (C)
Cell cycle analysis (icKi67 andHoechst) of HSCs fromwtmice treatedwithODN1585, ODN1826 orODN2395
(1.25 mg/kg, 18h). (D) Sca-1 expression of LK CD150+ cells from wt mice treated with ODN1585, ODN1826 or
ODN2395 (1.25 mg/kg, 18h). (E) Cell cycle analysis (icKi67 and Hoechst) of HSCs from TLR4-/- mice treated
with Flagellin (1.0 mg/kg), ODN1826 (1.25 mg/kg) or Pam3CSK4 (1.5 mg/kg) for 18h.
Data are the mean +/- SD of at least 3 mice per condition, representing similar results of 2-3 independent
experiments; *p ≤ 0.05, **p ≤ 0.01
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C). The ligands, leading to an activation of HSCs, reect a quite diverse set of molecules,
sensed by different TLRs. An increase in cell cycle activity of HSCs could be detected
after treatment with Pam3CSK4, a synthetic lipopeptide, mimicking the amino terminus
of LPS, Flagellin, the major component of bacterial agellar laments, and ODN1826, a
B type CpGODNmimicking bacterial DNA (Figure 3.7 A and C). These ligands are sensed
by TLR2, TLR5 and TLR9 respectively (Takeuchi et al., 2002; Hayashi et al., 2001; Hemmi
et al., 2000). The activation of HSCs by these ligands was again accompanied by an in-
crease in Sca-1 expression on the surface of LK CD150+ cells (Figure 3.7 B and D). The
treatment with Lipoteichoic acid, Peptidoglycan, ssPolyU, ODN1585 and ODN2395 how-
ever, did not lead to an increased cell cycle activity of HSCs (Figure 3.7 A and C). As
these ligands are often contaminated with LPS, we treated TLR4-/- mice with Flagellin,
ODN1826 and Pam3CSK4, to exclude that the effect on the proliferation of HSCs is only
due to such a contamination. The treatment of TLR4-/- micewith Flagellin andODN1826
led to an increased cell cycle activity of HSCs, comparable to wildtype mice. Hence, the
activation of HSCswith Flagellin andODN1826was not due to a contaminationwith LPS,
but an actual effect of Flagellin and ODN1826 on the cycling behaviour of HSCs. The
treatment of TLR4-/- mice with Pam3CSK4, however, did not lead to an increased cell
cycle activity of HSCs, indicating that the Pam3CSK4 solution was contaminated with
LPS.
These experiments show that treatment with some, but not all TLR ligands leads to
an increase in cell cycle activity of HSCs and an upregulation of Sca-1 on the surface
of HSPCs, suggesting a rather specic effect of certain TLR ligands, instead of a general
feature of TLR signalling.
3.3. Signalling pathways involved in the LPS-induced activation of
HSCs
3.3.1. The LPS-induced activation of HSCs is dependent on TRIF
In contrast to other TLRs, TLR4 signalling can lead to the activation of two differ-
ent pathways: the MyD88-dependent and the MyD88-independent pathway, via TRIF
(Kaisho et al., 2001). To investigate if only one of these pathways, or both, are involved
in the LPS-induced activation of HSCs, mice lacking either MyD88 or TRIF were used.
Those mice, together with wildtype mice, were treated with either 0.25 mg/kg LPS or
0.025 mg/kg LPS. We used two different doses of LPS, because 0.25 mg/kg is a rela-
tively high dose, as treatment with 12.5 µg/kg LPS was sufcient to induce cycling of
HSCs (Figure 3.3 A), and therefore leads to such a strong response that small effects in
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Figure 3.8.: The LPS-induced activation of HSCs is dependent on TRIF
(A) Cell cycle analysis (icKi67 and Hoechst) of HSCs from wt or Trifmc-/- mice after treatment with 0.25 or
0.025 mg/kg LPS (18h) (B) Cell cycle analysis (icKi67 and Hoechst) of HSCs from wt orMyD88-/- mice after
treatment with 0.25 or 0.025 mg/kg LPS (18h).
Data are the mean +/- SD of at least 3 mice per condition, representing similar results of 2-3 independent
experiments; *p ≤ 0.05, **p ≤ 0.01
the knockout models might be not be clear. Treatment of Trifmc-/- mice with LPS did
not lead to a signicant activation of HSCs, independent of the LPS dose used. Never-
theless, the LPS effect on HSCs was completely rescued when the lower dose was used,
while a slight, but not signicant, increase in cell cycle activity could be observed with
0.25 mg/kg (Figure 3.8 A). In contrast, the treatment ofMyD88-/- mice with either dose
of LPS led to a clear cell cycle activation in HSCs comparable to wildtype mice (Fig-
ure 3.8 B), indicating that the LPS-induced activation of HSCs is dependent on TRIF, but
not on MyD88. While MyD88 alone is sufcient to induce the production of inamma-
tory cytokines throughmost of the TLRs, activation of MyD88, as well as TRIF signalling,
has been shown to be necessary for the TLR4-induced production of inammatory cy-
tokines (reviewed in Akira and Takeda, 2004; Kawai and Akira, 2010; Lester and Li, 2014).
It can therefore not be concluded that the LPS-induced effects on HSCs are mediated
through TRIF signalling alone, as TRIF signalling is necessary for the MyD88-induced
production of cytokines.
3.3.2. The role of NFκB in the LPS-induced HSC activation
It is known, that TLR4 signalling leads to an activation of NFκB (reviewed in Kawai and
Akira, 2010). To investigate the role of NFκB in HSCs upon LPS treatment, we rst anal-
ysed NFκB activation using p65-GFP mice. These mice express p65 as a fusion protein
with GFP, which can be used to detect translocation of NFκB to the nucleus upon ac-
tivation (de Lorenzi et al., 2009). The localisation of p65 in LK CD150+CD48- cells was
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Figure 3.9.: The role of NFκB in the LPS-induced HSC activation
(A) Immunouorescence staining of sorted LK CD150+CD48- cells fromp65-GFPmice after PBS or LPS (0.25
mg/kg, 16h) treatment on Poly-L-Lysine slides, stained for GFP and with DAPI, recorded with a LSM700
confocal microscope, Z-Stack of representative images made with ImageJ. (B) Quantitative and statistical
analysis of colocalisation of GFP and DAPI signal from images described above, calculated with the JaCoP
plugin for ImageJ using theMander’s Coefcient. (C) Sca-1 expression of LK CD150+ cells after in vitro treat-
ment of lin depl cells with PBS or LPS (100 ng/ml, 20h) in combination with the NFκB inhibitors PDTC or
JSH-23. (D) Experimental set-up: SclCreERT2 p65 ox2 RosaEYFP ox2 mice or littermate controls were
given Tamoxifen food for 30 days, followed by a Tamoxifen-free period of 2 weeks, after that mice were
treated with PBS or LPS. (E) Cell cycle analysis (icKi67 and Hoechst) of HSCs from PBS or LPS (0.25 mg/kg,
18h) treated SclCreERT2 p65 ox2 RosaEYFP ox2 mice (p65Δ/Δ) or littermate controls (p65 ox2 RosaEYFP
ox2). (F) p65 expression in control, eYFP+ and eYFP- LK CD150+CD48- cells, measured by qRT-PCR.
Data are the mean +/- SD of at least 3 mice per condition, representing similar results of 2-3 independent
experiments; *p ≤ 0.05, **p ≤ 0.01
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analysed by microscopy. Furthermore, the localisation of p65 was quantied using the
JaCoP Plugin for Image J (Abramoff et al., 2004; Bolta and Cordelieres, 2006). After LPS
treatment a signicantly higher colocalisation of GFP and DAPI could be detected, com-
pared to the PBS treated cells (Figure 3.9 A and B), indicating an activation of NFκB in
HSCs upon LPS treatment.
As the activation of HSCs with LPS was accompanied by an activation of NFκB sig-
nalling in HSCs, further experiments were performed to investigate if the activation of
HSCs with LPS is also dependent on NFκB signalling. First, two different inhibitors of
NFκB signalling were used in vitro. For this experiment lineage depleted cells were cul-
tured with PDTC, JSH-23 (Liu et al., 1999; Shin et al., 2004) or without an inhibitor and
treated with PBS or LPS (100 ng/ml, 20h). The expression of Sca-1 on the surface of LK
CD150+ cells was analysed. After treatment with PDTC, a clear block of the LPS-induced
upregulation of Sca-1 could be detected, while the increase in Sca-1 expressionwas only
slightly lower after treatment with JSH-23 compared to the untreated control (Figure 3.9
C). This data suggests that the LPS-induced activation of HSCs might be dependent on
NFκB signalling, however this experiment does not reect the in vivo situation and from
this experiment it can not be concluded, if the LPS effect is dependent on NFκB activa-
tion in the HSCs themselves.
We next used p65 ox2 mice to analyse the role of NFκB in vivo. First experiments
were performed with the p65 ox2 mice interbred with the MxCre mouse strain. How-
ever, the treatment of those mice with polyI:C, to induce the deletion of p65, led to
death of the mice within a few days. We therefore tried to transplant bone marrow
cells of these mice into lethally irradiated wildtype mice, before inducing Cre expres-
sion. However, a stable engraftment of those cells was not achieved (data not shown)
and this model could not be used to analyse the role of NFκB in the LPS-induced acti-
vation of HSCs. Thus, p65 ox2 mice were crossed with SclCreERT2 and the RosaEYFP
ox2 mouse strain. In these mice Cre is activated upon Tamoxifen treatment. However,
as the Cre activation with the SclCreERT2 system is not as effective as with the MxCre
model, we crossed in the RosaEYFP ox allele to identify p65-deleted cells. We treated
the mice with Tamoxifen for 30 days, followed by a 2 week Tamoxifen-free period, as
Tamoxifen itself has been shown to increase the proliferation of HSCs. Subsequently the
mice were treated with PBS or LPS (0.25mg/kg, 18h). Littermate controls without SclCre,
were submitted to the same Tamoxifen treatment (Figure 3.9 D). In the PBS treated lit-
termate controls, most of the HSCs could be found in the G0 phase of the cell cycle,
indicating that after the Tamoxifen induced activation of HSCs, the cells had returned to
their normal homeostatic state of quiescence. In contrast, HSCs from the PBS treated
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SclCreERT2 p65 ox2 RosaEYFP ox2 mice showed a slight increase in cell cycle activity,
compared to the littermate controls, indicating that the deletion of p65 alone already led
to an activation of HSCs. However, after LPS treatment the increase in cell cycle activity
was similar between the HSCs from control and p65Δ/Δ mice (Figure 3.9 E), suggesting
that the deletion of p65 does not have an effect on the LPS-induced activation of HSCs
in this setting. Unfortunately, we could not use the eYFP signal to specically analyse the
HSCs, with the most effective p65 deletion, since the eYFP signal did not correspond to
the p65 deletion, as p65 was efciently deleted in eYFP+ as well as eYFP- cells (Figure 3.9
F).
3.4. The LPS-induced activation of HSCs is indirectly mediated by
myeloid cells
3.4.1. LPS induces activation of HSCs via an indirect mechanism
HSCs have been shown to express TLRs, like TLR2 and TLR4, and respond to stimu-
lation with TLR ligands (Nagai et al., 2006; Megías et al., 2012). However, it is not clear
whether the LPS-induced proliferation of HSCs is mediated by direct activation of TLR4
signalling in HSCs. Therefore mixed chimeras with 50% wildtype (CD45.1+) and 50%
TLR4-/- (CD45.2+) bone marrow were used (Figure 3.10 A and C) to test whether the
LPS-induced activation of HSCs is directly mediated. When a direct activation of TLR4
signalling in HSCs is necessary for the LPS-induced proliferation, the TLR4-/- cells in
the chimeric setting would not respond to the LPS treatment, while the wildtype cells
would start to proliferate. However, if the effect of LPS on HSCs is indirect, an activation
of TLR4 on the wildtype cells would be enough to also activate the TLR4-/- HSCs. The
chimeras were treated with PBS or LPS for 18 hours and the proliferation of wildtype
and TLR4-/- HSCs was compared. As expected, the wildtype HSCs showed a decrease of
cells in the G0 phase after treatment with LPS (Figure 3.10 B). Similarly, the TLR4-/- HSCs
showed an elevated cell cycle activity after LPS treatment in this chimeric setting (Figure
3.10 B), indicating that the LPS-induced activation of HSCs is indirect. Reverse chimeras,
in which wildtype bone marrow cells were transplanted into lethally irradiated TLR4-/-
mice, were used to determine whether the indirect effect is mediated by bone marrow
or niche cells. As shown in Figure 3.10 D the wildtype HSCs started to proliferate after
treatment with LPS in this setting, excluding a direct necessity to activate TLR4 signalling
in cells of the bone marrow niche.
An in vitro approach was used to conrm the results of the in vivo experiments. Bone
marrow cells of wildtype mice were sorted for LK CD150+ cells. These cells were taken
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Figure 3.10.: The LPS-induced activation of HSCs is mediated by an indirect mechanism
(A) Experimental set-up of TLR4-/- mixed bone marrow chimeras: a mixture of 50% wt and 50% TLR4-/-
bone marrow cells was transplanted into lethally irradiated wt mice. (B) Cell cycle analysis (icKi67 and
Hoechst) of HSCs in mixed bonemarrow chimeras (50% CD45.1+ wt - 50% CD45.2+ TLR4-/-) after treatment
with PBS or LPS (0.25 mg/kg, 18h). (C) Percentage of wt (CD45.1, white) or TLR4-/- (CD45.2, black) granulo-
cytes in peripheral blood of mixed bonemarrow chimeras after PBS or LPS (0.25mg/kg, 18h) treatment. (D)
BrdU incorporation (14h) in wt HSCs of reverse TLR4-/- chimeras after PBS or LPS (0.25 mg/kg, 18h) treat-
ment. (E) Experimental set-up of in vitro experiments: LK CD150+ bonemarrow cells ofwildtypemicewere
sorted, the sorted cells were treated with PBS, IFNα or LPS in culture, the cells were analysed by Flow Cy-
tometry after 20h. (F,G) Sca-1 expression on sorted LK CD150+ cells after in vitro treatment with PBS, IFNα
(1000 U/ml) or LPS (100 ng/ml) for 20h. Quantitative and statistical analysis (F) and representative FACS
proles (G). (H) BrdU incorporation (3h) in LK CD150+ cells after in vitro treatment of lin depleted cells with
PBS, IFNα (1000 U/ml) or LPS (100 ng/ml) for 20h.
Data are the mean +/- SD of at least 3 mice per condition, representing similar results of 2-3 independent
experiments; *p ≤ 0.05, **p ≤ 0.01
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into culture and treated with PBS, IFNα or LPS (Figure 3.10 E). It is known that IFNα has a
direct effect on HSCs (Essers et al., 2009), therefore IFNα was used as a positive control
in this experiment. The in vitro treatment of sorted LK CD150+ cells with IFNα led to a
signicant increase in Sca-1 expression on the surface of those cells, while the treatment
with LPS did not have an effect on the Sca-1 expression (Figure 3.10 F and G). The up-
regulation of Sca-1 on the surface of the LK CD150+ cells was used as a readout for all in
vitro experiments, as the treatment of bonemarrow cells with IFNα in vitro did not lead
to an increase in proliferation of HSPCs comparable to the in vivo situation, but rather
led to a decrease in proliferation, probably reecting a necessity of the HSC niche in the
activation of HSCs. This decreased proliferation could not be detected after treatment
of HSPCs with LPS (Figrue 3.10 H).
These experiments show that LPS-induced activation of HSCs is indirectly mediated
via other cells of the bonemarrow. Further experiments were performed to identify the
type of bone marrow cells mediating the LPS-induced activation of HSCs.
3.4.2. The upregulation of Sca-1 in HSPCs upon LPS treatment is mediated by
CD11b+ cells in vitro
Weperformed in vitro co-culture experiments, to identify the bonemarrow cell type,
mediating the LPS-induced activation of HSCs. Therefore, LK CD150+ cells from CD45.1+
mice were sorted and taken into culture, alone or in co-culture with dened popula-
tions of bone marrow cells from CD45.2+ mice. The cells were in vitro treated with PBS
or LPS and the expression of Sca-1 on the HSPCs was used as a readout (Figure 3.11 A).
To gain insight into which cell type mediates the effect of LPS on the HSPCs, LK CD150+
cells were co-cultured with lineagelow (linlow) or lineagehigh (linhigh) cells. Only after co-
culture with linhigh cells a Sca-1 upregulation on the surface of HSPCs could be detected
(Figure 3.11 B), indicating that the LPS-induced effect is mediated by mature bone mar-
row cells. Consequently, we tested different populations of mature bone marrow cells,
to determine which of these cells is involved in the mediation of the LPS-induced ef-
fect. CD11b+ myeloid cells, CD4/CD8+ T cells and NK1.1+ NK cells were used. Sca-1 was
upregulated on HSPCs after LPS treatment only in co-culture with CD11b+ myeloid cells
(Figure 3.11 C). To conrm that the upregulation of Sca-1 after LPS can only be mediated
by CD11b+ cells, LK CD150+ cells were co-cultured with either CD11b+ or CD11b- cells.
Only co-culturewith CD11b+ cells led to an upregulation of Sca-1 on the surface ofHSPCs
(Figure 3.11 D), conrming that only CD11b+, but none of the CD11b- bone marrow cells,
can mediate this effect. To conrm that the LPS-induced upregulation of Sca-1 is medi-
ated by an activation of TLR4 signalling on the CD11b+ myeloid cells and not on the LK
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Figure 3.11.: The upregulation of Sca-1 on HSPCs upon LPS treatment is mediated by CD11b+ cells in vitro
(A) Experimental set-up of in vitro co-culture experiments: LK CD150+ (HSPCs) from CD45.1+ mice were
sorted and co-cultured with dened populations of bone marrow cells from CD45.2+ mice, the cells were
treated with PBS or LPS (100 ng/ml) for 20h. After 20h the cells were harvested and the Sca-1 expres-
sion was analysed by Flow Cytometry. (B-H) Sca-1 expression of sorted wt (B-H) or TLR4-/- (E) LK CD150+
cells treated with PBS or LPS (100 ng/ml, 20h) after co-culture with (B) linlow or linhigh cells, (C) CD11b+
myeloid, CD4/CD8+ T cells or NK1.1+ NK cells, (D) CD11b+ or CD11b- cells, (E) wt or TLR4-/- CD11b+ cells, (F) Gr-
1-CD115-F4/80+ macrophages, Gr-1+CD115+ monocytes, Gr-1+CD115- neutrophils or Gr-1-CD115+ monocytes,
(G) CD11b+CD115+ or CD11b+CD115- cells and (H) CD11b+CD115+Ly6C+ or CD11b+CD115+Ly6C- cells.
Data are the mean +/- SD of at least 3 mice per condition, representing similar results of 2-3 independent
experiments; *p ≤ 0.05, **p ≤ 0.01
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CD150+ cells, a co-culture experiment with cells from TLR4-/- mice was performed. An
upregulation of Sca-1 could only be detected after co-culturewithwildtype CD11b+ cells,
while co-culturewith TLR4-/- CD11b+ cells did not have an effect on the Sca-1 expression
of HSPCs (Figure 3.11 E). The upregulation of Sca-1 could also be detected when TLR4-/-
HSPCs are co-cultured with wildtype CD11b+ cells (Figure 3.11 E), excluding a necessity
of TLR4 activation on HSPCs, demonstrating that the LPS-induced effect on HSPCs is
mediated by activation of TLR4 signalling in CD11b+ myeloid cells.
3.4.3. Only CD11b+CD115+Ly6C+ monocytes can mediate the increase in Sca-1
expression in vitro
As CD11b is expressed on several types of bone marrow cells, including monocytes,
macrophages, neutrophils and NK cells (reviewed in Solovjov et al., 2005), further ex-
periments were performed to understand the LPS effect on HSPCs in vitro. With the
data shown in Figure 3.11 C it has already been excluded that the effect is mediated
by NK cells, as the co-culture of HSPCs with NK cells did not lead to an upregulation
of Sca-1 in response to LPS. Therefore, the role of macrophages, monocytes and neu-
trophils was further evaluated. For this purpose a gating scheme established by Chow
et al. was used to differentiate between neutrophils, macrophages, Gr-1high and Gr-1low
monocytes (for gating scheme see Figure 5.2 A) (Chow et al., 2011). In this experiment,
only HSPCs that were co-cultured with monocytes, independent of their Gr-1 expres-
sion, showed an upregulation of Sca-1 (Figure 3.11 F). Since monocytes are dened as
CD115+ cells in the gating scheme used, it was further conrmed that only CD115+, but
not CD115- cells can mediate the LPS-induced upregulation of Sca-1 on the surface of
HSPCs (Figure 3.11 G). These results indicate that the LPS-induced effect on HSPCs in
vitro is mediated by CD11b+CD115+ monocytes. Monocytes can be further subdivided
into two populations by Ly6C expression. Ly6Chigh monocytes are dened as inamma-
tory monocytes, while Ly6Clow cells are termed resident monocytes (Geissmann et al.,
2003; Gordon and Taylor, 2005). To investigate, if the LPS effect is mediated by either
of the two monocyte types or by both types, LK CD150+ cells were co-cultured with
CD11b+CD115+Ly6Chigh or CD11b+CD115+Ly6Clow cells (for gating scheme see Figure 5.2 B).
An increase in Sca-1 expressionwas only detected after co-culture with Ly6Chigh mono-
cytes, but not with Ly6Clow cells (Figure 3.11 H), suggesting that the LPS-induced effect is
mediated by inammatory monocytes in vitro.
In summary, these experiments show that only Ly6Chigh inammatorymonocytes can
mediate the LPS-induced upregulation of Sca-1 in vitro. However, these experiments
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were performed in vitro, using Sca-1 upregulation as a readout, and this had to be further
supported by in vivo experiments.
3.4.4. The LPS-induced activation of HSCs is mediated by myeloid cells in vivo
Three in vivo approaches were used to deplete CD11b+ cells from the bone marrow,
to investigate whether the LPS-induced increase in proliferation of HSCs in vivo is also
mediated by myeloid cells. A depletion of neutrophils was achieved by twice treating
wildtype mice with an anti-Ly6G (1A8) antibody (Figure 3.12 A) (Casanova-Acebes et al.,
2013). This treatment led to a nearly complete depletion of neutrophils from the bone
marrow (Figure 3.12 C). However, the depletion of neutrophils prior to the LPS treat-
ment did not have an effect on the LPS-induced proliferation of HSCs (Figure 3.12 B).
This result, together with the in vitro data (Figure 3.11 F), excludes a role for neutrophils
in the LPS-induced activation of HSCs. To analyse the role of CD11b+ monocytes and
macrophages in the LPS-induced activation of HSCs in vivo two different approaches
were tested. For the rst approach we used the macrophage Fas-induced apoptosis
(Maa) mouse model (Burnett et al., 2004). These mice express a drug-inducible sui-
cide gene under the control of the c-fms (CD115) promotor. Upon treatment with the
homodimerizer AP20187 apoptosis is induced in all CD115 expressing cells. As in vitro
experiments indicate a role for CD115+ cells in the activation of HSCs (Figure 3.11 F and
G), the Maa mouse model could be used to show if these cells are also involved in the
LPS-induced activation of HSCs in vivo. Unfortunately, the treatment ofMaamicewith
AP20187 led tomobilisation of HSCs into the bloodstream accompanied by an increased
cycling of HSCs in the bonemarrow (data not shown). For that reason, thosemice could
not be used to investigate the role of CD115+ cells in the LPS-induced cell cycle induc-
tion in HSCs in vivo. As a second model we used clodronate-loaded liposomes to de-
plete phagocytic cells from the bone marrow (van Rooijen et al., 1997). These liposomes
are not membrane-permeable and are therefore only taken up by phagocytic cells. The
accumulation of clodronate within these cells leads to apoptosis (Figure 3.12 D). Thus,
wildtype mice were treated once i.v. with clodronate- or PBS-loaded liposomes. The
depletion of myeloid cells after clodronate treatment occurs rather fast, within 12 hours
and is accompanied by a mobilisation of HSCs from the bone marrow to the periph-
ery (Chow et al., 2011). Therefore, the LPS treatment was performed 5 days after the
clodronate treatment, when a signicant decrease in bone marrowmacrophages could
still be detected, while the proliferation of bone marrow HSCs was not affected (Figure
3.12 E, F and G). The proliferation of HSCs was analysed by icKi67 and Hoechst stain-
ing. While HSCs from PBS treatedmice did not show any difference in cell cycle activity
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Figure 3.12.: The LPS-induced activation of HSCs is mediated by myeloid cells in vivo
(A) Schematic overview of neutrophil depletion experiment: mice were treated twice with the anti-Ly6G
antibody 1A8 on two following days, the LPS treatment was performed 6h after the second 1A8 treatment,
cycling activity of BMHSCswas analysed after 18 h. (B) Cell cycle analysis (icKi67 andHoechst) of HSCs from
wildtype mice, treated with PBS or 1A8 to deplete neutrophils, after PBS or LPS (0.25 mg/kg, 18h) treatment.
(C) Neutrophil count in the bone marrow after treatment with PBS or 1A8 (2 times, 2.5 mg/kg). (D) Effect
of clodronate-loaded liposomes: the liposomes are not membrane-permeable and therefore only taken
up by phagocytic cells, upon clodronate accumulation the cells undergo apoptosis. (van Rooijen et al.,
1997) (E) Schematic overview of clodronate treatment: mice were treated with PBS- or clodronate-loaded
liposomes 5 days before the LPS treatment, BM analysis was performed 18 h after the LPS treatment (F) Cell
cycle analysis (icKi67 and Hoechst) of HSCs from wt mice treated with PBS- or clodronate-loaded (3.75
g/kg) liposomes 5 days before treatment with PBS or LPS (0.25 mg/kg, 18h). (G) Macrophage count in the
bonemarrow after treatment with PBS- or clodronate-loaded (3.75 g/kg) liposomes 5 days after treatment.
Data are the mean +/- SD of at least 3 mice per condition, representing similar results of 2-3 independent
experiments; *p ≤ 0.05, **p ≤ 0.01
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after clodronate treatment, a signicant difference could be detected in the cell cycle
activity of HSCs after LPS treatment between the PBS and clodronate liposome treated
mice (Figure 3.12 F).
These data suggest a role of myeloid cells in the in vivo effect of LPS on the prolifer-
ation of HSCs, even though the depletion of myeloid cells with clodronate-loaded lipo-
somes did not lead to a complete rescue of the LPS effect.
3.5. The activation of HSCs with LPS is mediated by IFN and TNFα
signalling
3.5.1. Upon LPS treatment soluble factors are produced that can mediate the
activation of HSCs in vitro
Having shown that the LPS-inducedeffects onHSCs are indirectlymediatedbymyeloid
cells, we asked whether this activation is mediated through cell-cell-interaction, the
production of soluble factors, or both. To investigate if cell-cell-interaction is neces-
sary for the LPS-induced upregulation of Sca-1 in vitro, a transwell assay was performed
(Figure 3.13 A). After 24 hours of culture the cells were harvested and the expression
of Sca-1 was analysed by FACS. Only in the control setting, when the HSPCs and the
myeloid cells were in contact, an upregulation of Sca-1 could be detected (Figure 3.13
B), suggesting that cell-cell-interaction is necessary to mediate the increase in Sca-1 ex-
pression upon LPS in vitro. Lineage depleted cells were culturedwith PBS or LPS to pro-
duce conditionedmedium and analyse whether soluble factors are produced upon LPS
treatment in vitro, which canmediate the upregulation of Sca-1 on HSPCs. The resulting
conditioned mediumwas used to treat either wildtype or TLR4-/- lineage depleted cells
in vitro (Figure 3.13 C). The TLR4-/- cells were used as a control to exclude an effect solely
by the LPS that might still be present in the conditioned medium. The wildtype, as well
as the TLR4-/- cells, showed a signicant increase in Sca-1 expression after treatment
with conditioned medium (Figure 3.13 D), indicating that soluble factors are produced
upon LPS treatment in vitro, which can mediate the effect on the expression of Sca-1
on the surface of HSPCs. However, this experiment does not exclude that initial cell-
cell-interaction could be necessary to promote this production of soluble factors, as
indicated by the transwell experiment (Figure 3.13 B).
These experiments show that after initial cell-cell-interaction between HSPCs and
myeloid cells in vitro, LPS leads to the production of soluble factors, which alone can
mediate the increase in Sca-1 expression on the surface of HSPCs. Hence, further exper-
iments were performed to gure out which factors are produced upon LPS treatment in
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Figure 3.13.: The LPS-induced effect is mediated by soluble factors in vitro
(A) Experimental set-up: LK CD150+ cells were sorted into the bottomwell of a transwell plate and cultured
either seperately or in co-culture with CD11b+CD115+ cells either in the same well or seperated through a
0.4 µm thick lter (dotted line), cells were treated with PBS or LPS (100 ng/ml, 24h, upper well). The LPS
was pipetted into the upper well, to ensure that the travelling of soluble factors through themembranewas
possible. (B) Sca-1 expression of sorted LK CD150+ cells after culture in transwell plate. (C) Experimental
set-up: conditioned medium was produced by treatment of lin depl cells with PBS or LPS (100 ng/ml, 18h)
and subsequent isolation of supernatant, the conditioned medium was then used to treat wt or TLR4-/- lin
depl cells for 18h. (D) Sca-1 expression of wt or TLR4-/- LK CD150+ cells after in vitro treatment of lin depl
cells with conditioned medium.
Data are the mean +/- SD of at least 3 mice per condition, representing similar results of 2-3 independent
experiments; *p ≤ 0.05, **p ≤ 0.01
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the bone marrow and which of those factors are mediating the LPS-induced activation
of HSCs in vivo.
3.5.2. The LPS-induced activation of HSCs is in part mediated by IFN signalling
Obvious candidates for cytokines produced upon LPS treatment are IFNα and IFNγ,
which have already been shown to lead to an increased proliferation of HSCs in vivo
(Essers et al., 2009; Baldridge et al., 2010). Therefore, an ELISA was performed to mea-
sure the expression of IFNα and IFNγ in the bone marrow after treatment of wildtype
mice with LPS (0.25 mg/kg). IFNα, as well as IFNγ were signicantly increased in the
bone marrow supernatant 4 hours after LPS treatment (Figure 3.14 A and B). As both
IFNα and IFNγ were upregulated in the bone marrow supernatant following LPS treat-
ment, the obvious assumption was that the LPS-induced effect on the proliferation of
HSCs is mediated by IFN signalling. Therefore, mice lacking either the receptor for IFNα
(Ifnar-/-) or the receptor for IFNγ (Ifngr-/-) were treated with 0.25mg/kg or 0.025mg/kg
LPS for 18 hours. After treatment, the proliferation behaviour of HSCs from those mice
was analysed by FACS and compared towildtypemice. TheHSCs of both knockoutmice
showed a signicant increase in proliferation after treatment with both doses of LPS
(Figure 3.14 C), indicating that neither IFNα nor IFNγ alone is mediating the LPS effect.
Nevertheless, it is likely that the IFNs can compensate for each other in the knockout
setting. Thus, a double-knockout mouse model for both IFN receptors (Ifnar-/-Ifngr-/-)
was established. The experiment described above was repeated with these double-
knockout mice. Upon treatment with 0.25 mg/kg of LPS, the HSCs of Ifnar-/-Ifngr-/-
showed a cycling behaviour similar to the HSCs of wildtype mice. However, after treat-
ment with 0.025mg/kg LPS, the effect on the proliferation of HSCs could be completely
rescued (Figure 3.14D). Interestingly, the upregulation of Sca-1 in the Ifnar-/-Ifngr-/-mice
was lower compared to wildtype mice after treatment with 0.25 mg/kg of LPS, although
the cell cycle induction is comparable (Figure 3.14 E). These results imply that the LPS-
induced activation is not completely dependent on, but in part mediated by IFN sig-
nalling. Hence, there might be other cytokines produced upon LPS that canmediate the
effects on HSCs. To show the production of cytokines, apart from IFNs, the conditioned
medium experiment, described above, was repeated using wildtype and Ifnar-/-Ifngr-/-
cells (Figure 3.13 C). Although the increase in Sca-1 expression was lower after in vitro
LPS treatment of Ifnar-/-Ifngr-/- lin depl cells compared to wildtype cells, the increase
in Sca-1 expression after treatment with conditioned medium was comparable to the
control setting, were the cells were directly treated with LPS (Figure 3.14 F), suggesting
cytokines apart from IFNs, able to mediate the effects of LPS on HSPCs.
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Figure 3.14.: The LPS-induced activation of HSCs is in part mediated by IFN signalling
(A) IFNα and (B) IFNγ levels (ELISA) in BM supernatant after in vivo treatment with PBS or LPS (0.25 mg/kg,
4h). (C) Cell cycle analysis (icKi67 andHoechst) of HSCs fromwt, Ifnar-/- or Ifngr-/- mice after treatmentwith
PBS or LPS (0.25mg/kg or 0.025mg/kg, 18h). (D) Cell cycle analysis (icKi67 and Hoechst) of HSCs fromwt or
Ifnar-/-Ifngr-/- mice after treatment with PBS or LPS (0.25 mg/kg or 0.025 mg/kg, 18h). (E) Sca-1 expression
of LK CD150+ cells from wt or Ifnar-/-Ifngr-/- mice after treatment with PBS or LPS (0.25 mg/kg or 0.025
mg/kg, 18h). (F) Sca-1 expression of wt or Ifnar-/-Ifngr-/- LK CD150+ cells after in vitro treatment of lin depl
cells with conditioned medium, obtained from wt cells, or direct treatment with PBS or LPS (control).
Data are the mean +/- SD of at least 3 mice per condition, representing similar results of 2-3 independent
experiments; *p ≤ 0.05, **p ≤ 0.01
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3.5.3. The LPS-induced activation of HSCs in vivo is not mediated by IL-6 or
CXCL10
To investigate which cytokines, apart from IFNs, are involved in the LPS-induced ac-
tivation of HSCs, we analysed the expression of LPS inducible cytokines in the bone
marrow of LPS treated wildtype mice (Björkbacka et al., 2004). The expression of Inter-
leukin 6 (IL-6) was highly induced upon treatmentwith LPS (Figure 3.15 A) and treatment
of wildtype mice with IL-6 led to a slight increase in Ki-67 expression in HSCs (Figure
3.15 B), indicating that IL-6might be a cytokine involved in the LPS-induced activation of
HSCs. Nevertheless, treatment of IL-6-/- mice with LPS did not lead to a reduced cell cy-
cle induction in HSCs compared to wildtype mice, if anything the IL-6-/- HSCs seemed
to cycle even more compared to the wildtype HSCs (Figure 3.15 C). These data indicate
that IL-6 is most likely not involved in the LPS effect on HSCs.
Another cytokine typically produced upon LPS treatment is C-X-C motif chemokine
10 (CXCL10) (Björkbacka et al., 2004). We therefore performed an ELISA, analysing the
bonemarrow supernatant of LPS treated wildtypemice for CXCL10 expression. CXCL10
was highly upregulated in the bonemarrow supernatant upon LPS treatment (Figure 3.15
D). Again, we treated mice with CXCL10 and analysed the BrdU incorporation of HSCs.
Although, there seemed to be a slight increase in proliferation of HSCs upon CXCL10,
this increase was not signicant (Figure 3.15 E). Nevertheless, we analysed the cell cy-
cle induction in Cxcr3-decient (Cxcr3-/-) mice after LPS treatment, to fully exclude a
role of CXCL10 in the LPS-induced activation of HSCs. Apart form CXCL10, Cxcr3 serves
as a receptor for CXCL9 and CXCL11. Treatment of Cxcr3-/- mice with either 0.25 or
0.025 mg/kg LPS led to a signicant increase in cell cycle activity of HSCs comparable
to wildtype mice (Figure 3.15 F), excluding a role of CXCL10, CXCL9 and CXCL11 in the
LPS-induced activation of HSCs.
3.5.4. The LPS-induced activation of HSCs is dependent on TNFα
Tumor necrosis factor alpha (TNFα) is typically produced upon LPS treatment (Björk-
backa et al., 2004). In the bone marrow supernatant of LPS treated mice the expression
of TNFαwas induced, as determined by ELISA (Figure 3.16 A). To investigate whether the
LPS-induced activation of HSCs is dependent on TNFα, we treated wildtype and Tnfrsf1
dKO mice, lacking both receptors for TNFα (Pronk et al., 2011), with 0.25 or 0.025 mg/kg
of LPS and analysed the cell cycle behaviour of HSCs. After treatment with the relatively
high dose of 0.25 mg/kg the HSCs of Tnfrsf1 dKOmice show a cell cycle induction com-
parable to wildtype HSCs. However, after reducing the dose to 0.025 mg/kg of LPS, the
effect on the cycling of HSCswas rescued in the Tnfrsf1 dKOmice (Figure 3.16 B), indicat-
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Figure 3.15.: The LPS-induced activation of HSCs in vivo is not mediated by IL-6 or CXCL10
(A) IL-6 levels (ELISA) in BMsupernatant after in vivo treatmentwith PBSor LPS (0.25mg/kg, 4h). (B) Ki-67 ex-
pression in HSCs after treatment of wtmicewith PBS or IL-6 (0.05mg/kg, 18h). (C) Cell cycle analysis (icKi67
and Hoechst) of HSCs fromwt or IL-6-/- mice after treatment with PBS or LPS (0.25 mg/kg, 18h). (D) CXCL10
levels (ELISA) in BM supernatant after in vivo treatment with PBS or LPS (0.25 mg/kg, 4h). (E) BrdU incor-
poration (14h) in wt HSCs after PBS or CXCL10 (0.5 mg/kg, 18h) treatment. (F) Cell cycle analysis (icKi67 and
Hoechst) of HSCs from wt or Cxcr3-/- mice after treatment with PBS or LPS (0.25 mg/kg or 0.025 mg/kg,
18h).
Data are the mean +/- SD of at least 3 mice per condition, representing similar results of 2-3 independent
experiments; *p ≤ 0.05, **p ≤ 0.01
ing that the LPS-induced activation of HSCs is in part dependent on TNFα. Comparable
to Ifar-/-Ifngr-/- (Figure 3.14 E), the increase in Sca-1 expression upon LPS, was lower in
Tnfrsf1 dKO mice in comparison to wildtype mice (Figure 3.16 C).
3.6. TNFα-induced activation of HSCs
3.6.1. TNFα activates HSCs to enter an active cell cycle
As the LPS-induced activation of HSCs is impaired in Tnfrsf1 dKO mice, we asked
whether TNFα alone would lead to an activation of HSCs. Wildtype and Tnfrsf1 dKO
mice were treated with 0.75 mg/kg of TNFα and the cell cycle activity of HSCs as well
as the incorporation of BrdU was analysed. Upon treatment with TNFα wildtype HSCs
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Figure 3.16.: TNFα-induced activation of HSCs in vivo
(A) TNFα levels (ELISA) in BM supernatant after in vivo treatment with PBS or LPS (0.25 mg/kg, 4h). (B) Cell
cycle analysis (icKi67 and Hoechst) of HSCs from wt or Tnfrsf1 dKO mice after treatment with PBS or LPS
(0.25 mg/kg or 0.025 mg/kg, 18h). (C) Sca-1 expression on LK CD150+ cells after treatment of wt or Tnfrsf1
dKO mice with PBS or LPS (0.25 mg/kg or 0.025 mg/kg, 18h). (D,E) Cell cycle analysis (icKi67 and Hoechst)
of HSCs from wt or Tnfrsf1 dKO mice after treatment with PBS or TNFα (0.75 mg/kg, 18h). Representative
FACS proies (D) and quantitative and statistical analysis (E). (F,G) BrdU incorporation of HSCs from wt or
Tnfrsf1 dKO mice after treatment with PBS or TNFα (0.75 mg/kg, 18h). Representative FACS proies (F) and
quantitative and statistical analysis (G). (H) HSCs in G0 after treatment of wt mice with different doses of
TNFα (18h). (I) HSCs in G0 after treatment of wt mice with 0.75 mg/kg TNFα at different time points.
Data are the mean +/- SD of at least 3 mice per condition, representing similar results of 2-3 independent
experiments; *p ≤ 0.05, **p ≤ 0.01
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exited the G0 phase of the cell cycle and entered the G1, S, G2 or M phase (Figure 3.16 D
and E). HSCswere also actively proliferating, shown by an increased BrdU incorporation
when compared to PBS treated mice (Figure 3.16 F and G). As expected, this increased
cell cycle activity of HSCs was dependent on the expression of the TNF receptors and
was therefore inhibited in the Tnfrsf1 dKOmice (Figure 3.16 D-G). This activation of HSCs
with TNFα can be induced with doses of 0.25 mg/kg (Figure 3.16 H). Comparable to the
treatment with LPS (Figure 3.3 B), the activation of HSCs with TNFαwas transient, with a
peak at 24 hours and the return to homeostasis after 72 hours (Figure 3.16 I). In summary,
these results show that TNFα treatment leads to a TNF receptor-dependent transient ac-
tivation of HSCs into an active cell cycle.
3.6.2. The TNFα-induced activation of HSCs is dependent on Sca-1
The activation of HSCs with LPS as well as IFNα is accompanied by upregulation of
Sca-1 and dependent on the presence of Sca-1. To ascertain if this is also the case for
the activation of HSCs with TNFα, expression of Sca-1 on the surface of TNFα treated
wildtype and Tnfrsf1 dKO LK CD150+ cells was analysed. Treatment of wildtype mice
with TNFα led to a signicant increase of Sca-1 expression on LK CD150+ cells, while an
increase could not be detected in Tnfrsf1 dKO mice (Figure 3.17 A and B). The increase
in Sca-1 expression was lower when compared to the treatment with LPS (Figure 3.6 B
and C). To investigate whether the activation of HSCs with TNFα is also dependent on
Sca-1, we treated wildtype and Sca-1-/- mice with TNFα and analysed the proliferation
of HSCs. LK CD150+CD48- cells of wildtypemice showed a signicant increase in prolif-
eration upon TNFα treatment. However, an increase in BrdU incorporation could not be
detected in Sca-1-/- LK CD150+CD48- cells (Figure 3.17 C), indicating that the activation
of HSCs with TNFα is dependent on Sca-1, despite a lower increase in Sca-1 expression
upon TNFα treatment.
3.6.3. TNFα activates dormant HSCs through an indirect mechanism
TNFα alone can activate HSCs to proliferate in a TNF receptor and Sca-1 dependent
manner. Thus, we asked whether this activation is mediated by direct TNFα signalling
in the HSCs or via an indirect mechanism. Wildtype (CD45.1) and Tnfrsf1 dKO (CD45.2)
bonemarrowcellswere transplanted into lethally irradiatedwildtypemice in a 50:50 ra-
tio (Figure 3.18 A). It has already been shown that the Tnfrsf1 dKO cells have a competitive
advantage over wildtype cells in transplantation assays (Pronk et al., 2011) and therefore
the ratio between wildtype and Tnfrsf1 dKO HSCs was approximately 20:80 at the time
of analysis (Figure 3.18 C).We treated thesemixed chimeras with TNFα and analysed the
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Figure 3.17.: The TNFα-induced activation of HSCs is dependent on Sca-1
(A,B) Sca-1 expression on the surface of LK CD150+ cells after treatment of wt or Tnfrsf1 dKO mice with
PBS or TNFα (0.75 mg/kg, 18h). Representative FACS proles (A) and quantitative and statistical analysis (B).
(C) BrdU incorporation (14h) in LKCD150+CD48- cells after treatment ofwt or Sca-1-/- micewith PBS or TNFα
(0.75 mg/kg, 18h).
Data are the mean +/- SD of at least 3 mice per condition, representing similar results of 2-3 independent
experiments; *p ≤ 0.05, **p ≤ 0.01
cell cycle behaviour of wildtype and Tnfrsf1 dKO HSCs. As expected, the wildtype HSCs
exited the G0 state of the cell cycle upon treatment with TNFα. However, the Tnfrsf1 dKO
HSCs also showed an increased cell cycle activity upon TNFα in this setting (Figure 3.18
B), suggesting that the TNFα-induced activation of HSCs is at least in part mediated via
an indirect mechanism. To investigate the role of the bone marrow niche in the TNFα-
induced activation of HSCs, wildtype bonemarrow cells were transplanted into lethally
irradiated Tnfrsf1 dKO mice, giving reverse chimeras. After 16 weeks these mice were
treated with PBS or TNFα and the cell cycle activity of HSCs was analysed by icKi67 and
Hoechst staining. In this setting, wildtype cells had a normal cell cycle induction (Figure
3.18 D), excluding a direct necessity of TNFα signalling in niche cells for the activation
of HSCs. The nding that TNFα-induced activation of HSCs is at least in part mediated
by an indirect mechanism raises the question of which factors are directly acting on the
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Figure 3.18.: TNFα activates dormant HSCs in part through an indirect mechanism
(A) Experimental set-up of mixed chimeras: bone marrow cells of wt (CD45.1) and Tnfrsf1 dKO (CD45.2)
mice were transplanted into lethally irradiated wt mice in a 50:50 ratio. (B) Cell cycle analysis (icKi67 and
Hoechst) of wt and Tnfrsf1 dKO HSCs in the chimeric setting after treatment with PBS or TNFα (0.75 mg/kg,
18h). (C) Chimerism of wt (CD45.1, black) and Tnfrsf1 dKO (CD45.2, white) HSCs in mixed bone marrow
chimeras at time of analysis (16 weeks after transplantation) (D) Cell cycle analysis (icKi67 and Hoechst) of
HSCs fromwtmice transplanted into lethally irradiated Tnfrsf1 dKOmice after treatment with PBS or TNFα
(0.75 mg/kg, 18h). (E) Cell cycle analysis (icKi67 and Hoechst) of wt and Ifnar-/-Ifngr-/- mice after treatment
with PBS or TNFα (0.75 mg/kg, 18h). (F) Survival curve of PBS or TNFα pre-treated mice after repeated 5-FU
treatments: wildtype mice were treated with PBS or TNFα (0.75 mg/kg) 24h hours before repeated 5-FU
treatments were started, mice were treated with 5-FU (150 mg/kg) every ten days.
Data are the mean +/- SD of at least 3 mice per condition, representing similar results of 2-3 independent
experiments; *p ≤ 0.05, **p ≤ 0.01
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HSCs to induce proliferation upon TNFα treatment. We therefore treated wildtype and
Ifnar-/-Ifngr-/- mice with TNFα to investigate if the TNFα-induced activation of HSCs is
mediated by IFN signalling. The HSCs of Ifnar-/-Ifngr-/- mice responded to TNFα with
an increase in cell cycle activity comparable to the wildtype HSCs (Figure 3.18 E). This
results, together with the data from the MxCre Rosa26eYFPox2 mouse model where
we did not see an increase in IFNα production in the bone marrow upon TNFα treat-
ment (Figure 3.1 J and K), excludes involvement of IFN signalling in the TNFα-induced
activation of HSCs. Thus far, the analysis of LSK CD150+CD48-CD34- HSCs after treat-
mentwith TNFα does not prove an activation of quiescent HSCswith TNFα. Activation of
quiescent HSCs has been shown to make mice susceptible to repeated 5-FU treatment
(Essers et al., 2009), thuswe testedwhether TNFα pre-treatmentwould sensitisemice to
5-FU (Figure 3.18 F). Indeed, mice treated with TNFα 24 hours before the rst treatment
with 5-FU died signicantly earlier compared to PBS treated mice after repeated 5-FU
treatments. While all PBS treatedmice survived at least 3 treatments with 5-FU and half
of the mice even survived more than 4 treatments, all of the TNFα treated mice died af-
ter the second 5-FU treatment (Figure 3.18 F), suggesting that TNFα sensitises the mice
to repeated 5-FU treatments by activating the quiescent HSCs.
In summary, these experiments show that TNFα activates quiescent HSCs, however
the mechanism seems to be at least in part indirectly mediated by another cell type of
the bone marrow.
3.7. Gene expression profiling of activated HSCs
3.7.1. Gene expression analysis of LPS treated wildtype and Ifnar-/-Ifngr-/- mice
As the LPS-induced effects onHSCs are in partmediated by IFN signalling, wewanted
to get a better understanding of the mechanisms involved in the activation of the HSCs
in wildtype and Ifnar-/-Ifngr-/- mice. Mice were treated with PBS or LPS for 16 hours
and LK CD150+CD48- were sorted from bone marrow. From these cells RNA was iso-
lated and gene expression analysis was performed using the Ilumina BeadChip® Sentrix
Array. Reverse transcription, as well as the expression analysis were performed by the
DKFZ Genomics and Proteomics Core Facility (Figure 3.19 A). After normalisation, data
was analysed using R. Figure 3.19 B shows a heat map after non-supervised hierarchi-
cal clustering using the 5000 most variable genes of all four sample groups. The tree
showed a clear separation between the wildtype and the Ifnar-/-Ifngr-/- samples, in-
dicating that the gene expression pattern of the Ifnar-/-Ifngr-/- HSCs was different to
wildtype HSCs at baseline. This clustering can also be shown by a principle compo-
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nent analysis, again using the 5000 most variable genes (Figure 3.19 C). Although the
clustering showed high variations between the wildtype and the Ifnar-/-Ifngr-/- HSCs,
commonly regulated genes could be identied (Figure 3.19 D and E). Among the upreg-
ulated genes were mainly genes involved in the immune response - Saa3, CCL5, Ffar2,
Plac8, CD74 and Psmb10 - as well as genes that might be associated with an increased
metabolic activity due to activation - Pgls, Bcs1l or Pgd. Furthermore, there were some
genes upregulated that might indicate a differentiation induced due to the activation,
such as S100a9, Erdr1 or Sdc3 (Figure 3.19 D). More interestingly, among the downreg-
ulated genes was Cdkn1c (p57), which has been shown to be essential for the mainte-
nance of HSC quiescence (Matsumoto et al., 2011; Zou et al., 2011). To validate the results
of the array, we analysed the expression of selected genes by qRT-PCR and compared
their regulation upon LPS treatment with the data of the array. Wewere able to conrm
the upregulation of Serpina3g, Socs3 and CCL5, as well as the downregulation of Apbb1,
Foxa3 and CXCL4 (Figure 3.19 F and G). Although the fold changes between the array and
the qPCR data are not comparable, this shows that the direction of regulation in the ar-
ray data resembles the results of the q-RT-PCR, demonstrating that the microarray data
reliably reects the expression of the analysed genes.
3.7.2. Gene expression analysis after treatment with IFNα, LPS or TNFα
The activation of HSCs can not only be achieved by treatment with IFNα and LPS, but
also with TNFα. Therefore, another MicroArray analysis was performed, treating wild-
typemicewith TNFα and comparing this data to the data from the previous array, where
we treated wildtype mice with PBS, LPS or IFNα (Figure 3.20 A). With this analysis we
aimed to identify a common mechanism that is regulating the increase in proliferation
after the different treatments. As outlined in section 3.7.1, weperformednon-supervised
hierarchical clustering as well as a principle component analysis using the 5000 most
regulated genes. In this analysis a clear similarity between the IFNα and the LPS treated
samples was detected, while the TNFα treated samples clustered separately from the
other treatments (Figure 3.20 B and C), indicating that the LPS-induced activation of
HSCs is very similar to the IFNα induced activation, while the TNFα-induced activation
seems touse anothermechanism. Nevertheless, this does not exclude a commonmech-
anism inducing the activation of HSCs at a downstream point of the signalling path-
ways. Also genes that are similarly regulated in all treatments could be identied (Figure
3.20 D and E). These include Oas2, Plac8, Prg2, Ffar2 and CD74, which were most likely
upregulated as a consequence of the immune response, as well as Fbox39, Aars and
Uqcrb, which again point towards increased metabolic activity after activation. Among
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Figure 3.19.: Gene expression analysis of LPS treated wildtype and Ifnar-/-Ifngr-/- mice
(A) Experimental set-up: LK CD150+CD48- cells from wt or Ifnar-/-Ifngr-/- mice treated with PBS or LPS
(0.25 mg/kg, 16h) were sorted and RNA was used for expression analysis with the Ilumina BeadChip® Sen-
trix Array. (B) Unsupervised hierarchical clustering of the 5000 most variable genes. (C) Principle com-
ponent analysis of the 5000 most variable genes. (D,E) Fold change of selected genes regulated in wt and
Ifnar-/-Ifngr-/- mice after LPS treatment. (F,G) Validation of expression of selected genes by qRT-PCR.
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the downregulated genes was Matn4, an extracellular matrix protein, which seems to
a have a role in haematopoiesis (Uckelmann and Essers, unpublished data). Further-
more, some genes that have been implicated to have a role in HSC self-renewal or have
been shown to be highly expressed in HSCs compared to progenitors, were downregu-
lated upon activation. These include Ptn, Fhl1 and Cadps2. The downregulation of these
genes might again point towards an increased differentiation of the activated cells. The
third group of downregulated genes, included genes that have been suggested to have
anti-proliferative effects (Rprm, Marcks and Sdc2), however a role of these genes in HSC
regulation has not been shown so far (Figure 3.20 E).
3.7.3. Gene expression analysis of IFNα, LPS or TNFα treated wildtype and LPS
treated Ifnar-/-Ifngr-/- mice
The LPS-induced activation ofHSCs ismediated in part by IFN and in part by TNFα sig-
nalling (Figures 3.14 and3.16), suggesting that the LPS-induced activationof Ifnar-/-Ifngr-/-
HSCs is mainly mediated by TNFα signalling. Hierarchical clustering was performed,
as well as a principle component analysis, using the 5000 most regulated genes in the
wildtype samples, comparing the gene expression data of wildtype HSCs treated with
IFNα, LPS or TNFα to Ifnar-/-Ifngr-/- HSCs treated with LPS. A clear separation of wild-
type and Ifnar-/-Ifngr-/- could be detected in the hierarchical clustering as well as in
the principle component analysis (Figure 3.21 A and B). Interestingly, the TNFα treated
samples formed a separate group, with low similarities to the wildtype treated samples,
as well as to the Ifnar-/-Ifngr-/- samples, indicating that the LPS-induced activation of
Ifnar-/-Ifngr-/- HSCs might not be solely mediated by TNFα (Figure 3.21 A and B). How-
ever, the gene regulation of Ifnar-/-Ifngr-/- HSCs after TNFαwas not analysed.
The only cell cycle regulator noted in the analysis of the array data, p57, has already
been implicated to have a role in themaintenance of HSC quiescence (Matsumoto et al.,
2011; Zou et al., 2011; Tesio and Trumpp, 2011). Expression of p57 was analysed by qRT-
PCR after treatment of wildtype mice with polyI:C, LPS or TNFα and Ifnar-/-Ifngr-/- af-
ter treatment with LPS. There was a decrease of p57 expression in all samples (Figure
3.21 C), suggesting a common regulatory mechanism leading to the activation of HSCs.
However, the decrease in p57 expression is likely a consequence of the LPS-induced ac-
tivation of HSCs. Identication of the signalling pathways leading to this decrease in p57
expressionmight therefore lead to a better understanding of the regulation of HSC pro-
liferation upon infection. The MicroArray data allows the identication of some com-
mon feature, like the decreased expression of p57 among all treatments, however it is
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Figure 3.20.: Gene expression analysis after treatment with IFNα, LPS or TNFα
(A) Experimental set-up: LK CD150+CD48- cells from wt mice treated with PBS, IFNα (50x105 U/kg), LPS
(0.25 mg/kg) or TNFα (0.75 mg/kg) for 16h were sorted and RNA was used for expression analysis with
the Ilumina BeadChip® Sentrix Array. (B) Unsupervised hierarchical clustering of the 5000 most variable
genes. (C) Principle component analysis of the 5000 most variable genes. (D,E) Fold change of selected
genes similarly regulated after all treatments.
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Figure 3.21.: Gene expression analysis of IFNα, LPS or TNFα treated wildtype and LPS treated
Ifnar-/-Ifngr-/- mice
(A) Unsupervised hierarchical clustering of the 5000most variable genes. (C) Principle component analysis
of the 5000 most variable genes. (C) p57 expression of LK CD150+CD48- cells from wildtype mice treated
with polyI:C (5 mg/kg), LPS (0.25 mg/kg) or TNFα (0.75 mg/kg) or Ifnar-/-Ifngr-/- mice treated with LPS, rel-
ative to PBS treated samples, analysed by qRT-PCR.
Data are the mean +/- SD of at least 3 mice per condition, representing similar results of 2-3 independent
experiments.
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difcult to nd a common mechanism leading to the increased cycling of HSCs upon
different stimuli.
3.8. The role of IL-1β in the activation of HSCs
3.8.1. IL-1β treatment leads to increased proliferation of HSCs in a MyD88
dependent manner
Our data suggests that the TNFα-induced activation of HSCs is indirectly mediated
(Figure 3.18 B) and that IFN signalling is not involved in the TNFα-induced activation of
HSCs (Figures 3.1 J and K, 3.18 E), implying that there are other cytokines mediating the
LPS and TNFα-induced activation of HSCs. As IL-1β is typically produced upon LPS sig-
nalling (Björkbacka et al., 2004), the production of IL-1β in the bone marrow was anal-
ysed after treatment of wildtype mice with LPS or TNFα by ELISA. LPS, as well as TNFα
treatment, led to an increase of IL-1β expression in the bonemarrow supernatant (Figure
3.22 A). We therefore hypothesised that IL-1β might be a potential activator of HSCs in
the context of LPS and TNFα treatment. To investigate the effects of IL-1β on HSCs, wild-
typemicewere treatedwith PBS or IL-1β and cells were analysed for cell cycle behaviour
aswell as the Sca-1 expression of HSPCs. After treatmentwith IL-1β theHSCs ofwildtype
mice exited the G0 phase and entered an active cell cycle (Figure 3.22 B and D). Further-
more, the HSCs started to actively proliferate upon IL-1β (Figure 3.22 C and E), indicating
that IL-1β leads to an activation of HSCs comparable to treatment with other cytokines
or LPS. Apart from the cell cycle induction, the expression of Sca-1 on LK CD150+ was
analysed, as Sca-1 has been shown to be involved in the activation of HSCs with polyI:C,
LPS and TNFα (Essers et al., 2009) (Figures 3.6 D and 3.17 C). The HSPCs of IL-1β treated
mice showed a slight, but not signicant, increase in Sca-1 expression (Figure 3.22 F and
G). Interestingly, treatment of Sca-1-/- mice with IL-1β still led to a rescue of the IL-1β-
induced increase in proliferation of HSCs, although the upregulation of Sca-1 on protein
as well as on mRNA level is negligible in comparison to the Sca-1 increase seen with
polyI:C or LPS (Figure 3.23 A and B), indicating that the activation of HSCs might not be
directly dependent on an increase in Sca-1 expression. The IL-1β signalling pathway is
mediated by the adaptor MyD88,MyD88-/- mice were treated with IL-1β and the cell cy-
cle induction and Sca-1 expression was compared to wildtype mice. As expected, the
HSCs ofMyD88-/- mice did not respond to IL-1β treatment with increased proliferation
or Sca-1 expression (Figure 3.22 B-G). To investigate if IL-1β directly activates HSCs, we
sorted LK CD150+ cells and treated themwith PBS, IFNα , LPS or IL-1β in culture. Because
the upregulation of Sca-1with IL-1β is very low, Sca-1 cannot be used as a readout for this
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Figure 3.22.: IL-1β treatment leads to increased proliferation of HSCs in a MyD88 dependent manner
(A) IL-1β levels (ELISA) in the bone marrow supernatant of PBS, LPS (0.25 mg/kg, 4h) or TNFα (0.75 mg/kg,
4h) treated wt mice. (B,D) Cell cycle analysis (icKi67 and Hoechst) of HSCs from wt orMyD88-/- mice after
treatment with PBS or IL-1β (0.125 mg/kg, 18h). Quantitative and statistical analysis (B) and representative
FACS proles (D). (C,E) BrdU incorporation (14h) in HSCs from wt or MyD88-/- mice after treatment with
PBS or IL-1β (0.125 mg/kg, 18h). Quantitative and statistical analysis (C) and representative FACS proles (E).
(F,G) Sca-1 expression on LK CD150+ cells fromwt orMyD88-/- mice after treatment with PBS or IL-1β (0.125
mg/kg, 18h). Quantitative and statistical analysis (G) and representative FACS proles (F). (H) BrdU incorpo-
ration (14h) in HSCs from wt or Sca-1-/- mice after treatment with PBS or IL-1β (0.125 mg/kg, 18h). (I) BrdU
incorporation (3h) after in vitro treatment of sorted LK CD150+ cells with PBS, IFNα (1000 U/ml), LPS (100
ng/ml) or IL-1β (100 ng/ml) for 20 h.
Data are the mean +/- SD of at least 3 mice per condition, representing similar results of 2-3 independent
experiments; *p ≤ 0.05, **p ≤ 0.01
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experiment. We therefore analysed BrdU incorporation. Treatment of sorted LK CD150+
with IL-1β in vitro led to a decreased cycling of these cells, comparable to the treatment
with IFNα, while the treatment with LPS did not lead to a decrease in BrdU incorpora-
tion (Figure 3.22 I). Nevertheless, this is indicative of, not proof of, a direct activation of
HSCswith IL-1β and thus it has to be further investigated, if the in vivo activation of HSCs
is also mediated by a direct mechanism. For that purpose a set of mixed bone marrow
chimeras with bonemarrow fromwildtype and IL-1 receptor (IL-1R) decientmice have
been prepared, to analyse the activation of the IL-1R-/- HSCs in this setting.
A B
Figure 3.23.: Sca-1 expression on protein and mRNA level after different treatments
(A) Increase in Sca-1 expression on LK CD150+ cells after treatment with polyI:C (5mg/kg), LPS (0.25mg/kg),
TNFα (0.75 mg/kg) or IL-1β (0.125 mg/kg) for 18h, measured by Flow Cytometry, relative to PBS treated cells.
(B) Increase in Sca-1 mRNA levels of sorted LK CD150+CD48- from wt mice treated with polyI:C (5 mg/kg),
LPS (0.25 mg/kg), TNFα (0.75 mg/kg) or IL-1β (0.125 mg/kg) for 16h, measured by qRT-PCR, relative to PBS
treated samples.
Data are the mean +/- SD of at least 3 mice per condition, representing similar results of 2-3 independent
experiments; *p ≤ 0.05, **p ≤ 0.01
3.8.2. The LPS-induced activation of HSCs is dependent on IFN, TNFα and IL-1β
signalling
IFNα, TNFα as well as IL-1β canmediate activation of HSCs (Essers et al., 2009) (Figures
3.16 D-G and 3.22 B-E) and that all of these cytokines are produced upon LPS treatment
(Figures 3.14 A and B, ?? A and 3.22 A). To further investigate the role of IFN, TNFα and IL-
1β signalling in the LPS-induced activation ofHSCs, two inhibitorswere used. Etanercept
is a synthetic TNFα inhibitor, used in the clinics to treat for example rheumatic diseases
(reviewed in Bradley, 2008), while the IL-1 receptor antagonist (IL-1RA) is a naturally-
occurring protein secreted by immune cells, to regulate the activity of IL-1α and IL-1β
(reviewed in Weber et al., 2010). Wildtype mice were treated with Etanercept for ten
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Figure 3.24.: The LPS-induced activation of HSCs is dependent on IFN, TNFα and IL-1β signalling
(A) Experimental set-up: wt or Ifnar-/-Ifngr-/- mice were treated with Etanercept (days 1-5 5 mg/kg, days 6-
10 7.5 mg/kg) or PBS for 10 days, at day 10 the mice were treated with IL-1RA or PBS 1h before the treatment
with PBS or LPS (0.25 mg/kg, 18h). (B) Cell cycle analysis (icKi67 and Hoechst) of HSCs from wildtype mice
treated with PBS or Etanercept for 10 days and PBS or LPS (0.25mg/kg) for 18h. (C) Cell cycle analysis (icKi67
and Hoechst) of HSCs from Ifnar-/-Ifngr-/- mice treated with PBS or Etanercept for 10 days and PBS or LPS
(0.25 mg/kg) for 18h. (D) Cell cycle analysis (icKi67 and Hoechst) of HSCs from Ifnar-/-Ifngr-/- mice treated
with PBS or Etanercept for 10 days and PBS or LPS (0.25 mg/kg) for 18h, as well as PBS or IL-1RA 1h before
the LPS treatment.
Data are the mean +/- SD of at least 3 mice per condition, representing similar results of 2-3 independent
experiments; *p ≤ 0.05, **p ≤ 0.01
days, to ascertain the effects of blocking TNFα alone. Mice were subsequently treated
with PBS or 0.25 mg/kg LPS (Figure 3.24 A) and the cell cycle induction of HSCs was
analysed. The Etanercept treated wildtype HSCs showed an increased cell cycle activ-
ity upon LPS, comparable to untreated controls (Figure 3.24 B). This was expected, as
the treatment of Tnfrsf1 dKO mice with 0.25 mg/kg of LPS also led to a normal cell cy-
cle induction of HSCs. Treatment of Ifnar-/-Ifngr-/- with 0.25 mg/kg LPS led to an in-
creased cell cycle of HSCs, while treatment with a lower dose of LPS led to a rescue of
the LPS effect in Tnfrsf1 dKO as well as Ifnar-/-Ifngr-/- mice. The Etanercept treatment
was therefore repeated in Ifnar-/-Ifngr-/- mice, to achieve a combined blocking of IFN
and TNFα signalling, before treating those mice with PBS or LPS. The increase in cell
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cycle activity of HSCs upon LPS treatment, was signicantly reduced compared to the
untreated controls, however we could not achieve a complete rescue of the effect (Fig-
ure 3.24 C), indicating that the LPS-induced effect on HSCs is not mediated by IFN and
TNFα signalling alone. To analyse the LPS-induced effects on HSCs, IFN, TNFα and IL-1β
signalling was blocked at the same time. Ifnar-/-Ifngr-/- mice were treated with Etaner-
cept for 10 days and additionally with IL-1RA, 1 hour before the LPS treatment. Again, a
signicant reduction in the increase in cell cycle activity upon treatment with Etaner-
cept alone was observed, which can be further enhanced by combined treatment with
Etanercept and IL-1RA (Figure 3.24D). Nevertheless, the effect of LPS onHSCs still cannot
be completely rescued, indicating that there might be some other cytokines involved in
the LPS-induced activation of HSCs or that the blocking effects of Etanercept and IL-1RA
are not complete.
In summary, this data shows that the LPS-induced activation of HSCs is mainly medi-
ated by a combination of IFN, TNFα and IL-1β signalling, however we could not exclude
the involvement of other cytokines produced upon LPS treatment.
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4.1. The short-term effect of LPS on HSCs differs from the long-term
effect
Wehave investigated the in vivo short-termeffects of LPS treatment on the cycling be-
haviour of HSCs. With this research we aimed to understand the rst response of HSCs
to infections and how this might be linked to already published data on the long-term
effects of infections or treatment with TLR ligands on HSCs (Zhang et al., 2008; Singh
et al., 2008; Rodriguez et al., 2009; Takizawa et al., 2011; Esplin et al., 2011; Choi et al.,
2011). Furthermore, we wanted to link our results to previously published data on HSC
behaviour in response to cytokines, such as IFNs and TNFα. As we had already shown
that IFNα treatment leads to an increase in proliferation of HSCs, we asked whether this
might be part of a feedback-loop induced upon infection. We were able to show that in
vivo, short-term treatment of mice with LPS led to an increase in proliferation of even
themost dormant HSCs (Figures 3.2 and 3.4). This is in accordance with previously pub-
lished data showing increased cycling of HSCs in response to long-term LPS treatment
or infection (Kaulen et al., 1983; Zhang et al., 2008; Yanez et al., 2009; Takizawa et al., 2011;
Esplin et al., 2011). In contrast to long-term LPS effects, we show that the short-term
effect of LPS on HSCs was transient, with a return of the HSCs to quiescence after 72
hours (Figure 3.3 B). This nding is in keeping with previously published work, showing
that HSCs can enter cycle upon stress, but rapidly return to their dormant state when
the situation is resolved (Wilson et al., 2008; Essers et al., 2009; Takizawa et al., 2011).
With these ndings we can now explain the loss of repopulation potential of HSCs seen
in long-term studies, as chronic activation of TLR signalling leads to constant cycling of
HSCs, resulting in their exhaustion, as shown in various studies (Rodriguez et al., 2009;
Takizawa et al., 2011; Esplin et al., 2011). This effect of constant cycling of HSCs on their
engraftment potential has also been shown in response to activation of HSCs with other
stimuli, such as IFNs (Essers et al., 2009; Sato et al., 2009; Baldridge et al., 2010). A more
recent study has, however, challenged the hypothesis that IFN treatment leads to an in-
creasedproliferationofHSCs, by showing that IFNγ treatment ofHSCs in culture leads to
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reduced cell numbers and that infection ofmicewith LCMV led to impaired engraftment
of HSCs upon competitive transplantations (de Bruin et al., 2013). From these results it
was concluded that IFNs have an anti-proliferative effect on HSCs and that the results
obtained in previous studies are due to a contamination of the population analysed, as
progenitor cells start to express Sca-1 upon IFN stimulation (Essers et al., 2009; Baldridge
et al., 2010; de Bruin et al., 2013). However, these results support the results obtained in
the previous studies, as the engraftment defect upon LCMV infection is very likely due
to constant cycling of HSCs in this setting (Essers et al., 2009; Sato et al., 2009; Baldridge
et al., 2010; de Bruin et al., 2013; King et al., 2013). It might be true that the induction of
Sca-1 expression on progenitor cells leads to an increase of progenitors in the LSK pop-
ulation, however, the use of further markers, like CD150, CD48 and CD34, nonetheless,
enables the identication of real HSCs also upon Sca-1 upregulation (King et al., 2013).
Furthermore, for IFNα as well as for LPS treatment we were able to show that even the
most dormant LRCs are activated into a state of active proliferation (Essers et al., 2009)
(Figure 3.4). Similarly, differences in long-term and short-term effects of TNFα on HSCs
can be observed. We have shown that TNFα treatment of mice leads to an increased
cell cycle activity of HSCs, as well as an activation of quiescent HSCs into proliferation
(Figures 3.16 D-G and 3.18 F). These ndings could explain the results of a recently pub-
lished study onHSCs ofmice lacking both TNF receptors (Tnfrsf1 dKO). This study shows
an enhanced repopulation activity of HSCs from Tnfrsf1 dKO mice compared to HSCs
from wildtype mice in competitive transplantations, concluding that TNFα has an anti-
proliferative effect on HSCs (Pronk et al., 2011). Nevertheless, these studies do not show
direct cell cycle analysis of HSCs from Tnfrsf1 dKO mice. Therefore, these ndings can
be explained by our ndings that TNFα treatment leads to an increased proliferation
of HSCs. This increased cycling upon TNFα signalling might lead to a reduced engraft-
ment potential of wildtype HSCs in competition with Tnfrsf1 dKO HSCs, which do not
respond to TNFα and are thereforemore quiescent, as quiescent HSCs have been shown
to exhibit an engraftment advantage over cycling HSCs (Spangrude and Johnson, 1990;
Passegue et al., 2005). TNFα induced activation of wildtype HSCs in this settingmight be
due to TNFα production upon irradiation, which represents major bone marrow stress,
or due to small amounts of TNFα thatmight be constantly produced in the bonemarrow.
In contrast to long-term activation of HSCs in response to infections, the repopulation
potential of HSCs treated with a single dose of LPS was not impaired (Figure 3.5). This
is in accordance with our nding that the LPS induced proliferation of HSCs is transient
(Figure 3.3 B) and ndings by others that HSCs are able to reestablish quiescence and
successfully repopulate a recipient after they have been activated with LPS (Takizawa
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et al., 2011). In summary, the short-term as well as the long-term effects of LPS exposure
on HSCs seen by us and others can be explained by increased cycling of HSCs, leading
to loss of quiescence as well as exhaustion of the HSC pool upon chronic LPS signalling.
Furthermore, increased cycling of HSCs might be a cause of bone marrow failure seen
in patients suffering from chronic infections.
CD11b+
TLR4
LPS
IFNα IFNγ
HSC
TNFα
IL-1β
TLR4
IFNAR
IFNGR TNFR
IL-1R
Sca-1
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Sca-1 upregulation
Sca-1
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Figure 4.1.: The LPS-induced activation of HSCs
The LPS-induced activation of HSCs is indirectly mediated through the production of inammatory cy-
tokines by CD11b+ cells and possibly other cells. These cytokines include IFNα, IFNγ, TNFα and IL-1β. The
IFNs and IL-1β lead to a direct activation of HSCs, while the effect of TNFα is most likely indirect. The HSCs
start to proliferate and upregulate Sca-1 upon LPS-induced stimulation.
4.2. The LPS-induced activation of HSCs is indirectly mediated
We have shown that the LPS-induced activation of HSCs is indirectly mediated (Fig-
ure 3.10) and thatmyeloid cells, more specically inammatorymonocytes are involved
in this activation (Figures 3.11, 3.12 and 4.1). These ndings suggest that at least in terms
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of HSC cycling the effects are not induced by direct activation of TLR signalling within
the HSCs. This is in contrast to a study proposing that differentiation of HSPCs upon LPS
treatment is directly mediated (Megías et al., 2012). In this study, LSK cells fromwildtype
mice were transplanted into non-irradiated TLR4-/- recipients and directly treated with
LPS, leading to a differentiation of the transplanted cells intomacrophages (Megías et al.,
2012). However, LSK cells are a rather heterogenous population and tend to rapidly dif-
ferentiate upon transplantation. Therefore, these experiments are a hint of direct sens-
ing of LPS by LSK cells, but no proof for a direct activation of TLR signalling in HSCs.
We demonstrated an indirect activation of HSCs with LPS using mixed bone marrow
chimeras, in which also TLR4-/- HSCs showed increased proliferation upon LPS treat-
ment (Figure 3.10 B). However, with this experiment we cannot rule out a direct effect
of LPS on HSCs, that might be overshadowed by the indirectly induced proliferation of
HSCs. To reduce the indirect effects upon LPS, one could analyse the cycling behaviour
of TLR4-/- HSCs in a chimeric setting with very few wildtype HSCs in relation to TLR4-/-
HSCs. However, it is very difcult to set up such chimeras, as the TLR4-/- HSCs show an
engraftment advantage over wildtype HSCs (reviewed in Baldrige et al., 2011), and will
therefore outcompete the wildtype HSCs in such a setting over time. Assuming that the
proliferation of HSCs upon LPS is linked to the increased expression of Sca-1, our in vitro
results point towards a solely indirect effect of LPS onHSCs. Although the LPS treatment
of HSPCs in culture does not lead to an increased cycling of HSCs, we can compare the
in vitro effects of LPS treatment to effects of IFNα treatment, which has been shown to
induce a direct activation of HSCs (Essers et al., 2009; Sato et al., 2009). IFNα treatment
of HSPCs in culture leads to an increased expression of Sca-1 on HSPCs, as well as a re-
duced proliferation of these cells, while these effects cannot be detected upon in vitro
LPS treatment (Figure 3.10 F-H), again pointing towards a solely indirect activation of
HSCs with LPS.
This difference between the in vivo and the in vitro treatment of HSCs has been ob-
served in various studies. While the in vivo treatment of mice with IFN leads to in-
creased proliferation of HSCs, in vitro studies have reported an opposite effect (Essers
et al., 2009; Sato et al., 2009; Baldridge et al., 2010; de Bruin et al., 2013). Similarly, the in
vitro treatment of HSPCs with TNFα led to inhibition of HSC cycling in various studies
(Jacobsen et al., 1992; Rusten et al., 1994; Jacobsen et al., 1994; Dybedal et al., 2001), while
we showed an increased proliferation of HSCs upon in vivo treatmentwith TNFα (Figure
3.16 D-G). These differences are likely due to the absence of the bonemarrow niche en-
vironment in culture (reviewed in Prendergast and Essers, 2014). Although, our results
exclude a direct necessity of TLR4 activation in niche cells to induce the activation of
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HSCs (Figure 3.10 D), it is likely that indirect effects alter the niche environment, pro-
moting the increased proliferation of HSCs, as the interaction of HSCs with their niches
has been shown to be essential for the maintenance of HSC quiescence. It is possible
that factors produced by mature immune cells or even by the HSCs themselves as re-
sponse to infections, alter the secretion of factors that mediate the retention of HSCs
in the niche. It has for example been shown that G-CSF, a cytokine produced upon in-
fection, leads to a reduced secretion of CXCL12 by osteoblasts, resulting in release of
HSCs from their niches (Winkler et al., 2010; Christopher et al., 2011). It can therefore be
assumed that other cytokines produced upon infection, such as IFNs, TNFα or others,
might have similar effects. It has been shown that activation of HSCs with polyI:C leads
to a relocation of these cells within the bone marrow niche (Kunisaki et al., 2013), in-
dicative of changes in the bone marrowmicroenvironment induced upon infections. A
typical effect of inammatory cytokines is the induction of adhesion molecule expres-
sion on endothelial cells, leading to the recruitment of immune effector cells to the sites
of infection (reviewed in Mogensen, 2009). These adhesion molecules "mark the way"
from the bone marrow, where for example monocytes and B cells are located during
homeostasis, to the infected tissue. It is therefore likely that similar to mature immune
cells, HSCs also adhere to the endothelial cells of the bone marrow vasculature upon
increased expression of adhesion molecules, leading to a relocation of HSCs from the
endosteum to the vasculature. This could in turn enable a fast release of newly pro-
duced progenitors into the periphery. As there is no increased mobilisation of HSCs
upon a single dose of LPS (data not shown), it is likely that the HSCs are retained within
the bone marrow, moving only to the periphery after they have differentiated into pro-
genitors or mature cells. In addition, immune cells, like macrophages and T cells, have
been suggested to be part of the HSC niche (Winkler et al., 2010; Chow et al., 2011; Fu-
jisaki et al., 2011). As these cells are clearly affected by immune stimulatorymechanisms,
it is very likely that these effects will also lead to an alteration of the HSC niche, resulting
in changes in HSC behaviour.
Our nding that myeloid cells can mediate the LPS-induced effects on HSCs (Figures
3.11 and 3.12), sheds new light on the role of these myeloid cells in the bone marrow
during infection. Our in vitro results suggest that the LPS-induced effects are mainly
mediated by inammatory monocytes (Figure 3.11), which are found in the bone mar-
row during homeostasis but can be rapidly recruited to the infected tissue where they
differentiate to macrophages or dendritic cells (Gordon and Taylor, 2005; Robbins and
Swirski, 2010; Shi and Pamer, 2011). This recruitment ofmonocytes and their subsequent
loss from the bonemarrow leads to the necessity to produce newmonocytes to ght in-
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fection and to restore homeostatic conditions. Therefore, it is possible that monocytes
produce factors that mediate re-production through direct activation of HSPCs or in-
direct induction of changes in the BM microenvironment, when they are activated and
leave the bone marrow. Thus, the activation of monocytes by LPS would indirectly lead
to a subsequent activation of HSCs to proliferate and differentiate towards the myeloid
lineage. This is supported by ndings, that LPS treatment actually leads to differentiation
of HSPCs to myeloid cells (Nagai et al., 2006; Luca et al., 2009; Yanez et al., 2010; Esplin
et al., 2011; Megías et al., 2012). Nevertheless, our ndings are based on in vitro experi-
ments alone andmay thereforenot correspond to the actual in vivo situation. Our in vivo
results, however, further support the in vitrondings. There is a decrease in cell cycle in-
duction ofHSCs fromclodronate treatedmice in comparison to the controlmice (Figure
3.12 F), indicating a role for myeloid cells in the LPS-induced activation of HSCs in vivo.
This difference is, however, low and the pre-treatment of mice with clodronate did not
lead to a complete rescue of the LPS-induced effects. This could be for several reasons,
one being that we treated the mice with clodronate 5 days before the LPS treatment, to
avoid the initial wave of HSC mobilisation upon loss of myeloid cells. After ve days
many of the initially depleted cells, like for example monocytes (Chow et al., 2011), have
already re-emerged (data not shown), while the number of bone marrowmacrophages
remains signicantly lower compared to the control treated mice (Figure 3.12 G). This
could, however, mean that the cells that are actually mediating the LPS-induced activa-
tion ofHSCs have already re-emerged and are therefore at least in part able to induce the
increased proliferation of HSCs upon LPS. This would support the in vitro nding that
only monocytes, but not macrophages, canmediate the increase in Sca-1 expression on
HSPCs upon LPS treatment. Another reason for the incomplete rescue of the LPS effect
could be the involvement of several cell types in the LPS-induced activation of HSCs,
as cytokines are produced by different cell types upon LPS signalling (Akira and Takeda,
2004; Kawai and Akira, 2010). For example, interferons are mainly produced by plas-
macytoid dendritic cells (pDCs) (Perussia et al., 1985; Asselin-Paturel et al., 2003), which
are not depleted upon clodronate treatment (data not shown). Therefore, the produc-
tion of interferons by pDCs might be responsibly for the increased cycling of HSCs in
this experiment. Furthermore, the depletion of myeloid cells with clodronate does not
lead to a complete loss of these cells and the remaining cells might be enough to induce
the cycling of HSCs upon LPS. It is unlikely that myeloid cells do not have any role in
the LPS-induced activation of HSCs, as they have been shown to be the main producers
of inammatory cytokines in response to LPS (reviewed in Kawai and Akira, 2010) and
macrophages have been shown to be in close contact with HSCs in their niche (Win-
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kler et al., 2010; Chow et al., 2011). It is therefore likely, that cells of the myeloid lineage,
like monocytes or macrophages, are at least in part producing the cytokines that are re-
sponsible for LPS-induced activation of HSCs. Nevertheless, there might be several cell
types, like other cells that have been proposed tomake up theHSC niche aswell as other
immune cells, involved in the process of HSC activation and further experiments need
to be performed to get a full understanding of this process.
4.3. The LPS-induced activation of HSCs is mediated by cytokines
We have shown that the LPS-induced activation of HSCs is mediated by IFNs, TNFα
and IL-1β (Figures 3.14, 3.16, 3.22 and 3.24). These are cytokines typically produced upon
TLR stimulation (reviewed in Akira and Takeda, 2004; Borden et al., 2007; Bradley, 2008;
Kawai and Akira, 2010;Weber et al., 2010) and the role of these cytokines during immu-
nity has been extensively studied. Furthermore, a role for IFNs and TNFα in the regu-
lation of HSC functions has been proposed. IFNα, as well as IFNγ, have been shown to
directly induce the proliferation of HSCs (Essers et al., 2009; Sato et al., 2009; Baldridge
et al., 2010). In combination with our ndings that IFNα and IFNγ are produced upon
LPS treatment (Figures 3.1 and 3.14 A and B), it is not surprising that these IFNs are also
involved in the LPS-mediated activation of HSCs. We furthermore showed that TNFα
alone can induce activation of HSCs (Figure 3.16) and that IFN, as well as TNFα signalling,
are involved in the LPS-induced activation of HSCs. However, the increase in prolifera-
tion of HSCs is not completely dependent on IFN or TNFα signalling alone upon a high
dose of LPS (Figures 3.14 and 3.16). Furthermore, even upon combined blocking of IFN
and TNFα signalling treatment of mice with a high dose of 0.25 mg/kg LPS still led to
a signicant increase in cycling HSCs (Figure 3.24 C). It is therefore likely that the acti-
vation of HSCs upon LPS is mediated by several cytokines, rather than just by IFNs and
TNFα, as LPS leads to the production ofmany different cytokines (Björkbacka et al., 2004)
and all of these cytokines could have a possible effect on the cycling behaviour of HSCs.
We excluded involvement of CXCL9, CXCL10 and CXCL11 in the LPS-induced activation
of HSCs to proliferate (Figure 3.15 F), although these cytokines might be involved in the
regulation of other responses of HSCs to infection, such as differentiation. A role for IL-6
in this effect of LPS on HSCs can, however, not be completely excluded with our results.
Treatment with a higher dose of IL-6 might actually lead to a clearer activation of HSCs
and treatment of IL-6-/-micewith a lowdose of LPS could verywell have an effect on the
induced cycling of HSCs. Interestingly, we were able to show for the rst time that IL-1β
treatment of mice led to an increased cycling of HSCs (Figure 3.22 B-E). As IL-1β is highly
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upregulated upon LPS treatment (Figure 3.22 A) (Björkbacka et al., 2004) and combined
blocking of IFN, TNFα and IL-1β signalling led to a further reduction of the cell cycle acti-
vation of HSCs upon LPS (Figure 3.24 D), we propose that IL-1β, as well as IFNs and TNFα,
are involved in the LPS-induced activation of HSCs. Furthermore, our data provides a
rst indication that the IL-1β induced activation of HSCs might be directly induced by
IL-1β signalling within the HSCs, as HSPCs respond to IL-1β treatment in vitro similar to
IFNα treatment. IL-1βmight therefore be the missing link in the LPS-induced activation
of HSCs in Ifnar-/-Ifngr-/- mice as well as in the TNFα -induced activation of HSCs, di-
rectly affecting the cycling behaviour of HSCs. This hypothesis is further supported by
the nding that IL-1β is not only upregulated upon LPS treatment, but is also highly in-
duced upon TNFα treatment (Figure 3.22 A), suggesting that IL-1β is one of the factors
leading to the TNFα-induced activation of HSCs. Our results, however, do not exclude
the involvement of further cytokines in the LPS-induced effects on HSCs, as even upon
combined blocking of IFN, TNFα and IL-1β signalling, a signicant increase in cycling
HSCs upon LPS could still be detected (Figure 3.24 D). It is therefore likely that the LPS
induced effects on HSCs can bemediated by several cytokines, excluding a dependency
on only one cytokine upon stimulation with a high dose of LPS. This observation makes
the identication of single cytokines that are involved in the LPS-induced activation of
HSCs more complex. Hence, it is necessary to perform further experiments to investi-
gate the effects of IL-6 and other cytokines, like CCL5, on the cycling behaviour of HSCs,
as well as their role in the LPS-induced activation of HSCs.
MicroArray analysis of activated HSCs upon different stimuli potentially allowed us
to investigate the commonmechanisms leading to increased cycling of HSCs. However,
from this data we could not convincingly conclude a common mechanism activated in
HSCs upon all different treatments. Nevertheless, a common feature of the signalling
pathways of LPS, as well as IFNs, TNFα and IL-1β, is NFκB activation. Furthermore, we
could show that NFκB is translocated to the nucleus in HSCs upon activation with LPS
(Figure 3.9 A and B), indicative of activation of theNFκB pathway. In addition, we showed
that the increase of Sca-1 expression in vitro was dependent on NFκB signalling (Figure
3.9 C). These ndings, suggest that NFκB could bemediating the activation of HSCs upon
different stimuli. In contrast, treatment of mice with a conditional deletion of p65 led
to a normal activation of HSCs (Figure 3.9 E), although the deletion efciency of p65 was
relatively high (Figure 3.9 F). Therefore, it will be necessary to perform further exper-
iments, to analyse whether activation of HSCs upon different stimuli is dependent on
NFκB activation within the HSCs. The use of different mouse models and inhibition of
NFκB signalling in vivomight be of use to answer this question.
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4.4. The role of HSC activation in the immune response
The activation of TLR signalling upon LPS or polyI:C treatment leads to an increased
cycling of HSCs (Essers et al., 2009; Sato et al., 2009) (Figure 3.2). As TLR signalling is im-
portant in the rst line against all kinds of infections, it is likely that activation ofHSCs is a
general feature of TLR signalling, initiating a fast production of immune cells to ght the
infection and replenish the system after the infection is cleared. An effect of other TLR
ligands onHSCs has been shown. Stimulation of HSPCswith the TLR2 ligand Pam3CSK4,
the TLR9 ligand ODN1585 as well as LPS led to an increased differentiation of HSPCs to-
wards themyeloid lineage (Nagai et al., 2006; Megías et al., 2012), indicating that LPS and
polyI:C are not the only TLR ligands regulating HSC functions. The activation of HSCs
into an active cycle, however, appears thus far to be a specic feature of some TLR lig-
ands, rather than a general effect of TLR activation, as only ODN1826 and Flagellin led
to a increased cell cycle of HSCs independent of TLR4 signalling (Figure 3.7). However,
we only limited our testing to TLR ligands from one company, therefore the treatment
of mice with these TLR ligands from another source could actually lead to increased
cycling of HSCs.
Nevertheless, our data provide new insight into the role of HSCs in the ght against
infection. We could show that LPS treatment, mimicking a bacterial infection, leads
to effective activation of dormant HSCs into proliferation, without impairing their self-
renewal potential (Figures 3.2, 3.4 and3.5). LPS signalling leads to ahugeburst of cytokine
production in the bone marrow and many of these cytokines are probably involved in
the regulation of HSC function upon infection. The activation of proliferation of HSCs in
this process is most likely only one initial step in the response of HSCs to infection, sub-
sequently leading to differentiation and production of immune effector cells, as well as
activation of effector function, thatmight be exhibited by theHSCs themselves. Further-
more, we can show that cytokines, that have long been known to play a role in the reg-
ulation of mature immune cells (reviewed in Borden et al., 2007; Bradley, 2008; Weber
et al., 2010), can also inuence the cycling behaviour of primitive HSCs and progenitor
cells (Figures 3.14, 3.16 and 3.22). This may provide a clever mechanism to simultane-
ously induce immune effector cells to ght the infection and HSCs to proliferate and
subsequently differentiate, saving time and energy. Interestingly, we could show that
the pro-inammatory cytokines TNFα and IL-1β, which are characterised by their ability
to induce inammation andmake infectionsworse (reviewed inDinarello, 2000), aswell
as IFNs, that have been shown to inhibit the spread of viruses by blocking infected cells
(reviewed in Borden et al., 2007), exhibit very similar effects on the cycling behaviour
of HSCs. Future research will be necessary to investigate the functional links between
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HSC activation upon pro-inammatory cytokines and IFNs, as well as the mechanistic
differences that might underly these two processes. A commonmechanism of action of
these cytokines is the initiation of expression of adhesionmolecules and chemokines by
endothelial cells, leading to the recruitment of immune effector cells to the sites of in-
fection (reviewed inMogensen, 2009). It is possible that these chemokines and adhesion
molecules have similar effects on the behaviour of HSCs, leading to the release of these
cells from the endosteal niche to the perivascular niche (Kunisaki et al., 2013), where
they start to proliferate and produce progenitor cells. The proximity to the vasculature
might then enable the fast release of the produced cells into the periphery, although
HSCs themselves are not mobilised upon short-term LPS treatment (data not shown).
Furthermore, many cytokines have been shown to regulate proliferation and differenti-
ation ofmature immune cells, such as B cells, it is therefore possible that they can exhibit
similar functions on HSCs, directly inducing increased proliferation and differentiation.
Our results furthermore suggest that LPS-induced activation of HSCs is mediated by
myeloid cells, more specically, inammatory monocytes (Figure 3.11) that require cell-
cell-interactions with HSCs in order to induce the production of cytokines mediating
the activation of HSCs (Figure 3.13). This is a likely scenario, as inammatory monocytes
are themain type ofmonocytes present in the bonemarrow and can bemobilised to the
periphery upon infection (Gordon and Taylor, 2005; Robbins and Swirski, 2010; Shi and
Pamer, 2011). This mobilisation may lead to an interaction between the HSCs and the
monocytes, before the monocytes leave the bone marrow. The monocytes might then
be activated to produce cytokines mediating the activation of HSCs to produce more
monocytes and perhaps even other immune cells to ght the infection, as well as for
the replenishment of the system after the infection is cleared. It has already been shown
that HSCs are found in close proximity to macrophages in the bone marrow (Winkler
et al., 2010; Chow et al., 2011), it is therefore likely that monocytes can also be found near
HSCs. It is consequential that only monocytes that are actually located close to HSCs
produce factors to induce activation of HSCs, as these inammatory cytokines medi-
ate the immune response and their production should thus be tightly regulated. It has
furthermore been shown that HSCs themselves produce cytokines in response to infec-
tions (Zhao et al., 2014). This might be a way to carry on the production of immune cells
in the bonemarrow, after the immune effector cells have beenmobilised to the periph-
ery. After the infection is cleared, the HSCs return to their dormant state and therefore
retain their self-renewal and multilineage reconstitution potential, as long as they are
not chronically induced to cycle, ensuring life-long production of blood cells.
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4.5. Concluding remarks and future perspective
Our research provides new insights into the regulation of HSC quiescence and pro-
liferation upon infection and the role of inammatory cytokines in this regulation. This
will help to further current understanding of the role of HSCs during infection, as well
as the effects of infections on HSC function. We propose a mechanism inducing HSC
exhaustion and eventually even BM failure upon chronic infection, due to a constant in-
crease in the cycling activity of HSCs. Future experiments will have to be performed to
investigate how the activation of HSCs upon different stimuli is mechanistically linked,
as well as the subsequent effects of LPS- and cytokine-induced activation of HSCs on
their behaviour and function. Furthermore, it will be interesting to analyse the relation-
ship of different cytokines in the activation of HSCs, as many cytokines can induce pro-
duction of each other. In addition, we would like to investigate which of these cytokines
are actually directly regulating HSCs and which are only leading to indirect effects on
HSCs. It will also be worthwhile to analyse if LPS might exhibit direct effects on HSCs,
in addition to the indirect effects on HSC activation. It will be of great benet to iden-
tify the common mechanisms leading to HSC activation upon different stimuli, as this
will help to gain further insight into the regulation of HSC quiescence. For this purpose,
it will be helpful to further investigate the role of NFκB signalling, as well as Sca-1, in
the activation of HSCs. Another future research interest is the role of cytokines during
homeostatic conditions, as most of the inammatory cytokines are constantly present
in small concentrations and might also inuence the behaviour of HSCs during home-
ostasis. Moreover, a thorough understanding of the effects induced by single cytokines
as well as combinations of cytokines, may help to improve the treatment of patients
suffering from bone marrow failure due to chronic infections or defective DNA repair
mechanism, by blocking certain cytokines. Furthermore, this research can give insight
into the behaviour of human HSCs as, in contrast to mice which are kept in a pathogen-
free environment, humans are exposed to various pathogens every day. This raises the
question, whether a quiescent or dormant HSC actually exists in humans, or whether
human HSCs might constantly cycle due to a constant stimulation by infectious parti-
cles. Indeed, the constant cycling of HSCs due to the daily exposure with pathogens,
might be a cause for HSC defects occurring upon ageing. Therefore, blocking of cy-
tokines leading to HSC activation might also be a treatment route for patients suffering
from immune defects or bone marrow failure due to ageing. Hence, our research not
only provides new insight into the behaviour of HSCs upon infection, but may also help
to improve treatment of patients suffering from immune defects and bonemarrow fail-
ure.
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5.1. Mouse strains
All mice were housed in individually ventilated cages at the DKFZ animal facility. Ani-
mal procedureswereperformedaccording toprotocols approvedby theRegierungsprä-
sidium Karlsruhe (no. G-181/08, G-266/12 and G-157/13). If not indicated differently, the
mice are on a C57Bl/6 background.
C57Bl/6 J. C57Bl/6 J mice are referred to as (CD45.2+) wildtype (wt) mice. These mice
were purchased from Harlan Laboratories.
B6.SJL-Ptprca-Pep3b-/BoyJ.B6.SJL-Ptprca-Pep3b-/BoyJmice are referred to asCD45.1+
wt mice. These mice were purchased from Charles River Laboratories, Italy.
B6.Tlr4lps-del/JthJ. B6.Tlr4lps-del/JthJ mice are referred to as TLR4-/- mice. These
mice show a defective response to LPS due to a mutation in the Tlr4 gene (Vogel et al.,
1979; Poltorak et al., 1998).
B6.Ly6atm1Pmf. B6.Ly6atm1Pmfmice are referred to as Sca-1-/-mice. Thesemice lack
the HSC marker stem cell antigen 1 (Sca-1) and show an engraftment defect of HSCs in
competitive transplantations. (Stanford et al., 1997; Ito et al., 2003).
B6.Cg Ifnar1tm1Agt, B6.Cg-Ifngr1tm1Agt and B6.Cg.Ifnar1tm1Agt Ifngr1tm1Agt. B6.Cg
Ifnar1tm1Agt are referred to as Ifnar-/-, B6.Cg-Ifngr1tm1Agt are referred to as Ifngr-/- and
B6.Cg.Ifnar1tm1Agt Ifngr1tm1Agt are referred to as Ifnar-/-Ifngr-/-mice. Themice lack the
receptors for IFNα, IFNγ or both, leading to a defect in the response to these cytokines.
(Huang et al., 1993; Müller et al., 1994).
Stock Tg(Mx1-cre)1Cgn Gt(ROSA)26Sortm1.1(EYFP)Cos.
StockTg(Mx1-cre)1CgnGt(ROSA)26Sortm1.1(eYFP)Cosmice are referred to asMxCreRosa-
26eYFP ox2 mice. This mouse line was established by crossing the MxCre strain with
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the Rosa26eYFP strain. These mice were used to monitor IFNα production in the bone
marrow. The mice are on a mixed background as described (Kuhn et al., 1995; Srinivas
et al., 2001).
B6.CgTicam1tm1Aki. B6.CgTicam1tm1Akimice are referred to asTrifmc-/-mice. These
mice lack the TRIF-adaptor of the TLR4 and TLR3 signalling pathways, leading to defec-
tive IFN production upon activation (Yamamoto et al., 2003).
B6.CgMyd88tm1Aki. B6.CgMyd88tm1Akimice are referred to asMyd88-/-mice. They
lack the MyD88-adaptor, which is part of most TLR signalling pathways. Lack of MyD88
leads to a defective production of cytokines upon TLR signalling (Adachi et al., 1998).
B6;129S-Tnfrsf1atm1Imx Tnfrsf1btm1Imx. B6;129S-Tnfrsf1atm1Imx Tnfrsf1btm1Imx
mice are referred to as Tnfrsf1 dKO mice. They lack both receptors for TNFα, the TNFR1
and the TNFR2, leading to a defective response to TNFα. Those mice are on a mixed
C57Bl/6 and 129S7/SvEvBrd background (Peschon et al., 1998; Pronk et al., 2011).
B6-Tg(Tal1-cre/ERT)42-056JrgRelatm1MpaGt(ROSA)26Sortm1(EYFP)Cos. B6-Tg(Tal1-
cre/ERT)42-056JrgRelatm1MpaGt(ROSA)26Sortm1(EYFP)Cosmice are referred to as Scl-
CreERT2 p65 ox2 RosaEYFP ox2 mice. These mice were obtained by crossing the
SclCreERT2mouse strain to the p65 ox2 and the RosaEYFP ox2 mouse strain. Through
activation of Cre expression by the Tamoxifen inducible Scl-promotor, p65, part of the
NF-κB molecule, is deleted, resulting in a defect in the canonical NFκB signalling path-
way. Furthermore, the activation of Cre leads to the expression of EYFP, enabling the
identication of cellswith active Cre expression (Srinivas et al., 2001; Göthert et al., 2005;
Luedde et al., 2008).
B6.Relatm2.1Mpa. B6.Relatm2.1Mpa mice are referred to as p65-GFP mice. The cells
of these mice express a fusionprotein of GFP and p65 from the endogenous p65 ge-
nomic locus, enabling the analysis of NFκB activation through translocation to the nu-
cleus (de Lorenzi et al., 2009).
B6.129P2-Cxcr3tm1Dgen/J.B6.129P2-Cxcr3tm1Dgen/Jmice are referred to asCxcr3-/-
mice. Those mice lack Cxcr3, the receptor for CXCL9, CXCL10 and CXCL11 (Deltagen,
2005).
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B6.Il6tm1Kopf. B6.Il6tm1Kopf mice are referred to as IL-6-/- mice. These mice lack
the cytokine IL-6, leading to an impaired immune response (Kopf et al., 1994).
B6.Tg(Csf1r-EGFP-NGFR/FKBP1A/TNFRSF6)2Bck. B6.Tg(Csf1r-EGFP-NGFR/
FKBP1A/TNFRSF6)2Bck mice are referred to as Maa mice. These mice express a drug-
inducible suicide gene under the control of the c-fms (CD115) promotor. Upon treatment
with the homodimerizer AP20187 apoptosis is induced in all CD115 expressing cells (Bur-
nett et al., 2004).
5.2. In vivo treatment of mice
For treatment of HSCs, 8-10 week old mice were injected intraperitoneally (i.p.) with
0.25 mg/kg LPS (E.coli 0111:B4, Sigma), 0.75 mg/kg TNFα (Peprotech), 0.125 mg/kg IL-1β
(Peprotech), 5 mg/kg polyI:C (Peprotech), 0.5 mg/kg CXCL10 (R&D Systems), 0.05 mg/kg
IL-6 (R&D Systems) in 200 µl PBS or subcutaneous (s.c.) with 50x105 U/kg IFNα (Miltenyi
Biotec) in 100 µl for 18 hours, unless indicated otherwise. Control mice were injected
with an equal volume of PBS.
For studieswithdifferent TLR ligands,micewere injected i.p. with 1.5mg/kg Pam3CSK4,
2.5mg/kg LTA, 2.5mg/kg PGN, 1.0mg/kg Flagellin, 1.0mg/kg ssPolyU, 1.25mg/kgODN1585,
ODN1826 or ODN2395 (Invivogen) in 200 µl for 18 hours.
For analysis of IFNαproduction inMxCre Rosa26eYFP ox2mice,micewere irradiated
with 200 or 400 rad or 5-6 drops of blood were taken from the vena facialis.
For p65 deletion in SclCreERT2 p65 ox2 RosaEYFP ox2 mice, micewere treatedwith
Tamoxifen (1 g/kg) in the food for 30 days, followed by 14 days without Tamoxifen.
5.2.1. Depletion of cells from the bone marrow
Fordepletionofmyeloid cellsmicewere injected i.v. with 3.75 g/kg (300µl) clodronate-
loaded liposomes (van Rooijen et al., 1997). Control mice were injected with an equal
volume of PBS-loaded liposomes.
For fas-induced deletion of myeloid cells Maa mice were injected i.p. with 0.5 mg/kg
AP20187 (Clontech) in 200 µl PBS on ve consecutive days (Burnett et al., 2004).
To deplete neutrophils mice were injected i.p. with 2.5 mg/kg anti-Ly6G antibody
(clone: 1A8) in 200 µl PBS on 2 consecutive days (Casanova-Acebes et al., 2013).
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5.2.2. LRC assay
For LRC assays, cells were labeled by one i.p injection of 18 mg/kg BrdU (Sigma) and
a 10 day pulse-period with BrdU (1 mg/ml, glucose) in the drinking water, followed by a
70-day BrdU free chase period (Wilson et al., 2008). After the chase period, mice were
injected with 0.25mg/kg LPS or PBS, three times, every third day. Bonemarrow analysis
was performed 2 weeks after the last LPS injection.
5.2.3. 5-FU treatments
For analysis of IFNα production upon 5-Fluoro-Uracil (5-FU) treatment, mice were
injected i.p. with 150 mg/kg 5-FU (300 µl).
For long-term 5-FU treatment mice were initially injected with 0.75 mg/kg TNFα or
PBS. The following day, repeated 5-FU treatmentswith 150mg/kg 5-FU (300µl) i.p. were
started. The 5-FU treatment was repeated every 10 days until the mice died.
5.2.4. Etanercept and IL-1RA
For inhibition of TNFα Etanercept (Enbrel®,FDA 1998) was injected i.p. for 10 days
(5 mg/kg in 100 µl PBS on day 1-5; 7.5 mg/kg in 150 µl PBS on day 6-10); LPS was injected
on day 10.
For inhibition of IL-1β signalling 2.5mg/kg IL-1 receptor antagonist (IL-1RA) (Peprotech)
was injected i.p. in 200 µl PBS 1 hour before the LPS treatment.
5.3. Isolation of bone marrow and peripheral blood
To collect bonemarrowcells, bones of legs, hips and spineswere isolated and crushed
inRPMI-1640mediumsupplementedwith 2% fetal bovine serum (FBS). Cell suspensions
were ltered with a 40 µm lter before use.
For isolation of peripheral blood (PBL), 4-5 drops of blood were collected from the
vena facialis into an EDTA containing tube. Erythrocytes were lysed with 1 ml of ACK
lysing buffer. Cells were washed and used for further analysis.
5.4. Lineage depletion
For depletion of lineage positive (lin+) cells, bone marrow cells were incubated with
lineage antibodies against CD4, CD8, CD11b, B220, Gr-1 and TER119 for 30 min. After
antibody incubation lin+ cells were depleted using Dynabeads®Magnetic Beads (Invit-
87
5. Materials and Methods
rogen). Cells were incubated with the beads for 20 min, before non-bound cells were
isolated using a magnet.
5.5. Generation of chimeras
Bone marrow was isolated as described. BM cells were Thy1 depleted: Cells were in-
cubated with an anti-Thy1 antibody (AT83) for 20 min, before rabbit complement and
Dnase 1 were added. Subsequently cells were incubated for 20 min at 37 ◦C. For trans-
plantation 3x106 cells were diluted in 100-200 µl of PBS and intravenously (i.v.) injected
into lethally irradiated (2x500 rad) mice. For mixed bone marrow chimeras cells were
mixed prior to injection in a 1:1 ratio and a FACS analysis of the injected cells was per-
formed to determine the input-ratio. PBL chimerismwas assessedby FACS analysis after
4-6 weeks. For long-term reconstitution assay of LPS treated HSCs mice were injected
with PBS or LPS 24 hours before bone marrow isolation. Bone marrow was Thy1 de-
pleted, as described. 3x106 cells were diluted in 20 µl PBS and injected intrafemorally
(i.f.) into lethally irradiated (2x500 rad) mice. After 4, 8 and 12 weeks PBL chimerism
was determined by FACS analysis. After 16 weeks mice were sacriced. Reconstitu-
tion in PBL and BMwas analysed and 3x106 whole BM cells from the primary recipients
were transplanted i.f. into lethally irradiated (2x500 rad) secondary recipients. Again
PBL chimerism was determined after 4, 8 and 12 weeks and reconstitution of PBL and
BM was analysed after 16 weeks. All mice were kept on antibiotic (Cotrim) containing
water for 3 weeks post transplantation. To enable identication of recipient and donor
cells, mice with different CD45 isoforms were used. Identication of donor cells is then
possible by FACS staining for CD45.1 and CD45.2.
5.6. FACS analysis
FACS antibodies were purchased from several suppliers (table 5.13.1). All antibodies
were titratedwithwhole bonemarrowprior to use in experiments. The antibodieswere
used in concentration according to this titration, to ensure optimal staining and avoid
unspecic signals. Antibodies were diluted in staining buffer (PBS/2% FBS and 24G2, 1:1),
to prevent unspecic binding. 100 µl of antibody solution were used for 5-20x106 cells.
BM cells were stained for HSC and progenitor subsets using lineage antibodies (CD4,
CD8, CD11b, Gr-1, B220 and TER119), cKit, Sca-1, CD150, CD48 and CD34 (Figure 5.1). BM
cellswere stained formyeloid cellswith antibodies against CD11b, Gr-1, CD115, Ly-6C and
F4/80 (Figure 5.2). For staining of BM cells for other mature haematopoietic cells anti-
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bodies against CD4, CD8, CD41, B220 and TER119 were used. All cell suspensions were
ltered through a nylon mesh lter (70 µm) prior to FACS analysis to prevent clumping.
For ow cytometric data analysis the BD™ LSRII or BD LSRFortessa™ (Becton Dickin-
son™, San Jose, CA), equippedwith a 350 nm, 405 nm, 488 nm, 561nm, and 640 nm laser,
or the 9 color Cyan™ ADP Analyzer (Beckman Coulter GmbH, Germany), equipped with
a 407 nm, 488 nm, and 635 nm laser, were used. Prior to analysis of multicolor samples,
OneComp eBeads stained with single antibodies were used to perform compensation
using the auto-compensation tool of the BD FACSDiva™ software. Analysis of ow cyto-
metric data was performed using the TreeStar FlowJo software version 9.6.4 or version
8.8.7.
FSC
lin
ea
ge
CD34
C
D
48
CD150
C
D
48
Sca-1
ti
K-c
A
CD34
C
D
48
CD150
C
D
48
CD150
ti
K-c
hoechst
ic
K
i6
7
BrdU
ce
ll 
co
un
t
B C
G0
G1 SG2M
Figure 5.1.: HSC Flow Cytometry gating scheme
(A) Gating scheme for FACS analysis of LSK CD150+CD48-CD34- (HSCs, upper panel) and LK
CD150+CD48-CD34- (lower panel) cells. (B) Representative FACS prole of HSCs stained for icKi67 and
Hoechst. (C) Representative FACS prole of BrdU incorporation in HSCs.
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Figure 5.2.: Gating scheme for in vitro co-culture experiments
(A) Gating scheme for neutrophils (I), Gr-1high monocytes (II), Gr-1low monocytes (III) and macrophages (V)
(Chow et al., 2011). (B) Gating scheme for CD11b+CD115+Ly6Chigh inammatory monocytes.
5.7. FACS sorting
To isolate HSCs and progenitor cells, BMwas isolated and cells were lineage depleted.
For in vitro cultures lineage negative cells were stained with antibodies against the lin-
eage markers, c-Kit and CD150. Lin-c-Kit+CD150+ (LK CD150+) cells were sorted. To sort
different populations of myeloid cells for in vitro culture BM cells were stained with
antibodies against CD11b, CD115, Gr-1, F4/80 and Ly-6C. For qRT-PCR or Immunouo-
rescence lineage negative cellswere stainedwith antibodies against the lineagemarkers,
c-Kit, CD150 and CD48. LK CD150+CD48- cells were sorted. Cell sorting was performed
on a FASC Aria I, FACS Aria II or FACS Aria III (Becton Dickinson™, San Jose, CA) at the
DKFZ Flow Cytometry Service Unit.
5.8. Cell cycle analysis and BrdU staining
For cell cycle analysis cell surface staining was performed in combination with intra-
cellular Ki67-Hoechst staining. After cell surface staining BM cells were xed with BD
Cytox/Cytoperm™ Buffer, washed and stained with anti-Ki67-FITC or -APC for 30min
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or over night. Cells were co-stained with Hoechst 33342 (Molecular Probes) at 25 µg/ml
for the nal 10 min.
For proliferation assays with BrdU, mice were injected i.p with BrdU (18mg/kg, Sigma)
14 hours prior to analysis. BM cells were stained with antibodies against surface mark-
ers. For BrdU staining the BD Pharmigen™ BrdU Flow Kit was used. Fixation and DNase
treatment were performed according to manufacturer’s instructions.
5.9. mRNA expression anaylsis
5.9.1. RNA isolation
RNA isolation was performed using the Arcturus PicoPure™ RNA Isolation Kit or the
RNeasy Micro Kit (Qiagen). Cells were collected in 50 µl Extraction Buffer and lysed
for 30 min at 42◦C. Protocol was performed according to manufacturer’s instructions,
including DNA digestion by RNase-free DNase (Qiagen). RNA was either directly tran-
scribed into cDNA or stored at -80◦C for further use.
5.9.2. Reverse transcription
Reverse transcription was performed using the SuperScript®VILO™Synthesis Kit ac-
cording tomanufacturer’s instructions. cDNAwasdiluted inRNase-freewater and stored
at -20◦C until further use.
5.9.3. MicroArray
For expression proling LK CD150+CD48- cells from wildtype mice treated with PBS,
LPS, IFNα or TNFα or Ifnar-/-Ifngr-/- mice treated with PBS or LPS were sorted directly
into 50µl ExtractionBuffer. RNA isolationwasperformedasdescribed, using theRNeasy
Micro Kit. The RNA was frozen at -80◦C and further processed by the DKFZ Genomics
and Proteomics Service Unit. Quality control of the RNA was performed using a Agi-
lent Bioanalyzer 2100. Samples with a RIN score below 7 were excluded from analysis.
Samples were amplied using the Ovation PicoSLWTA system and labeled with the Bi-
otinIL Module fromNuGEN. For expression analysis the samples were hybridised to the
Illumina MouseWG-6 v2.0 Expression BeadChip®.
5.9.4. Analysis of expression data
After normalisation the expression data was analysed using R. As the MicroArray in-
cludes several probes for some genes the data was rst aggregated. Subsequently the
means were calculated for all replicates of one treatment. These means were then used
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to calculate the fold changes between different treatments. Only the genes with a fold
change higher than 1.5 or lower than 0.66were considered as regulated. The genes simi-
larly regulated upon different treatments were identied usingMicrosoft Ofce™ Excel.
Furthermore, R was used to construct a heat map as well as perform principle compo-
nent analysis (PCA). For that, the variancewas calculated for all genes and the 5000genes
with the highest variancewere used for the calculation of the heatmap and the principle
component analysis. The heat map was constructed using the pheatmap function, the
principle component analysis was conducted using the prcomp function. Before these
calculations were performed not assigned expression values were replaced by 0.
Examples of R code used
data <- read.table(file = "file-location", header=T, dec = ".", sep ="\t")
#Aggregation of data
agg.data <- aggregate(data[,-1], by = data["Symbol"], FUN = mean)
#Fold change calculation
PBS <- data.frame(agg.data[,1], Means = rowMeans(agg.data[,2:7]))
IFN <- data.frame(agg.data[,1], Means = rowMeans(agg.data[,8:13]))
FC.PBS.IFN <- data.frame(agg.data[,1], IFN[,2]/PBS[,2])
#Calculation of variance
variance<-apply(expression[,4:ncol(agg.data)],1,var)
agg.data<-cbind(agg.data, variance)
agg.data<-agg.data[order(agg.data[,"variance"], decreasing=T),]
#Replacement of n.a. expression values by 0
agg.data<-agg.data[which(rowSums(is.na(agg.data))==0),]
#Assigment of matrix
agg.data_selected<-expression[,-1:-3]
agg.data_selected<-apply(agg.data_selected,2,as.numeric)
#Generation of heatmap
pheatmap(agg.data_selected[1:5000,1:ncol(agg.data_selected)-1],
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scale="row",clustering_distance_cols="euclidean", clustering_method="ward",
color=colorRampPalette(c("darkblue","blue","yellow","orange"))(256),
treeheight_row=0)
#PCA and PCA plot
pca<-prcomp(t(agg.data_selected[1:5000, 1:ncol(agg.data_selected)-1]))
IDstype<-IDstype<-substring(colnames(agg.data_selected)
[-ncol(agg.data_selected)],4,99)
colors<-brewer.pal(6,"Set1")
IDstoEdge<-c("wt.PBS"=colors[1],"wt.IFN"=colors[2],"wt.LPS"=colors[3],
"wt.TNFa"=colors[4], "IFNRdKO.PBS"=colors[5], "IFNRdKO.LPS"=colors[6])
colors<-IDstoEdge[IDstype]
ar(font=2, font.axis=2, font.lab=2)
plot(pca$x[,1:2], col=colors, pch=20)
legend("topleft", legend=c("WT PBS", "WT IFN", "WT LPS", "WT TNFa",
"IFNRdKO PBS", "IFNRdKO LPS"), fill=brewer.pal(6, "Set1"), ncol=2)
5.9.5. Quantitative real-time PCR
For quantitative real-time PCR (qRT-PCR) RNA isolation, using the Arcturus PicoPure™
RNA Isolation Kit, and reverse transcription were performed as described. 384-well
plates were used to set up qRT-PCR reactions, with primer (table 5.1) concentrations of
0.5 µM and a 2x-DNA-polymerase-SYBR-Green master-mix from Applied Biosystems.
qRT-PCR was performed using the Applied Biosystems ViiA™ 7 Real-Time PCR System
with an initial denaturation step of 95◦C for 10min followed by 40 cycles of 15 s 95◦C and
60 seconds 60◦C. Expression values were normalized to sdha and oaz1 levels. Relative
gene expression was calculated by comparative ΔΔCT-method.
5.10. Protein expression analysis
5.10.1. Immunofluorescence
For immnuouorescence stainings cells were sorted into PBS/2% FBS. Subsequently
cells were coated on Polysine™ slides for 20min. Fixtation of cells was performed using
BD Cytox/Cytoperm™ Buffer for 10 min. After washing with PBS slides were stored
at -20◦C. Cells were blocked with PBS/10% BSA/0.3% Triton X-100 for 1 hour. Primary
antibodies were diluted in PBS/1% BSA/0.3% Triton X-100 and staining was performed
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gene primer sequence product [nt]
sdha fwd AAGTTGAGATTTGCCGATGG 74
sdha rev TGGTTCTGCATCGACTTCTG 74
oaz1 fwd TTTCAGCTAGCATCCTGTACTCC 77
oaz1 rev GACCCTGGTCTTGTCGTTAGA 77
p57 fwd TCTCGGGGATTCCAGGAC 136
p57 rev ACGTTTGGAGAGGACACC 136
serpina3g fwd CAGGAACCAAGGATCTGAGAGT 104
serpina3g rev GACACCTGCCATTCCTGTG 104
socs3 fwd CACACAAGGAGCCAAACACA 59
socs3 rev TAGCCACCTGGGTGAATCC 59
ccl5 fwd TGCAGAGGACTCTGAGACAGC 149
ccl5 rev GAGTGGTGTCCGAGCCATA 149
apbb1 fwd CCTGTTGGGGTAGACGTGAT 60
apbb1 rev ACGGCTACTGGAAGACAGGA 60
foxa3 fwd CCAAACCACCATATTCCTACATC 77
foxa3 rev ACTCAGGGTCAGCATCTTGC 77
cxcl4 fwd TGGGATCCATCTTAAGCACA 93
cxcl4 rev CCATTCTTCAGGGTGGCTAT 93
p65 fwd TGGCGAGAGAAGCACAGATA 135
p65 rev CCCACAAGTTCATGTGGATG 135
Table 5.1.: List of qRT-PCR primers
at 4◦C over night or for 2 hours at RT. After washing 3 times with PBS, cells were again
blocked with PBS/10% BSA/0.3% Triton X-100 for 15 min. Secondary antibodies were
diluted in PBS/1% BSA/0.3% Triton X-100 and staining was performed at RT for 2 hours.
Before slides were covered with ProLong® Gold Antifade Reagent with DAPI, they were
washed 3 times with PBS. Microscopy was performed using a Zeiss LSM 700 confocal
microscope. Analysis of microscopic images was performed using the ImageJ software
(Abramoff et al., 2004). Co-localisation analysis was performed using the JaCop plugin
for ImageJ. This plugin enables the measurement of the co-localisation of two signals
using the Mender’s coefcient (Bolta and Cordelieres, 2006).
5.10.2. ELISA
For ELISA, bones of legs and hips were ushed or crushed in 750 µl RPMI/2% FBS.
ELISAs were performed according to manufacturer’s instructions using different ELISA
kits (5.13.2). Absorbance was measured using the SpectraMax M5 Microplate Reader
fromMolecular Devices.
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5.11. In vitro cultures
Lineage depleted or sorted cells were cultured in StemPro®-34 SFMmedium supple-
mented with L-Glutamine, Penicillin/Streotpmycin, Flt3 (50 ng/ml), mTPO (50 ng/ml)
andmSCF (50 ng/ml) for 18-20 hours at 37◦C, 5%CO2. Cells were treatedwith 100 ng/ml
LPS or 1000 U/ml IFNα. For cell cycle analysis BrdU (10 µM) was added to the medium
for the nal 3 hours of culture. Subsequently cells were harvested and stained for FACS
analysis.
For co-culture experiments sorted LK CD150+ cells (HSPCs) were cultured with dif-
ferent subsets of mature haematopoietic cells in a 2:1 ratio. To enable identication of
sorted HSPCs by Flow Cytometry, HSPCs were sorted from CD45.1+ mice, while differ-
entiated cells were sorted from CD45.2+ mice or vice versa.
For NFκB inhibition lineage depleted cells were cultured with 10 µg/µl JSH-23 or 100
µg/ml PDTC and treated with PBS or LPS (100 ng/ml) for 18 hours.
For transwell experiments, LK CD 150+ cells were sorted into the lower well of a tran-
swell plate. The cells were then culture either alone, in co-culture with CD11b+CD115+
cells in the same well or separated through a 4 µm thick lter, to avoid cell-cell-contact.
The cells were treated with LPS (100 ng/ml) or PBS, by pipetting the LPS or PBS into the
upper well.
Conditioned medium was obtained by culturing lineage depleted cells, treated with
PBS or LPS. After 18 hours cells were harvested and pelleted. Supernatant was used to
treat freshly isolated lineage depleted cells for another 18 hours in culture.
5.12. Statistics
For statistical analysis and graphical representation of data the GraphPad Prism® soft-
ware version 6.0 was used. Statistical analysis was performed using an unpaired t-test.
Statistical signicance is indicated by * p < 0.05 or ** p < 0.01. Error bars indicate the
standard deviation. Each graph represents similar results of two to three independent
experiments with at least three mice per condition.
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5.13. Materials
5.13.1. Antibodies
Antigen Label Clone Company
B220 PECy5, PECy7 RA3-6B2 eBioscience
B220 biotin RA3-6B2 BioLegend
CD4 PECy7 GK1.5 eBioscience
CD4 biotin GK1.5 BioLegend
CD8a PECy7 53-6.7 eBioscience
CD8a biotin 53-6.7 BioLegend
CD11b biotin M1/70 BioLegend
CD11b PECy7 M1/70 eBioscience
CD34 Alexa700, FITC RAM34 eBioscience
CD45.1 FITC A20.1 eBioscience
CD45.2 Pacic Blue 104 BioLegend
CD45.2 Alexa700 104 BD Pharmigen
CD48 PE HM48-1 eBioscience
CD48 Pacic Blue HM48-1 BioLegend
CD115 APC AFS98 eBioscience
CD150 PECy5, APC TC15-12F12.2 BioLegend
c-Kit PE, APC, eFluor780 2B8 eBioscience
F4/80 FITC CI:A3-1 AbD Serotec
F4/80 eFluor450 BM8 eBioscience
GFP unlabelled - Invitrogen
Gr-1 (Ly6G) PE, PECy7 RB6-8C5 eBioscience
Gr-1 biotin RB6-8C5 BioLegend
Ki67 FITC, APC B56 BD Pharmigen
Ly-6C APCCy7 HK1.4 BioLegend
NK1.1 PE PK136 eBioscience
Sca-1 APCCy7 D7 BD Pharmigen
Streptavidin PETexasRed - BD Pharmigen
TER119 PECy7, APCCy7 TER119 eBioscience
TER119 biotin TER119 BioLegend
Table 5.2.: List of FACS antibodies
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5.13.2. Kits
Name Company Order no.
FITC BrdU Flow Kit BD Pharmigen 559619
APC BrdU Flow Kit BD Pharmigen 552598
SuperScript® VILO™ cDNA Synthesis Kit Life Technologies 11754250
Arcturus® PicoPure® RNA Isolation Kit Life Technologies KIT0204
RNeasy Micro Kit Qiagen 74004
Mouse TNF-alpha Quantikine ELISA Kit R&D Systems MTA00B
Mouse IL-1 beta/Il-1F2 Quantikine ELISA Kit R&D Systems MLB00C
Mouse CXCL10/Ip-10/CRG-2 Quantikine ELISA Kit R&D Systems MCX100
Mouse IFN-gamma Quantikine ELISA Kit R&D Systems MIF00
VeriKine™Mouse Interferon Alpha ELISA Kit PBL Assay Science 42120-1
VeriKine™Mouse Interferon Beta ELISA Kit PBL Assay Science 42400-1
Mouse IL-6 ELISA Kit Thermo Scientic EM2IL6
Table 5.3.: List of kits
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